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9CHAPTER 1
Introduction and outline of this thesis
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Chapter 1
InTRoduCTIon
Subfertility is defined as a failure to conceive after at least one year of regular unprotected 
intercourse (Zegers-Hochschild et al. 2009). It affects approximately 10% of couples in their 
reproductive lives (Boivin et al. 2007; Gnoth et al. 2003). The incidence of subfertility is 
increasing in the developed world mainly due to postponement of maternity. After a basic 
fertility work up about 25% of couples is diagnosed with unexplained subfertility, 30% with 
a mild male factor, 5% with a severe male factor, 20% with an ovulation disorder and in 20% 
of the couples other diagnoses as tubal factor, cervical subfertility, endometriosis and sexual 
disorders are made (Brandes et al. 2010; Collins and Van 2004). 
In couples with unexplained or mild male subfertility the first step in the treatment cascade 
is often intra uterine insemination (IUI) with or without ovarian stimulation (OS). If 6-9 cycles 
of IUI with ovarian stimulation do not lead to a live birth (Custers et al. 2008), the second 
step in the treatment cascade for these couples is often In vitro fertilisation (IVF) (ESHRE 
2008; NVOG: national guideline subfertility 2011).
Intra uterine Insemination
The rationale for performing IUI is that motile spermatozoa are concentrated in a small 
volume and inseminated directly into the uterine cavity close to the released oocyte, 
bypassing the cervix. The aim of ovarian stimulation is to increase the number of oocytes 
available for fertilisation and to optimise timing of insemination. The first scientifically 
described homologous insemination dates from 1799, where the author describes how a 
man with severe hypospadias collected his semen in a syringe and introduced it into the 
vagina of his wife. The insemination was successful (Hogerzeil 1997). 
The first publication of a randomised clinical trial on intra uterine insemination in couples 
with poor semen quality was in 1984 (Kerin et al. 1984). This 3-armed trial compared IUI 
on the day of the luteinising hormone surge with intercourse in which timing was based 
on either the luteinising hormone surge or on the basal body temperature. After 39 
inseminations, 8 women conceived. Intra uterine insemination was more successful than 
LH-timed intercourse (0/38; p<0.05) and natural intercourse timed by the basal temperature 
curves (1/34; p = 0.022). 
Since this first randomised controlled trial (RCT) on IUI, the number of IUI treatments with 
and without ovarian stimulation has increased rapidly. However, no national or international 
registrations are available concerning the exact number of treatments and pregnancy rates. 
One retrospective study estimated that 28,500 IUI cycles were performed in the Netherlands 
in 2003 with an ongoing pregnancy rate of 7% per cycle and with a multiple pregnancy rate 
of 9% (Steures et al. 2007c). 
The first Cochrane review was published in 2000 on IUI with or without ovarian stimulation 
(OS) for couples with male subfertility included 3,662 completed cycles and concluded that 
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IUI offers couples with male subfertility benefit over timed intercourse (TI), both in natural 
cycles (combined odds ratio with 95% confidence intervals: 2.4, 1.5 - 3.8) and in cycles with OS 
(combined odds ratio with 95% confidence intervals: 2.1, 1.3 - 3.5). Intrauterine insemination 
in cycles with OS improved the probability of conception compared with IUI in natural cycles 
but significance was not reached (Odds Ratio (OR) with 95% confidence intervals (CI): 1.7, 
0.98 - 3.2). So, the authors concluded that intra-uterine insemination offered couples with 
male subfertility benefit over timed intercourse, both in natural cycles and in cycles with 
COH. In case of a severe semen defect (with more than 1 million motile sperm after semen 
preparation) IUI in natural cycles should be the treatment of first choice, but the value of COS 
needed to be further investigated in RCTs. (Cohlen et al. 2000). 
The most recent update of this Cochrane review on IUI for male subfertility was performed 
in 2007. For the comparison IUI versus timed intercourse both in natural cycles no evidence 
of difference between the probabilities of pregnancy rates per woman after IUI was found 
(OR 5.3, 95% CI 0.42 to 67). No statistically significant difference between pregnancy rates 
per couple for IUI with OS versus IUI could be found (OR 1.4, 95% CI 0.92 to 2.3). For the 
comparison of IUI versus TI both in stimulated cycles there was also no evidence of a 
statistically significant difference in pregnancy rates per couple either (OR 1.6, 95% CI 0.83 
to 3.3). There were insufficient data available for adverse outcomes such as OHSS, multiple 
pregnancy, miscarriage rate and ectopic pregnancy to perform a statistical analysis. They 
concluded that there was insufficient evidence of effectiveness to recommend or advice 
against IUI with or without OS above TI, or vice versa. The authors thus recommended that 
large, high quality randomised controlled trials, comparing IUI with or without OS with 
pregnancy rate per couple as the main outcome of interest needed to be performed before 
firm conclusions can be drawn (Bensdorp et al. 2007). 
A recent update of a Cochrane review on IUI for couples with unexplained subfertility was 
published this year. One trial compared IUI in a natural cycle with expectant management 
and showed no evidence of increased live births (334 women: OR 1.6, 95% CI: 0.92 to 2.8). In 
the six trials where IUI was compared with TI, both in stimulated cycles, there was evidence 
of an increased chance of pregnancy after IUI (six RCTs, 517 women: OR 1.68, 95% CI 1.1 
to 2.5). A significant increase in live birth rate was found for women where IUI with OS 
was compared with IUI in a natural cycle (four RCTs, 396 women: OR 2.0, 95% CI 1.2 to 
3.5). The trials provided insufficient data to investigate the impact of IUI with or without 
OS on several important outcomes including live births, multiple pregnancies, miscarriage 
and risk of ovarian hyperstimulation. There was no evidence of a difference in pregnancy 
rate for IUI with OS compared with TI in a natural cycle (two RCTs, total 304 women: data 
not pooled). The final comparison of IUI in natural cycle to TI with OS showed a marginal, 
significant increase in live births for IUI (one RCT, 342 women: OR 1.9, 95% CI 1.1 to 3.4). Data 
on multiple pregnancies and other adverse events for treatment with OS were insufficient to 
allow conclusions (Veltman-Verhulst SM et al. 2012). 
12
Chapter 1
In general, the two Cochrane reviews discussed above, concluded that the quality of the 
included trials was poor, the sample sizes were small, and complications like multiple 
pregnancies were poorly reported and more well-designed and well powered studies are 
necessary.
In Vitro Fertilisation
IVF was introduced for couples who are infertile due to tubal occlusion. Lesley Brown, the first 
woman ever to give birth after IVF had severe tubal pathology after several failed surgical 
procedures. In the next decennia after the birth of Louise Brown in 1978, IVF turned out 
to be effective in women with tubal pathology (Steptoe et al. 1980). In 1992 IVF with Intra 
Cytoplasmatic Sperm Injection (ICSI) was developed for men with very poor semen quality 
failing to fertilize in vitro (Palermo et al. 1992). In ICSI, fertilization is induced by directly 
injecting a motile, normally formed sperm cell into the oocyte. In couples with severe tubal 
pathology and severely impaired semen quality it is nearly impossible to achieve fertilization 
in vivo and these couples are thus dependent on IVF or ICSI to have a chance of pregnancy. 
Approximately 20% of all couples with an unfulfilled child wish are at present diagnosed 
with one of these two indications (Collins and Van 2004; van der Steeg et al. 2007a; Brandes 
et al. 2011). 
In 1990 around 50% of all patients treated with IVF were diagnosed with a tubal factor 
(Annual reports 1990-2010 AMC & VUmc 2010). Although the absolute number of patients 
with a tubal factor remained stable, in 2010 this group accounted for just 10-12% of all IVF 
patients (Annual reports 1990-2010 AMC & VUmc 2010). Over the years the indications for 
IVF have thus been widely broadened. 
At present, more than half of all IVF/ICSI treatments are performed in couples with 
unexplained or mild male subfertility, leading to an increase in the total number of IVF cycles 
performed (Brandes et al. 2010). Over the past 13 years the number of IVF cycles has risen by 
more than 50% in the Netherlands (Kremer et al. 2008a). The number of IVF cycles in Europe 
has doubled in the period between 1997-2006 (de Mouzon et al. 2010). In 2009, one in every 
39 newborns in the Netherlands originated from IVF or ICSI treatment (www.lirinfo.nl). In 
2012 the mean ongoing pregnancy rate per cycle was 19% for IVF and 23% for ICSI (www.
nvog.nl 2011).
In contrast to couples with a tubal factor or very poor semen quality, couples with unexplained 
or mild male subfertility still have a chance of natural conception (Brandes et al. 2010). 
Empirical data proving the effectiveness of IVF/ICSI over coitus for these indications are 
scarce. Randomised controlled trials comparing IVF/ICSI for these indications with expectant 
management or IUI with or without OS are limited to small-scale trials with heterogeneous 
patient groups (Goverde et al. 2000; Hughes et al. 2004; Reindollar et al. 2010). 
A systematic Cochrane review with meta-analysis concluded that the added value of IVF in 
relation to expectant management or IUI with or without OS in couples with unexplained 
subfertility has not been proven, due to paucity of data: only one trial study with 51 women 
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compared IVF with expectant management and the live birth rate per woman was significantly 
higher with IVF (45.8%) than expectant management (3.7%) (OR 22, 95% CI 2.5 to 189). There 
were no comparative data for comparing IVF with the use of clomiphene citrate. There was 
no significant difference in live birth rate between IVF (40,7%) and IUI alone (25,9%) (OR 
1.9, 95% CI 0.88 to 4.3, 1 RCT, 113 women). In studies comparing IVF versus IUI with OS, 
live birth rate per woman did not differ significantly between the groups among treatment-
naive women (OR 1.0, 95% CI 0.74 to 1.5, 2 RCTs, 234 women) but was significantly higher 
in a large RCT of women pre-treated with clomiphene citrate IUI (OR 2.6, 95% CI 1.9 to 3.6, 1 
RCT, 341 women). These three studies could not be pooled due to high heterogeneity (I(2) = 
84%). There was no evidence of a significant difference in multiple pregnancy rate or ovarian 
hyperstimulation syndrome (OHSS) between the two treatments (OR 0.64, 95% CI 0.31 to 1.2, 
3 RCTs, 351 women; OR 1.5, 95% CI 0.25 to 9.4, 1 RCT, 118 women, respectively). The authors 
concluded that IVF may be more effective than IUI+SO but due to paucity of data from 
RCTs the effectiveness of IVF for unexplained infertility relative to expectant management, 
clomiphene citrate and IUI alone remains unproven. Adverse events and the costs associated 
with these interventions have not been adequately assessed (Pandian et al. 2012). In a cohort 
of newly referred subfertile couples, the contribution of IVF in couples with unexplained 
subfertility was extremely limited, with ongoing pregnancy rates of 13%, compared with 
45%, 45% and 37%, respectively for  patients with tubal factors, endometriosis and severe 
male factors (Brandes et al. 2010). 
One of the causes for the increase in the number of IUI and IVF cycles is modern reproductive 
behaviour. The average age at which women give birth for the first time is increasing on 
a yearly basis. At the same time, the average age of women requiring medical aid at the 
clinic for assisted reproduction is increasing every year (de Mouzon et al. 2010; Kremer et al. 
2008a). Women’s pregnancy chances are decreasing from the age of 30. From the age of 35 
there is a severe drop and from the age of 40 the chances of pregnancy are very low (Hunault 
et al. 2004). Modern assisted reproduction techniques cannot compensate for this “ovarian 
aging” – the pregnancy chances with assisted reproductive techniques also decrease with 
age – as does the in vivo conception (Templeton 2000; Lintsen et al. 2007).
Expectant management
In couples without a major cause for their unfulfilled child wish expectant management may 
be a good option. In a large cohort study concerning subfertile couples with unexplained 
subfertility, 74% of all pregnancies was conceived naturally (Brandes et al. 2011). The 
problem is how to identify the couples that would benefit from expectant management, 
since gynaecologists differ widely in estimating fertility prognoses in subfertile couples, 
prognostic models may be of help here (van der Steeg et al. 2007a). For several treatment 
policies, prognostic models have been developed. For eight models, the validity was assessed 
in populations other than the one in which the model was developed (external validation), 
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and only three of these showed good performance (Leushuis et al. 2009). One model predicting 
the chance of natural conception had reached the phase of impact analysis (Hunault et al. 
2004). This impact analysis showed that in couples with an intermediate chance of natural 
conception (between 30%-40% chance of live birth within 12 months), IUI with OS had no 
beneficial effect on live birth rate compared to expectant management (Steures et al. 2006). 
Based on these results our national guideline concerning fertility treatment recommends an 
expectant management for 6-12 months in couples with a intermediate or good prognosis 
(>30% chance of natural conception), so called tailored expectant management (TEM) 
(NVOG: national guideline subfertility 2011). 
BACkgRound oF THIs THEsIs
Implementation of tailored expectant management
It is unclear how TEM is implemented, but large cohort studies suggest poor implementation 
(Kremer et al. 2008a; Mourad et al. 2008; van der Steeg et al. 2007a). Optimal implementation 
of expectant management for 6-12 months for subfertile couples with good chances of 
natural conception can cause a reduction in healthcare costs without compromising live 
birth rates. Besides a cost reduction, optimal implementation of TEM is likely to lead to a 
lower number of multiple pregnancies. Even though multiple pregnancy rates per treatment 
cycle are decreasing, the risks are still substantially higher than those in natural conceptions. 
Multiple pregnancies are associated with a higher morbidity and mortality in both mothers 
and neonates (Helmerhorst et al. 2004). Finally, fertility treatments carry a significant physical 
and psychological burden (Verberg et al., 2008;Verhaak et al., 2002;Verhaak et al., 2007). 
To improve the implementation of TEM a systematic approach is needed including acquisition 
of data of current practice; identification of potential determinants; analysis of barriers and 
facilitators for the implementation, development of an implementation strategy and finally 
an evaluation of the implementation strategy (Grol and Grimshaw 2003; Kremer et al. 2008a).
In the first part of this thesis we performed the first steps of this systematic implementation 
study to improve the implementation of TEM in subfertile couples with unexplained or male 
subfertility. In a prospective cohort study we evaluated the adherence to tailored expectant 
management and we identified risk factors for non-adherence to tailored expectant 
management. Subsequently we identified patients’ and professionals’ barriers and facilitators 
of TEM and its´ influence on patients’ appreciation of TEM and professionals’ adherence to 
TEM. Finally, we developed an implementation strategy to improve the implementation of 
tailored expectant management based on our previous findings.
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Applicability of prognosis of natural conception
The second part of this thesis is twofold. First we compared a selection strategy based on 
prognosis of natural conception with a funding based selection strategy used in New Zealand. 
In New Zealand public funding for fertility treatment is restricted to subfertile women who 
are unlikely to conceive naturally, based on clinical and social criteria known as the clinical 
priority access criteria (CPAC-score). In this study this CPAC score was compared with the 
prognostic model developed in the Netherlands (the Hunault model) in a New Zealand cohort 
of 663 couples. 
Second, we aimed to explore the capacities of prognostic models to select couples for IUI or 
IVF. At the moment prognostic models are not used to select couples for fertility treatment. 
As evidence from randomised trials underpinning the use of fertility treatments like IUI with 
or without OS and IVF in couples with unexplained or male subfertility is poor, international 
guidelines differ in their recommendations concerning specific treatment strategies. However, 
most guidelines recommend starting with less invasive treatments (without OS) and moving 
on to more aggressive interventions if these are unsuccessful or when the woman is older 
and the duration of subfertility is longer (The Practice Committe of the American Society 
of Reproductive Medicine 2012; NICE 2004; ESHRE 2001). Data from RCTs are contradictory 
and occasionally counterintuitive (Bhattacharya et al. 2008; Goverde et al. 2000; Guzick et 
al. 1999; Hughes et al. 2004; Reindollar et al. 2010; Soliman et al. 1993a; Steures et al. 2006). 
A possible explanation for this may be the inclusion of couples with varying prognostic 
profiles as evident from wide ranges in female age and duration of subfertility. As a result, 
the prognosis of the included couples could be quite heterogeneous with respect to their 
chances of natural conception. 
To test our hypothesis, we performed an individual-patient data analysis of published RCT’s, 
and evaluated whether couples’ prognosis of natural conception attenuated or strengthened 
the impact of assisted reproduction. Authors of published randomised trials comparing 
expectant management (EM), intracervical insemination (ICI), intra-uterine insemination 
(IUI), all three with or without ovarian stimulation (OS) and in vitro fertilisation (IVF), in 
couples with unexplained or male subfertility were contacted and invited to share their 
original data. In all datasets, we calculated the chances of natural conception for each couple 
with the validated prognostic Hunault model. We then constructed prognosis-by-treatment 
curves and tested whether the effect of prognosis on treatment outcome differed between 
the treatment strategies compared in the trials. 
16
Chapter 1
ouTlInE oF THE THEsIs
The adherence to tailored expectant management (TEM) is evaluated in a large cohort study 
(n=1130) in chapter 2. In this chapter we also assess factors associated with non-adherence 
to TEM using multivariable logistic regression.
To make an inventory of patients’ and professionals’ barriers and facilitators of TEM we 
performed a qualitative study among both patients and professionals (chapter 3). Semi-
structured in-depth interviews were performed in 21 subfertile couples counseled for TEM 
and in 21 professionals. 
In a nationwide survey, we assess the prevalence of those barriers and facilitators of TEM 
among 96 subfertile couples and 117 professionals. Multivariate analysis was performed to 
evaluate which factors predicted patients’ appreciation of TEM and professionals’ adherence 
to TEM (chapter 4).
The contents of chapters 2, 3 and 4 are used to develop an implementation strategy to 
implement TEM. In chapter 5 a study protocol of a cluster randomized trial in which the 
(cost-) effectiveness of this implementation strategy can be tested, is described. 
In most countries, there are limitations in public health funding for ART because of costs. 
Different countries have different ways to select subfertile couples for fertility treatment, 
not all evidence-based. To emphasize the importance of evidence based treatment selection 
for subfertile couples, we compared a selection strategy based on prognosis with a funding 
based selection strategy used in New Zealand (chapter 6).
In chapters 7 and 8 we evaluate if the chances of natural conception calculated with a 
validated prognostic model, could help in selecting the best treatment (IUI with or without 
OS, IVF) for couples with unexplained or mild male subfertility. We collected data of published 
RCTs comparing IUI with or without OS, IVF or EM in couples with unexplained or male 
subfertility and calculated their prognosis of natural conception. Subsequently, we analyse 
if this calculated prognosis could help to select the most effective treatment strategy for the 
individual couple.
 
Finally in the general discussion, the results presented in the abovementioned chapters are 
evaluated. The future implications for clinical practice and research are discussed (chapter 
9).
In chapter 10 we summarize the results of the studies presented in this thesis in both English 
and Dutch. 
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Introduction
prediction models for spontaneous pregnancy are useful tools to prevent overtreatment, 
complications and costs in subfertile couples with a good prognosis. The use of such models 
and subsequent expectant management in couples with a good prognosis are recommended 
in the Dutch fertility guidelines, but not fully implemented. In this study, we asses risk 
factors for non-adherence to tailored expectant management.
Methods 
Couples with mild male, unexplained and cervical subfertility were included in this 
multicenter prospective cohort study. If the probability of spontaneous pregnancy within 12 
months was ≥40%, expectant management for 6 to 12 months was advised. Multivariable 
logistic regression was used to identify patient and clinical characteristics associated with 
non-adherence to tailored expectant management.
Results 
we included 3,021 couples of whom 1,130 (38%) had a ≥40% probability of a spontaneous 
pregnancy. Follow-up was available for 1,020 (90%) couples of whom 214 (21%) had started 
treatment between 6 and 12 months and 153 (15%) within 6 months. A higher female age 
and a longer duration of subfertility were associated with treatment within 6 months (OR 
1.06; 95% CI 1.01 to 1.1, OR 1.4; 95% CI 1.1 to 1.8).A fertility doctor in a clinical team reduced 
the risk of treatment within 6 months (OR 0.62; 95% CI 0.39 to 0.99).
Conclusion 
in couples with a favorable prognosis for spontaneous pregnancy, there is considerable 
overtreatment, especially if the woman is older and duration of the subfertility is longer. The 
presence of a fertility doctor in a clinic may prevent early treatment.
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InTRoduCTIon
In 50% of subfertile couples no major cause of the unfulfilled child wish is found (Aboulghar 
M et al. 2009). In these couples, the chances of a spontaneous pregnancy can be calculated 
with validated prediction models (Hunault et al. 2004; van der Steeg et al. 2007a). If chances 
on spontaneous pregnancy are 30% or higher, treatment offers no genuine benefit and 
expectant management is preferable (Steures et al. 2006). Tailored expectant management 
- expectant management for 6 to 12 months in couples with a good prognosis - prevents 
unnecessary early treatment and its complications, such as multiple pregnancies, and costs. 
For this reason tailored expectant management is recommended in the Dutch Fertility 
Guidelines. 
Nevertheless, the use of prognostic models and subsequent expectant management is not 
fully applied in clinical practice. In a study on the quality of Dutch fertility care, the initial 
fertility assessment resulted in only 23% of the cases in both a diagnosis and a prognosis 
(Mourad et al. 2008). On the other hand, the number of ART cycles performed in Europe 
has more than doubled  in the period 1997-2006 (de Mouzon et al. 2010). Implementation 
of prognostic models and subsequent tailored expectant management may slow down this 
increase without reducing pregnancy rates.
A better understanding of the factors associated with non-adherence may prevent early 
treatment and can improve the implementation of tailored expectant management. The aim 
of this study was to identify patient and clinical characteristics associated with an early start 
of fertility treatment in couples with a good prognosis. 
 
Material and Methods
Between January 2002 and February 2004, 5,214 consecutive couples presenting at 38 
hospitals in The Netherlands were invited to participate in a prospective cohort study. The 
Institutional Review Board of the Academic Medical Centre in Amsterdam approved the 
protocol. The board of directors of all participating hospitals gave local approval to the study. 
The study protocol was discussed with the gynaecologists of all participating hospitals, after 
which they agreed to participate. All couples underwent a basic fertility work-up according 
to the guidelines of the Dutch Society of Obstetrics and Gynecology. The details of this work-
up have been described in detail previously (van der Steeg et al. 2007b).
Couples with bilateral tubal pathology, severe male factor, or anovulation were excluded 
from this study. The probability of a spontaneous pregnancy was calculated using the 
prognostic model of Hunault (Hunault et al. 2004; www.amc.nl/prognosticmodel 2010). 
Couples with a probability of natural conception <40% were invited to participate in various 
randomised controlled trials, depending on their diagnosis (Steures et al. 2006; Steures et 
al. 2007a; Steures et al. 2007b) or were counseled for treatment according to the Dutch 
fertility guidelines. Couples with a probability of natural conception of 40% or higher were 
recommended tailored expectant management for 6 to 12 months. Physicians were free to 
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start treatment at any time. Follow-up started at the completion of the fertility work-up and 
ended after 12 months. Primary outcomes were patient and clinical characteristics associated 
with non-adherence to tailored expectant management. 
Including data of 1000 couples in the logistic regression analysis, and analyzing a binary 
feature, we would have 80% power at a 0.05 significance level to detect odds ratios for non-
adherence of 1.4 or higher, assuming a 50% prevalence and a baseline probability of 0.36. 
At a 20% prevalence, statistically significant odds ratios of 1.6 or higher could be detected 
(Hsieh et al. 1998)
Analysis
In this analysis, we included couples with a calculated probability of natural conception 
of 40% or higher. We focused on patient and clinical characteristics associated with non-
adherence to tailored expectant management.  Non-adherence was defined as treatment 
within 6 months of couples with calculated probability of natural conception of 40% or 
higher. 
A Kaplan-Meier curve was plotted to illustrate the cumulative fraction of couples with a 
good prognosis who started treatment over time. Multivariable logistic regression was used 
to identify patient and clinical characteristics that were associated with non-adherence to 
expectant management in patients with a good prognosis. Associations between patient and 
clinical characteristics and non-adherence were expressed as odds ratios and corresponding 
95% confidence intervals. 
We evaluated the patient characteristics female age, duration of subfertility, previous live 
birth or miscarriage, and socio-economic status. Socio-economic status was obtained from 
the Dutch Institute for Social Research/SCP based on the mean income level in a postal code 
area, the percentages inhabitants without a paid job and the percentage of inhabitants with 
a low education level. In addition, we evaluated a number of characteristics of the clinic: 
presence of a dedicated fertility doctor, presence of a regular fertility meeting, clinic with 
an IVF-ICSI lab or a satellite clinic (satellite clinics can initiate and monitor the stimulation 
phase and refer to another hospital for both oocyte retrieval and embryo transfer). A fertility 
meeting is weekly or monthly meeting with the staff-members were fertility patients are 
discussed. 
Missing data were imputed using ‘aRegImpute’ imputation function on Splus 6.0. This is 
an efficient implementation of Bayesian multiple imputation, a recommended state of the 
art method (Schafer and Graham 2002). More details of this procedure described in detail 
elsewhere (van der Steeg et al. 2006). For the analysis we used SPSS 16.0. (Statistical Package 
for the Social Sciences: SPSS, Chicago, IL, USA).
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Results
During the study-period we registered 5,214 subfertile couples, of whom 3,021 couples had 
normal semen quality, at least one patent tube and an ovulatory cycle. Of these couples, 
1,130 (37%) had a probability of 40% or higher (figure 1). In this group, 110 couples were lost 
to follow-up (10%) and not used in further analyses. 
Imputation was done on all patients who had at most two missing values in the six core 
prognosticators for spontaneous pregnancy, which was the case 4.3% of all data points.   Of 
the 1,020 couples in our analyses, 367 (36%) couples started treatment within 12 months: 
Figure 1. Study ProfileFigure 1. Study profile 
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153 (15%) did so within 6 months and 214 (21%) between 6 and 12 months. Follow up ended 
when treatment was started. Forty-two percent of the couples that did not start treatment, 
had a spontaneous ongoing pregnancy within 12 months (276 couples, 27% of all couples) 
and 377 couples (58% of the couples that did not start treatment, 37% of all couples) had no 
spontaneous ongoing pregnancy and did not start treatment within 12 months. The Kaplan-
Meier curves in Figure 2 show the fraction of couples who started treatment and the fraction 
with an ongoing pregnancy as a function of time after the fertility work-up.  
Figure 2. A Kaplan-Meier Curve of the fraction of couples who started treatment over time in relation to 
the fraction of couples without a spontaneous ongoing pregnancy. Dashed line represents the fraction 
of couples without a spontaneous ongoing pregnancy. Continuous line represents the fraction of 
couples who started with treatment.
Characteristics of patients and clinics of the following four groups are summarized in Table 
1: couples who started treatment within 6 months, couples who started treatment between 
6 and 12 months, the couples with a spontaneous ongoing pregnancy within 12 months and 
the couples without treatment and without an ongoing pregnancy within 12 months. 
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Table 1. Baseline-characteristics of the 1,020 couples with a prognosis ≥40%
Treatment 
within
6 months
n=153 (15%)
Treatment 
between 
6-12 months
n=214 (21%)
Spontaneous 
ongoing 
pregnancy
within 12 
months
n=276 (27%)
No Treatment &
no spontaneous 
ongoing 
pregnancy
within 12 
months
n=377 (37%)
PATIENT CHARACTERISTICS
Mean maternal age in years 
(SD)
31.9 (4.4) 31.2 (3.8) 31.1 (3.7) 30.8 (3.84)
Mean duration of subfertility 
in years (SD)
1.69 (0.77) 1.64 (0.62) 1.49 (0.71) 1.65 (0.70)
History ≥1 live birth with or 
without miscarriages (%)
48 (32%) 62 (29%) 92 (34%) 107 (28%)
History ≥1 miscarriage (%) 27 (18%) 21 (10%) 48 (19%) 42 (11%)
Socio Economic Status (%)
        High
        Median
        Low
23 (15%)
129 (70%)
23 (15%)
40 (18%)
141 (67%)
33 (15%)
47 (17%)
182 (66%)
47 (17%)
65 (17%)
243 (65%)
69 (18%)
CHARACTERISTICS of the 
CLINIC
Fertility meeting (%) 78 (52%) 140 (65%) 168 (62%) 244 (64%)
Fertility doctor (%) 76 (51%) 148 (68%) 162 (60%) 244 (64%)
Clinic with IVF-ICSI license, (%) 21 (14%) 36 (17%) 47 (17%) 80 (21%)
Clinic with Satellite IVF (%) 89 (60%) 116 (55%) 133 (49%) 152 (40%)
The results of the multivariable logistic regression analysis of non-adherence to tailored 
expectant management, using patient and clinic characteristics, are summarized in Table 2. A 
higher female age and a longer duration of subfertility were each associated with treatment 
within 6 months (OR 1.06; 95% CI 1.01 to 1.1 and OR 1.4; 95% CI 1.1 to 1.8, respectively). 
A history of at least one live birth was not associated with early treatment. Couples with 
a history at least one miscarriage were more often treated within 6 months than couples 
without, but this difference did not reach statistical significance (OR: 1.54; 95% CI 0.93 to 
2.6). Socioeconomic status and a regular fertility meeting were not associated with treatment 
within 6 months. The presence of a dedicated fertility doctor in a clinical team reduced the 
chance of starting treatment within 6 months (OR 0.62; 95% CI 0.39 to 0.99). The presence 
of an IVF-ICSI lab was not associated with early treatment, but we observed more frequent 
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early treatment in satellite clinics (OR 1.43; 95% CI 0.89 to 2.3), but this difference was not 
significant. 
Table 2. Factors associated with treatment within 6 months in couples with a good prognosis, logistic 
regression
Treatment within 6 months
n=153 (15%)
PATIENT CHARACTERISTICS OR 95% CI
Mean maternal age (per year older) 1.06 1.01 to 1.1
Mean duration of subfertility (per year longer) 1.37 1.1  to 1.8
History ≥1 live birth with or without miscarriages (%) 0.99 0.65 to 1.5
History ≥1 miscarriage (%) 1.54 0.93 to 2.6
Socio Economic Status (%)            
High
Low
0.88
0.99
0.53 to 1.5
0.59 to 1.6
CLINICAL CHARACTERISTICS
Fertility meeting (yes) 0.84 0.52 to 1.36
Fertility doctor (yes) 0.62 0.39  to 0.99
Clinic with IVF-ICSI license (yes) 0.89 0.47 to 1.7
Clinic with Satellite IVF (yes) 1.43 0.89 to 2.3
dIsCussIon 
In this study we found that in one out of three couples with a good prognosis for spontaneous 
pregnancy, treatment was started within 12 months, and in one out of seven even within 6 
months. Higher female age and a longer duration of subfertility were significantly associated 
with treatment within 6 months. The presence of a dedicated fertility doctor in a clinical 
team reduced the risk of early treatment within 6 months. 
It is remarkable that female age and duration of subfertility were risk factors for early 
treatment in couples with a good prognosis because they are already main prognostic 
factors in the model of Hunault. So the clinician accounts for these factors when calculating 
the prognosis and when the prognosis is good the clinician uses the same factors again to 
refrain from expectant management. We hypothesize that this clinically important paradox 
transpires from other patients and physician-related factors. Physicians describe a lack of 
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confidence in their ability to convince patients about low success rates of intra-uterine 
insemination and the risk of multiple pregnancies (Haagen et al. 2005). In subfertile couples, 
there is a high sense of urgency leading to pressure for treatment, which can increase with 
age and duration of subfertility. In couples with unexplained miscarriages for whom no 
effective treatment is available, there is an instinctive drive to ‘do something’ from both 
patients and doctors (Rai and Regan 2006; Kaandorp et al. 2010).
A strength of this study is the large number of couples included in the cohort, which was 
prospectively assembled in a multicentre setting. A potential weakness of this study is that 
we measured the adherence to a study protocol instead of the adherence to an (inter)national 
guideline. As the recruiting doctors in this cohort will be more dedicated compared to an 
‘average doctor’, we hypothesize that early treatment in daily practice must be even higher, 
as has been demonstrated previously (Mourad et al. 2008).
In our study 36% of the couples had a good prognosis and were eligible for expectant 
management. This fraction is in concordance with a longitudinal cohort study, performed 
between 2002 and 2006 in the Netherlands. In this cohort of newly referred subfertile 
couples, 45% of the 1,391 couples were eligible for tailored expectant management (Brandes 
et al. 2010). In contrast, the contribution of IVF in couples with ‘unexplained subfertility’ 
and ‘ovulation disorders’ was extremely limited (ongoing pregnancy rates of 13 and 4.5%, 
respectively) compared to patients with ‘tubal factor’, ‘endometriosis’ and ‘male factor’ in 
whom pregnancy rates were 45, 45 and 37%, respectively. Steptoe and Edwards introduced 
IVF to bypass tubal blockage and apparently, IVF is still only effective for the indications for 
which it was invented, i.e. fertilisation failure due to the inability of the male and female 
gametes to meet or the inability of the spermatozoa to penetrate the egg.  
Early treatment is a common phenomenon in fertility care. For example, the increasing use 
of preimplantation genetic screening (PGS) has been debated widely, even though there is 
no evidence of increased live births after PGS (Mastenbroek et al. 2008a; Mastenbroek et al. 
2008b; Twisk et al. 2008). Apart from harm, costs and complications, early treatment is also 
to be avoided because of its negative impact on the patients’ physical and psychological well 
being (Cousineau and Domar 2007; Kallen et al. 2005). 
In conclusion, this study shows that advanced female age, longer duration of subfertility, a 
history of at least one miscarriage and work up in a satellite clinic were associated with early 
treatment in couples with a good prognosis. An increased awareness of these factors may 
help to prevent overtreatment, contributing to the development of a strategy to implement 
tailored expectant management. Before this implementation strategy can be developed, we 
recommend performing a qualitative study among patients and professionals to evaluate the 
barriers and facilitators of tailored expectant management. 
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Background 
European guidelines on fertility care emphasize that subfertile couples should receive 
information about their chances of a natural conception and should not be exposed to 
unnecessary treatments and risks. Prognostic models can help to estimate their chances and 
select couples with a good prognosis for tailored expectant management (TEM). Nevertheless, 
TEM is not always practiced. The aim of this study was to identify any barriers or facilitators 
for TEM among professionals and subfertile couples.
Methods 
A qualitative study was performed with semi-structured in-depth interviews of 21 subfertile 
patients who were counselled for TEM and three focus-group interviews of 21 professionals in 
the field of reproductive medicine. Two theoretical models were used to guide the interviews 
and the analyses. The primary outcome was the set of identified barriers and facilitators 
which influence implementation of TEM.
Results 
Among the subfertile couples, main barriers were a lack of confidence in natural conception, 
a perception that expectant management is a waste of time, inappropriate expectations 
prior to the first consultation, misunderstanding the reason for expectant management and 
overestimation of the success rates of treatment. Both couples and professionals saw the 
lack of patient information materials as a barrier. Among professionals, limited knowledge 
about prognostic models leading to a decision in favour of treatment was recognized as a 
main barrier. A main facilitator mentioned by the professionals was better management of 
patients’ expectations.
Conclusions 
We identified several barriers and facilitators which can be addressed to improve the 
implementation of TEM. These should be taken into account when designing future 
implementation strategies.
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InTRoduCTIon
Approximately 9% of all couples of reproductive age fail to conceive after 12 months of 
unprotected intercourse (Boivin et al. 2007; Gnoth et al. 2003). When they subsequently 
undergo a fertility work up, no major cause can be found in half of them (Aboulghar M et al. 
2009).  Previous studies have shown that many of these couples can still conceive without 
treatment (Brandes et al., 2010;Collins, 2004;Evers et al., 1998;Pinborg et al., 2009;Steures 
et al., 2006). It is therefore crucial to be aware of the prognosis in these couples so we can 
discriminate between those who would benefit from active treatment from those who are 
likely to conceive naturally (Brandes et al. 2011). 
The chances of a spontaneous pregnancy can be calculated with the help of validated 
prediction models (Hunault et al. 2004; van der Steeg et al. 2007a). When the calculated 
prognosis to conceive within 12 months is ≥30%, tailored expectant management (TEM) is as 
effective as treatment, which makes TEM a cost effective strategy that prevents overtreatment, 
complications and costs (Steures et al. 2006). Therefore, expectant management is in the 
Dutch fertility guidelines recommended for couples with a ≥30% chance to conceive within 
12 months (NVOG 2004). In agreement with this, both the  European Society of Human 
Reproduction and Embryology (ESHRE) guidelines and the guidelines of the National Institute 
of Clinical Excellence (NICE) emphasize that couples should not be exposed to unnecessary 
risks or ineffective treatments and encourage that each couple should receive information 
about the estimate of their chances of natural conception (ESHRE 2001; NICE 2004).
Despite this, the number of Assisted Reproductive Therapy (ART) cycles performed in 
Europe has more than doubled in the period 1996 to 2006 (Andersen et al. 2009). This 
development is disconcerting for several reasons. First, this increase is likely to lead to a 
high number of multiple pregnancies. Even though multiple pregnancy rates per ART cycle 
are decreasing, the risks are still substantially higher than those in spontaneous conceptions. 
Multiple pregnancies are associated with a higher morbidity and mortality in both mothers 
and neonates (Helmerhorst et al. 2004). Second, ART carries a significant physical and a 
psychological burden (Verberg et al., 2008;Verhaak et al., 2002;Verhaak et al., 2007). Third, 
ART is expensive and puts considerable financial strain on societies where ART is reimbursed 
or on the couples in societies where ART is not or only partially reimbursed. 
For all these reasons, it is important to treat couples who genuinely need ART and are likely 
to benefit from it. Prognostic models, such as the prognostic model of Hunault, can help to 
select those couples. Nevertheless, these models and subsequent TEM are not fully applied 
in clinical practice (Mourad et al., 2008;van den Boogaard et al., 2011).  A clear understanding 
of why the prognostic models and subsequent tailored expectant management are not 
used in practice is lacking. Therefore, the aim of this study was to identify patients’ and 
professionals’ barriers and facilitators for the implementation of TEM. 
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Materials and Methods
A qualitative study was performed with subfertile couples and professionals working within 
the field of reproductive medicine. We performed semi structured in depth interviews among 
subfertile couples and professionals in an individual and group-setting, respectively. We 
opted for semi-structured interviews to let the participants (i.e. patients and professionals) 
talk freely with structured guidance from the interviewer, using a topic list. The topic list 
(appendix 1) was based on the literature and knowledge and experiences of experts in the 
fields of reproductive medicine, qualitative research or implementation research, all co-
authors of this article. The topic list was adapted when new barriers or facilitators were 
identified. Prior to the start of the interviews, confidentiality was assured and the process 
of the interview was explained. We continued interviewing until data saturation was 
achieved, i.e. no additional information was gathered during subsequent interviews. The 
interviews were audio taped and fully transcribed and quotes were all made anonymous. The 
primary outcome was the set of identified barriers and facilitators which might influence the 
implementation of TEM. 
The subfertile couples whom we interviewed were diagnosed with unexplained subfertility 
and had a chance to conceive within 12 months of ≥30%. For that reason they had been 
counselled for TEM. We interviewed couples that had been advised TEM between April 2008 
and April 2009. The couples were recruited from two hospitals in Amsterdam: one academic 
hospital and one non-academic teaching hospital. We chose for an individual setting while 
we expected in this setting patients would feel more freely to speak. For the same reason 
we preferred to interview the woman men and women separately. We purposively sampled 
couples with different ethnic backgrounds and education levels because we hypothesized 
these characteristics could influence their experience of the expectant management. The 
couple could choose the location of the interview which was conducted either at their 
hospital or at their own home. We preferred to interview the man and the woman separately, 
unless the couple preferred to be interviewed together. We performed 15 interviews with 
21 patients. Six women and three men were interviewed individually and six couples were 
interviewed together. The interviews were performed by two researchers (N.B. and A.B.) and 
took 30-50 minutes. 
We also interviewed 21 professionals in 3 focus-group interviews. Gynaecologist specialized 
in Reproductive Medicine and registered as such at the Dutch Society of Obstetrics 
and Gynaecology (NVOG) and gynaecologists with interest in the field of reproductive 
endocrinology and infertility and fertility doctors, from 17 different hospitals from 4 different 
regions were all invited per mail. In total we invited 53 professionals: 3 gynaecologists and 
7 fertility doctors from an academic hospital, 27 gynaecologists and 16 fertility doctors from 
non academic hospitals. Gynaecologists and fertility doctors of 10 different academic and 
non academic hospitals from 4 different provinces in the Netherlands participated voluntary. 
In the Netherlands fertility doctors are basic doctors working in the fertility care, while 
most gynaecologists also work in the field of obstetrics and general gynaecology. Prior to 
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the interviews, it was unclear to what extent the professionals used the prognostic models 
and subsequent TEM. The group setting was chosen because we expected that the group 
interaction might lead to the identification of more relevant barriers. The focus-group 
interviews were guided by a chairman (E.B.) and another researcher (N.B.) attended as a back 
up. The focus- group interviews took 60-90 minutes.
setting
In the Netherlands intra uterine insemination (IUI) is performed in 91 of the country’s 101 
hospitals and IVF is performed in 13 licensed hospitals. All 101 hospitals can perform a 
fertility work up and advice on TEM. The costs of IUI (for an undefined number of cycles) 
and the first three fresh In Vitro Fertilisation (IVF) or Intra Cytoplasmatic Sperm Injection 
ICSI cycles are currently reimbursed by medical insurance companies. In the Netherlands it 
is compulsory to have a medical insurance. Professionals have access to prognostic models 
via 2 websites (www.amc.nl/prognosticmodel and www.freya.nl), with the help of electronic 
patient files or with the use of paper versions of the models.
Analysis
All interview transcripts were independently analysed by two researchers: the interviews 
with the subfertile couples by A.B. and N.B. and the focus-group interviews with the 
professionals by E.B. and N.B. MAXqda10, an analysis program for qualitative data-analysis, 
was used for the analysis which was based on the strategy described by Boeije et al. (Boeije 
2010). The aim of the analysis was to conceptualize the content of the interviews in structured 
categories. First, the interviews were analysed by means of line by line coding, using a 
constant comparison method: newly gathered data are continually compared with previously 
collected data and their coding in order to refine the development of theoretical categories. 
After this open coding, the codes were rearranged by axial coding and finally categorised by 
means of selective coding. Axial coding is relating codes to each other and selective coding is 
the process of choosing one category to be the core category, and relating all other categories 
to that category. Finally, all transcripts were reread and recoded, using the improved coding 
structure to ensure no codes were missing. To ensure consistency, codes were compared and 
any discrepancies were resolved by discussion between the two researchers. Differences of 
opinions were discussed with a third researcher (MZ for the patient interviews and WN for 
the focus-group interviews).
We used two theoretical models to group our findings within four domains: characteristics 
of the intervention itself (TEM), of the professional, of the patient and of the context (Cabana 
et al. 1999; Peters et al. 2003). 
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Results
Patient characteristics, summarized in Table I show a degree of variety in terms of educational 
and cultural backgrounds. Characteristics of the professionals are listed in Table II which 
shows the variation in experience and use of the prognostic model between gynaecologists 
(50%) and fertility doctors (100%).     
Factors (barriers and facilitators) mentioned by at least two participants are listed in Table III 
(subfertile couples) and Table IV (professionals). Factors mentioned by more than 50% of the 
participants are described in the text and marked in the tables with an asterisk (*).In both 
the tables and the text, the barriers and facilitators are ranked by the frequency in which 
they are mentioned. Quotes illustrating some of the barriers and facilitators are provided in 
Appendix 2, Table 1. 
Barriers and facilitators related to the implementation of TEM 
according to subfertile couples
There were 16 barriers and facilitators were identified among the 15 subfertile couples, i.e. 
21 patients (Table III). Three men did not participate because they had no time or did not 
remember the details and referred us to their partners, who were more involved. Overall 
women were more committed and informed about the whole procedure than men. At the 
time of the interview, two couples were pregnant and three couples had started treatment 
of intrauterine insemination with controlled ovarian hyperstimulation. The other nine 
interviewed couples were still in the period of expectant management.
Domain 1, characteristics of the intervention 
A lack of confidence in natural conception and a perception that expectant management is 
a waste of time were barriers in this domain. These two factors had a common underlying 
cause in that they were based on the perception of the couples that they had already been 
trying to conceive for a long period. 
The subfertile couples could not remember the information that had been given concerning 
their prognosis and the reason for expectant management. Therefore, information provision 
by means of a brochure or a website about the prognostic model and subsequent expectant 
management was mentioned as a facilitator.   
Domain 2, characteristics of the professional
Not informing the couple about the option of TEM during the first consultation was 
mentioned as a barrier in this domain. Couples expected treatment after the fertility work 
up unless they were already told beforehand that TEM was an option. 
Domain 3, characteristics of the patient
Barriers mentioned in domain 3 were: inappropriate expectations prior to the first 
consultation, misunderstanding the reason for TEM, overestimation of success rates of 
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treatment, inability to comprehend and retain the information given during the consult and 
irrational interpretations of pregnancy chances. The last i.e. ‘Irrational interpretations of 
chances’ refers to the finding that despite awareness of their prognosis and understanding 
why it was better to wait, couples still wanted treatment. Couples saw treatment as a forgone 
conclusion after the fertility work up, did not understand why expectant management was 
advised and had unrealistic high expectations of treatment outcomes. 
Domain 4, characteristics of the context
The length of time taken for the whole process was mentioned as a barrier: the period 
prior to the couples’ hospital visit plus the subsequent time needed for the fertility work-
up already took ‘too long’ such that tailored expectant management was seen as another 
delaying factor. 
Barriers and facilitators related to the implementation of TEM 
according to professionals 
Among the 21 professionals, 20 barriers and facilitators influencing the implementation 
of TEM were identified (Table IV). There was a wide range of knowledge and attitudes 
concerning prognostic models and subsequent TEM. For some professionals it made sense 
to use a prognostic model to plan TEM, but others had less faith in the TEM strategy and did 
not use it in their clinic on a regular basis. 
Domain 1, characteristics of the intervention 
Two barriers were identified in this domain: existing prognostic models do not include all 
the relevant predictors and a lack of appropriate patient information materials. The missing 
predictors within prognostic models mentioned by professionals were mainly lifestyle factors 
such as body mass index and frequency of coitus. To overcome the barrier ‘lack of adequate 
patient information materials’ the professionals suggested the development of a brochure 
and/or the introduction of a website.
Domain 2, characteristics of the professional 
Limited knowledge about the prognostic models and subsequent TEM, - difficulties in 
convincing the couple who have their minds made up and - difficulties in counselling 
and communicating pregnancy chances, were barriers in the second domain. There was 
consensus that good counselling skills were very important to be able to communicate to 
the patient that TEM was their best treatment option at that moment. 
A facilitator in this domain was the comparison between the spontaneous chances of a 
pregnancy with the realistic pregnancy chances after treatment. Professionals mentioned 
that many couples have unrealistically high expectations of treatment, which make it 
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difficult for the professional to convince them that TEM is the best option. In this way, the 
comparison helped in counselling the couples for TEM.  
Domain 3, characteristics of the patient
The couples’ high expectations of treatment, - urgency for action, - expecting immediate 
treatment after the fertility work up and the couples’ misreading of chances were barriers in 
this domain. According to professionals, couples had too high expectations of treatment and 
the couples’ urgency for action made it difficult to counsel them for TEM. Managing couples’ 
expectations regarding treatment success and moment of treatment were mentioned as a 
major facilitator. 
Domain 4, characteristics of the context
A regular fertility meeting involving other professionals, a clinical protocol based on local 
consensus, and centralisation of fertility care were facilitators mentioned in this domain. 
A fertility meeting is a weekly or monthly meeting, during which all fertility patients who 
have finished their basic fertility workup are discussed. 
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Table I. Patient characteristics
* Primary school or less, ** High school, *** University/post graduate 
**** The place of birth of the patient or both parents is outside the Netherlands, excluding its dominions. 
Characteristics Value n (%)
Gender 
- Female
- Male
12 (57%)
 9  (43%)
Age (median)
  Female (range)
  Male (range)
32 (21-37)
35 (27-43)
Diagnosis 
  Unexplained primary subfertility
  Unexplained secondary subfertility
9 (43%)
12 (57%)
Prognosis (median, range) 36% (33% - 57%)
Duration subfertility (months)
(median, range)
22 (18-48)
Education level 
  Low*
  Medium**
  High***
4   (19%)
6   (29%)
11 (52%) 
Ethnic background 
Dutch  
Non Dutch****   
- Turkish 
- Moroccan
- Afghan
- Colombian
- Unknown
 
12 (57%) 
  9 (43%)
  2
  3
  1
  2
  1
Table II. Characteristics of professionals
 
Gynaecologists
N = 9
Fertility doctors
N = 13
Male, n (%) 3 (33%) 3 (23%)
Female, n (%) 6 (67%) 10 (77%)
Median age, (range) 48 (41-64) 34 (27-45)
Median years of expertise (range) 17 (8-35) 6 (1-13)
Academic hospital n(%) 1 (11) 5 (38)
Regular use of the prognostic model n (%) 4 (50) 13(100)
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Table III. Barriers (b) and facilitators (f) of tailored expectant management (TEM) according the subfertile 
couples
* Factors mentioned by more than 50% of the participants
Domain 1
Characteristics of the 
intervention
Domain 2
Characteristics of the 
professional
Domain 3
Characteristics of the 
patient
Domain 4
Characteristics of the 
context
Lack of confidence 
in the natural 
conception (b) *
Not informing the 
couple about the 
option of TEM during 
the first consultation 
(b) *
Inappropriate 
expectations prior to 
the   first consult (b) *
The length of time 
taken for the whole 
process (b) *
Patient information 
material about 
prognosis and TEM 
(f) *
Unclear way of 
counselling and 
communicating 
chances (b)
Misunderstandings 
the reason for TEM 
(b) *
Practice in other 
clinics (b)
A perception that 
TEM is considered as 
a waste of time (b) *
Not explicitly 
mentioning TEM,  
but conceal TEM in 
waiting period for 
treatment (f)
Overestimation of 
the success rates of 
treatment (b)  *
Complexity of the 
prognostic model (b)
Inability to 
comprehend and 
retain information 
given during the 
consult (b) *
Irrational 
interpretation of 
pregnancy chances 
(b) *
Progressing female 
age (b)
Twin is a welcome 
complication (b)
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Table IV. Barriers (b) and facilitators (f) of tailored expectant management according professionals 
* Factors mentioned by more than 50% of the participants
Domain 1
Characteristics of the 
intervention
Domain 2
Characteristics of the 
professional
Domain 3
Characteristics of the 
patient
Domain 4
Characteristics of the 
context
Existing prognostic 
models do not include 
all the relevant 
predictors (b) *
Limited knowledge 
about the prognostic 
models and 
subsequent TEM (b) *
High expectations 
of success with 
treatment (b)  *
A regular Fertility 
meeting (f) *
Lack of adequate 
patient information         
materials (b) *
Difficulties convincing 
couples who have 
their minds made up 
(b) *
Urgency for action in 
the couple (b) *
Local protocol (f)  *
Not convinced about 
the usefulness of the 
prognostic models 
and TEM (b)
Difficulties in 
counselling and 
communicating 
chances (b) *
Expectations of 
immediate treatment 
after the fertility 
work up  (b)*
Local consensus (f)  *
Explaining TEM takes 
time (b)
Comparison of 
treatment chances 
versus  spontaneous 
pregnancy chances 
(f)  *
Couples’ 
misinterpretation of 
chances (b) *
Centralisation of 
fertility care (f) *
Close relationship 
with couple (b)
Progressing female 
age (b)
Regional organisation 
(f)
Miscarriage 
population (b)
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dIsCussIon 
We identified a wide variety of barriers and facilitators influencing the implementation of 
tailored expectant management for unexplained subfertility. Among the subfertile couples 
the main barriers were: I) lack of confidence in natural conception, II) inappropriate 
expectations at the first consultation, III) misunderstanding the reason for the expectant 
management, and IV) overestimation of the chances of success with treatment. Both couples 
and professionals experienced the lack of patient information materials as a barrier. Among 
the professionals limited knowledge about prognostic models and subsequent tailored 
expectant management and inappropriate expectations of couples were recognised as main 
barriers. Better management of couples’ expectations was suggested as a main facilitator.  
Many barriers involved patients, which is in line with results of existing studies on barriers for 
implementation within the scope of fertility health care (Haagen et al. 2005; van Peperstraten 
et al. 2008b). The professional’ barriers concerning the difficulties counselling, convincing 
and communicating with the couple can be summarised as a lack of self-efficacy, which is a 
common barrier in guideline adherence (Cabana et al. 1999; Haagen et al. 2005; Lugtenberg 
et al. 2009). The barriers concerning misunderstanding of prognosis, inappropriate 
expectations and lack of patient information materials all have to do with communication and 
information provision. Previous research among 1,499 Dutch subfertile couples who fulfilled 
a questionnaire concerning their experiences with fertility care also found that information 
provision is poor and in need for improvement (Mourad et al. 2009; Mourad et al. 2010). Also 
in other countries, couples often express a need for more written information about fertility 
treatment (Schmidt 1998; Souter et al. 1998). The subfertile couples’ preference for treatment 
compared to expectant management is consistent with the findings of several other studies, 
including a three arm randomised controlled trial in which women treated actively with 
intra uterine insemination or clomifene citrate, found the process of treatment more 
acceptable than those randomised to expectant management (Bhattacharya et al. 2008). In 
a questionnaire study where coping strategies of couples presenting for IVF were evaluated, 
taking direct action was the coping strategy most frequently used (Edelmann et al. 1994). A 
preference study evaluating patients’ preference between intra uterine insemination with or 
without controlled ovarian hyperstimulation and expectant management, couples preferred 
treatment when the treatment independent pregnancy chances in the next 12 months were 
lower than 50% and 40%, respectively (Steures et al. 2005). 
Only half of the gynaecologists, but all of the fertility doctors interviewed in this study 
reported using a prognostic model to recommend subsequent tailored expectant 
management on a regular basis. This corresponds with a previous study about risk factors for 
overtreatment, in which the non-adherence to TEM was 40% and the presence of a fertility 
doctor was associated with an increase of this adherence (van den Boogaard et al. 2010). This 
variation in adherence to TEM in the interviewed professionals as well as the heterogeneity 
of the cultural background and educational level of the interviewed patients leaded to the 
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identification of a wide variety of barriers and facilitators and is there for a stronghold of 
our study. 
In our study, both the subfertile couples and the professionals mentioned difficulties in 
interpreting and communicating chances of success. From previous research we know that 
the perception of chances is influenced by the way chances are framed. In this respect a 
comparison with a baseline-risk and the use of visual tools can help to communicate chances 
in a more user friendly manner. (Edwards and Prior 1997; Grimes and Snively 1999; Shiloh 
S and Saxe L 1989; Wertz et al. 1986). Regarding the chances on a natural conception in our 
study, no defined ‘baseline prognosis’ is available yet and the professionals in this study 
did not use visual tools to facilitate the communication of the prognosis. So, here is an 
opportunity for improvement. 
Among the subfertile couples, women were generally more committed and informed than 
men. This gender difference is in concordance with other studies where were couples asked 
about their expectations and motivation for seeking fertility treatment. In most cases the 
woman sought treatment for herself and her partner and the man more for his partner than 
for himself (Schmidt et al. 2003). 
We realise there are some limitations in this study that should be considered. First, all 
interviewed couples were recruited from only two hospitals both in the region of Amsterdam. 
The barriers and facilitators could be biased by the way fertility care was provided in those 
two hospitals. However, the two hospitals are large training hospitals, one academic and one 
non academic hospital, working according the guidelines and we do not expect the provided 
fertility care differs much from other hospitals. Couples living in rural areas might have a 
different view on tailored expectant management compared to patients from an urban area. 
Nevertheless we think patients’ origin has limited influence on the experienced barriers 
and facilitators because in such a densely inhabited country as the Netherlands differences 
between urbanised and non urbanised areas are small and with the current use of internet 
and social media, patients from the ‘non urbanised’ areas are able to be as informed and up 
to date as patients from the “non- urbanised areas”. Moreover, further quantification of the 
barriers and facilitators is needed among patients from more hospitals. Second, a limitation 
of this study might be the Dutch setting. Dutch patients and professionals may have different 
opinions about the use of prognostic models and subsequent tailored expectant management 
than patients and professionals in other countries. However, the barriers and facilitators we 
found were not specifically related to the Dutch setting. We therefore consider the identified 
barriers applicable for an international setting, if the reimbursement system is comparable. 
Third, the participation rate of the professionals (21 out of 54) was low, possibly because 
the participation was voluntarily. Because we continued interviewing until data saturation 
was achieved, we do not think this response influences the set of identified barriers and 
facilitators. Fourth, a potential limitation of qualitative research is the introduction of 
bias by different interpretations of the transcripts. Therefore, two individual researchers 
examined all transcripts and differences of opinions were discussed with a third researcher. 
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Discrepancies were discussed until agreement was reached. Finally, although we aimed to 
interview men and women separately, we interviewed half of the couples together at their 
request. Nevertheless, we did not find different results in couples interviewed together 
compared to couples interviewed separately. We also did not get the impression during the 
interviews that one of the interviewees was unable to speak freely because of the presence 
of the other partner. 
As stated above, to measure the impact of the barriers and facilitators found in this study a 
further quantification of these results is needed. After quantification of these barriers and 
facilitators an implementation strategy can be developed. Based on the results of this study, 
this strategy needs to focus on better management of couples’ expectations, education of 
the professionals about prognostic models and subsequent tailored expectant management, 
training professionals to communicate about tailored expectant management and offering 
adequate patient information materials. 
In summary, this study gives insight into the barriers and facilitators of the use of prognostic 
models and subsequent tailored expectant management. Knowledge of these factors may 
help to improve implementation of tailored expectant management in clinical practice and 
reduce potentially harmful and costly overtreatment. 
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APPEndIx 1: ToPIC-lIsTs 
Focus group interviews with professionals 
Current practice concerning prognostic model and expectant management
Professional opinion concerning prognostic model and expectant management
Experienced barriers concerning the prognostic model and expectant  
management:
- No knowledge about the model
- Model not available
- No consensus with the model or subsequent expectant management
- Difficult to counsel the couple, while the couple wants treatment
- Treatment means more income 
Possibilities to stimulate the prognostic model and tailored expectant 
management:
- Fertility meeting
- Protocol with the prognostic model
- Local consensus
- Electronic patient file with application concerning prognostic model 
Topic-list interviews with subfertile couples 
Expectations before the first consult: fertility work up & treatment
First consult: 
- Change of expectations 
- Option expectant management discussed?
Influence of the environment: 
- Couples with children 
- Emotional support
First reaction on expectant management: 
- Rational and emotional
- Faith in spontaneous conception
- (Dis)advantages treatment; OHSS, Multiple pregnancy, Physical and psychological burden
- Need for more information?
- Need for more coaching/support in the expectant management period.
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APPEndIx 2, TABlE 1: quoTEs IllusTRATIng THE IdEnTIFIEd 
BARRIERs And FACIlITAToRs 
Barrier/facilitator Quote
PATIENTS
Domain 1: 
Characteristics of 
the intervention
Lack of confidence in the 
natural conception
“At that moment, that they sent us home to try it 
again ourselves I really thought: but we are already 
trying for such a long time, why would we succeed 
now? We did not come to the hospital to be sent 
home!”
Domain 2: 
Characteristics of 
the professional 
Not informing the 
couple about the option 
of TEM during the first 
consultation
“If we would have known from the beginning that 
expectant management could be an option I could 
have changed my expectations and I would not have 
been so disappointed and sad.”  
Domain 4: 
Characteristics of 
the context
The length of time taken 
for the whole process 
“When you add up the time between all the 
investigations and the waiting time….it is really
time for action now.”
PROFESSIONALS
Domain 1: 
Characteristics of 
the intervention
Existing prognostic 
models do not include all 
the relevant predictors
“When I see a coitus frequency of once a month and 
a lifestyle of which I think hallelujah, then I assume 
the model can be improved on those items” 
Domain 2: 
Characteristics of 
the professional 
Difficulties in counselling 
and communicating 
chances
“I think it is unbelievably difficult to start no 
treatment after the fertility work up: the patients 
have the strong feeling they have already been 
trying for such a long time and they come to you to 
hear a concrete proposal and then you have to tell 
you are going to do nothing? For me, that makes it 
really hard…”
Domain 2: 
Characteristics of 
the professional
Comparison of treatment 
chances versus  
spontaneous pregnancy 
chances
“When you are able to put the treatment chances 
in perspective of the chances spontaneously, it 
would be easier to counsel couples for expectant 
management…” 
Domain 3: 
Characteristics of 
the patient
Expectations of 
immediate treatment 
after the fertility work 
up
“If you take your time for the first consultation 
and explain the steps of the fertility work up 
and all the options after the work up, including 
expectant management, you will save a lot of time, 
incomprehension, discussions and dissatisfied 
patients”
Domain 4: 
Characteristics of 
the context
A regular Fertility 
meeting, a local protocol 
and local consensus
“When I have to decide on my own this couple needs 
an expectant management I think the consult will 
end differently than when it was decided during a 
central fertility meeting. It feels more comfortable 
when it is discussed with the whole team”
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ABsTRACT
Background 
prognostic models for natural conception help to identify subfertile couples with high 
chances of natural conception, who do not need fertility treatment yet. The use of such 
models and subsequent tailored expectant management (TEM) is not always practiced. 
Previous qualitative research has identified barriers and facilitators of TEM among patients 
and professionals. The aim of this study was to assess the prevalence of those barriers 
and facilitators and to evaluate which factors predict patients’ appreciation of TEM and 
professionals’ adherence to TEM.
Methods 
we performed a nationwide survey. Based on the previously identified barriers and facilitators 
two questionnaires were developed and sent to 195 couples and 167 professionals. Multivariate 
analysis was performed to evaluate which factors predicted patients’ appreciation of TEM 
and professional adherence to TEM.
Results 
in total, 118 (61%) couples and 117 (70%) professionals responded and 96 couples and 117 
professionals were included in the analysis. Patients’ mean appreciation of TEM was 5.7, 
on a 10-point Likert scale. Patients with a lower appreciation of TEM had a higher need for 
patient information (P = 0.047). The professionals reported a mean adherence to TEM of 
63%. Adherence to TEM was higher when professionals were fertility doctors (P = 0.041). 
Facilitators in the clinical domain were associated with a higher adherence to TEM (P = 
0.091). Barriers in the professional domain had a negative impact on adherence to TEM (P = 
0.008).
Conclusions 
the limited implementation of TEM is caused by both patient and professional-related factors. 
This study provides practical tools to improve the implementation of TEM.
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InTRoduCTIon
In approximately 50% of subfertile couples, no major cause for their unfulfilled childwish 
is found (Brandes et al. 2011; The ESHRE Capri Workshop Group 2009; van der Steeg et al. 
2007a). Almost half of those couples have moderate to high chances of natural conception 
and would benefit from expectant management (Brandes et al. 2010; Brandes et al. 2011; 
Collins et al. 1983; van der Steeg et al. 2007a). These couples can be identified by prognostic 
models (Hunault et al. 2004; Steures et al. 2006; van der Steeg et al. 2007a). The prognostic 
model of Hunault predicts the chance of natural conception within 12 months  and contains 
the variables female age, duration of subfertility, primary or secondary subfertility, sperm 
motility and referral status and performed well in external validation in a cohort of more 
than 3000 couples (van der Steeg et al. 2007a). In a randomised controlled trial, expectant 
management for six months, in couples with an intermediate (30-40%) chance of natural 
conception, was as effective as treatment with intra uterine insemination (IUI) with ovarian 
stimulation (OS) (Steures et al. 2006). Based on these studies expectant management is 
recommended in our guidelines in couples with a chance of natural conception of ≥30% 
for at least 6 months (NVOG: national guideline subfertility 2011; NVOG guideline 2004). 
Nevertheless, the implementation of prognostic models and subsequent expectant 
management in couples with a good prognosis, i.e. tailored expectant management (TEM), is 
poor, leading to unnecessary treatment (van den Boogaard et al. 2011a). 
Previous qualitative research has identified barriers and facilitators of TEM (van den 
Boogaard et al. 2011b). Among subfertile couples, the barriers are lack of confidence in the 
effectiveness of natural conception, expecting immediate treatment after the fertility work 
up, misunderstanding the reasons for expectant management and overestimating the success 
rates of treatment. Among professionals, limited knowledge and limited communication 
skills are experienced as the main barriers. Better management of patients’ expectations is 
seen as one of the most important facilitators. Both professionals and patients indicate a lack 
of adequate patient information materials as a main barrier (van den Boogaard et al. 2011b). 
Knowledge of the impact of these barriers and facilitators on patients’ appreciation of TEM 
and professionals’ adherence to TEM is necessary to be able to implement TEM. Therefore, 
the aim of this study was to quantify the barriers and facilitators of TEM among patients 
and professionals in a nationwide survey and to analyse which factors influence patients’ 
appreciation of TEM and professionals’ adherence to TEM.  
Materials and Methods
study population 
All subfertile couples who had been counselled for TEM for 6-12 months from seven hospitals 
(two academic and five non academic hospitals) from four different regions in the Netherlands 
were sent a questionnaire by post, 1-12 months after they had been counselled for TEM. 
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We included couples who were in their expectant management period of 6-12 months. 
These couples could as yet not have conceived, they could have conceived naturally in the 
TEM period or they could have started treatment in the TEM period. Couples who started 
treatment after their TEM period were excluded from the analysis because we suspected 
their appreciation might have been biased by their failure to become pregnant and needing 
treatment. 
All Dutch gynaecologists sub-specialised in the field of reproductive medicine and registered 
as such with the Dutch Society of Obstetrics and Gynaecology (NVOG) were invited to 
participate. Next to that, all fertility doctors registered with the Dutch Society of Fertility 
Doctors (VVF) were invited. Fertility doctors are basic doctors who work in fertility care and 
had an in-house education in reproductive medicine. We invited the professionals to fill in 
an online questionnaire.
setting
All 101 hospitals in the Netherlands do fertility work-ups and can advise tailored expectant 
management according to the national guideline (NVOG: national guideline subfertility 
2011). In the Netherlands IUI with and without OS is performed in 91 hospitals. In Vitro 
Fertilisation (IVF) and Intra Cytoplasmatic Sperm Injection (ICSI) is performed in 13 licensed 
hospitals (Kremer et al. 2008b; Steures et al. 2007c)
questionnaire 
The questionnaires for the patients were sent by post between December 2010 and February 
2011. The questionnaire included a letter, explaining the purpose of the study. To ensure the 
highest possible response rate we used a short questionnaire (maximum 15 minutes fill in 
time), prepaid return envelopes and two reminder questionnaires (Edwards et al. 2002). The 
two reminders were sent to non-respondents within a period of 10 weeks. 
The link to the questionnaire for the professionals was sent by email in November 2010. The 
questionnaire itself was developed in surveymonkey.com and had also a maximum fill in 
time of 15 minutes. Two reminders were sent in a period of 10 weeks. 
The questionnaires for both patients and professionals were based on previously identified 
barriers and facilitators for TEM (van den Boogaard et al. 2011b). The barriers and facilitators 
were translated into statements and with each statement, the participant could choose 
between strongly disagree(1), disagree, neutral, agree and strongly agree(5). An example of a 
statement of a patients’ barrier was: “I have no confidence in a good chance of natural 
conception” and the couple could report their level of agreement with this statement. An 
example of a statement testing a facilitator for professionals was: “I think that a regular 
fertility meeting would improve my adherence to TEM” and the professional could report 
their level of agreement. 
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Both questionnaires contained three parts. The questionnaire for the patients started with 
closed and open ended questions concerning baseline characteristics. The second part 
contained two closed-ended questions and five five-point-Likert scale items concerning 
expectations prior to the first consultation. The third part included interpretations of and 
experiences with TEM, divided into nine closed-ended questions and 27 five-point-Likert scale 
items. This last part also contained one question with a ten-point-Likert-scale concerning 
their appreciation of TEM. We defined appreciation of TEM as approval and understanding 
of TEM.  
The questionnaires for the professionals’ started with open and closed ended questions about 
the characteristics of the professional and the hospital. The second part consisted of four 
closed-ended questions, eight five-point-Likert scale items, and three open-ended questions 
concerning the use of the prognostic model and barriers for the use of the model. The third 
part contained seven closed-ended questions, 19 five-point-Likert scale items, and four open-
ended questions about barriers and facilitators of advising expectant management. This 
last part also contained one question with a ten-point-Likert- scale about the professionals’ 
adherence to TEM. 
Both questionnaires were pilot tested. The questionnaire for patients was pilot tested 
among five couples who had been counselled for TEM in two hospitals. The questionnaire 
for professionals was pilot tested among two gynaecologists, three fertility doctors and two 
PhD students from two hospitals. The three parts of the questionnaires were well understood 
by all participants of the pilot study and therefore only minor modifications were made to 
the final version of the survey.
statistical analysis 
To quantify which barriers and facilitators the patients and the professionals experienced, 
the five point Likert scale responses were recoded into 3 point classification as 1=not agree, 
2=neutral or 3=agree and the percentages per barrier or facilitator were calculated. 
The barriers and facilitators were categorised per domain, i.e. the domain of the intervention, 
professional, the patient and the clinic (Cabana et al. 1999; Grol and Grimshaw 2003). For the 
statistical analyses the sum scores for each domain were calculated. To assess the internal 
consistency of those sum scores a Cronbach α was calculated for each sum score. If the 
Cronbach α was <0.5 a factor analysis was performed. 
The characteristics of the participants, hospitals and the sum scores of the barriers and 
facilitators were tested for univariable relationship with the reported appreciation of TEM 
(patients) and adherence to TEM (professionals). The reported appreciation of TEM and the 
reported adherence to TEM served as the dependent variable. To evaluate the influence of the 
pregnancy status of the couple, i.e. not pregnant, natural conception or treatment in the TEM 
period, we included this variable in the analysis. We considered variables with p≤0.15 to be 
eligible for the multivariable variable regression analysis. Interaction analysis was performed 
between the variables included in the multivariable model and in case of significant 
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interaction (p<0.05) the interaction-terms were included in the multivariable model. In the 
multivariable analyses the variables with a p<0.05 were considered statistically significant. 
Statistical Products Service and Solutions (SPSS) PASW 18.0 was used for all analyses. 
Ethical approval
Subjects did not undergo additional investigations nor treatment. As assessed by the 
Institutional Review Board (IRB), Academic Medical Center Amsterdam, the study was not 
subject to the Dutch “Medical Research Involving Human Subjects Act” (meaning that no 
formal IRB approval was needed).
REsulTs
Patients
We sent questionnaires to 195 couples who had been counseled for TEM, of whom 142 
(73%) returned their questionnaire. Of these 142 couples, 24 couples did not fill in the 
questionnaire: 16 couples had not been advised TEM, five couples declined to fill in the 
questionnaire without a given reason, one couple split up, one woman had surgery for 
endometriosis and one couple terminated their wish for a child. This left 118 couples that 
filled in the questionnaire of whom 31 (26%) couples were not pregnant in their TEM period, 
54 (46%) conceived in their TEM period, 11 (9%) started treatment in their TEM period and 
22 (19%) had already finished their TEM period, and had treatment thereafter. The latter 
group (n=22) was excluded from the analysis because, as mentioned in the method section, 
their appreciation might have been biased by their failure to become pregnant and needing 
treatment. The flowchart of the patients is depicted in figure 1.
Patient characteristics of the included couples are summarized in Table 1. The mean age 
of the female and male participants was 32 and 35 years, respectively. The mean reported 
appreciation of TEM was 5.7 on a 10 point scale (Table 1). 
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Figure 1. Flowchart of the pregnancy status of patients at the time the couples filled in the questionnaire. 
TEM: tailored expectant management, IUI: intra uterine insemination.
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Table 1. Characteristics of the included couples (n = 96)
Patient characteristics (n = 96) Female      Male
Mean age in years (SD) 32 (4.0)      35 (4.5)
Ethnic background          Dutch (%) overall
                                        Non-Dutch (%)*
86 (90%)
10 (12%)
     84 (88%)
     12 (13%)
Level of education**        Low
                                        Medium
                                        High
6 (6%)
33 (34%)
57 (59%)
     10 (10%)
     24 (25%)
     60 (63%)
 Couples 
Type of hospital               Academic
                                        Non-academic
8 (8%)
88 (92%)
Duration subfertility at first hospital visit, 
months, median (IQR) ***
13.4 (7.0)
Mean self-reported prognosis (SD) **** 42.5 (13.0)
Mean appreciation of TEM (1-10) (SD) 5.7 (2.2)
* The place of birth of the patient or both parents is outside the Netherlands, excluding its 
dominions 
** Low: primary school / intermediate vocational education, Medium: higher general secondary 
education pre-university secondary education, High: higher vocational education / university 
*** Duration between start conception-focused intercourse and first consultation fertility care
**** Chance of natural conception within 12 months according to the prognostic model of Hunault 
(Hunault et al. 2004)
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Table II. Barriers and facilitators for TEM experienced by subfertile couples, 
(b) = barrier (f) = facilitator. * happy, relieved, ** sad, disappointed, angry and expelled
Percentage of couples that perceive this as a barrier (b) or facilitator (f) Couples
n= 96
Characteristics of the intervention
Lack of confidence in the natural conception (b) 85 (89%)
Knowledge of the factors used in the prognostic model (b) 75 (78%)
A need for more instructions about TEM period (b) 45 (47%)
A need for more information material about prognosis and TEM (b) 39 (41%)
Characteristics of the professional
Preference for being informed about the option of TEM during the first consultation (f) 42 (44%)
Comparing spontaneous pregnancy chance with treatment (f) 29 (30%)
Unclear way of counselling and communicating chances (b) 9  (9%)
Characteristics of the patient
Expected to get a cause for the subfertility (b) 84 (88%)
Expected to get treatment (b) 27 (28%)
Expected to get a cause for the subfertility and treatment (b) 19 (20%)
First reaction to prognosis and subsequent TEM:
    positive*
    negative**
    mixed feelings: happy and disappointed
43 (45%)
28 (29%)
66 (69%)
Understanding that with good prognosis, treatment was not indicated (f)
Twin is a welcome complication despite the risks (b)
Knowledge that good prognosis was reason for TEM (f)
Inability to remember prognosis (b)
Progressing female age (b)
Longer duration of subfertility (b) 
Expected that with treatment >50% of all couples conceive (b)
85 (89%)
76 (79%)
74 (77%)
52 (54%)
52 (54%)
63 (66%)
43 (45%)
Expected to have a good spontaneous prognosis and not needing treatment (f) 36 (38%)
Characteristics of the clinic
Other clinics offering reproductive treatment (b) 12 (12%)
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Table III. Multivariable relationship between patients’ appreciation of TEM and the patient 
characteristics, the barriers and facilitators of the four domains. Variables with p<0.15 in the 
univariable analyses were selected for the multivariable analysis.
Multivariable association between the patients’ appreciation of TEM and patient 
characteristics, barriers and facilitators P- value
Domain of the intervention
Need for patient information about prognosis and TEM, sum score 0.047
Domain of the professional
Not informing the couple about the option of TEM during the first consultation 0.955
Comparing natural conception chance with treatment 0.124
Domain the patient
Understanding that with good prognosis, treatment was not indicated 0.810
Domain of the clinic
Practice in other clinics 0.463
The percentages of couples that experienced a barrier or facilitator are summarized in 
Table II. In the domain of the intervention itself a majority of the couples reported a lack of 
confidence in the desired effect of natural conception and were aware of the factors used in 
the prognostic model. Almost half of the couples reported a need for more instructions or 
information material for the TEM period. In the domain of the professional almost half of 
the couples preferred being informed about the option of TEM during the first consultation 
and one third of the couples found it helpful if the chances of a natural conception were 
compared with the chances of a treatment related pregnancy. Prior to the first consultation 
a majority of the couples expected to get a diagnosis after the fertility work up and one 
third of the couples expected fertility treatment. Most couples had a positive or mixed first 
reaction on the advise for TEM. Understanding that treatment was not indicated and that 
good prognosis was the reason for TEM was reported by a large majority of the couples. 
The Cronbach alphas of the sumscores of the domain of the intervention, the domain of the 
professional and the domain of the patient, were <0.5. For that reason a factor analysis 
was performed and the following sumscores showed internal consistency: the sumscores 
‘Need for patient information about prognosis and TEM’ (Cronbach α 0.83) and ‘Complexity of 
the prognostic model’ (Cronbach α 0.63). The sumscore ‘Need for patient information about 
prognosis and TEM’ includes the barriers ‘a need for more instructions for the TEM period’ 
and ‘a need for information material about prognosis and TEM’. The sumscore ‘Complexity 
of the prognostic model’ includes the facilitators ‘knowledge of the factors used in the 
prognostic model’, ‘knowledge that good prognosis was reason for TEM’ and ‘understanding 
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that with good prognosis, treatment was not indicated’. The domain of the clinic contained 
only one barrier, so for this domain no Cronbach alpha was calculated.
The univariable analyses between the couples’ appreciation of TEM as the dependent variable 
and patient’ characteristics and the barriers and facilitators as the independent variable 
selected five variables for multivariable analysis: the sumscore of the need for patient 
information about prognosis and TEM, not informing the couple about the option of TEM 
during the first consultation, comparing natural conception chance with treatment chance, 
understanding that with good prognosis treatment was not indicated and the sumscore of 
practice in other clinics. Pregnancy status did not influence patients’ appreciation of TEM 
in the univariable analysis. Interaction analysis showed no significant interaction between 
the included variables. Multivariable analysis showed a negative correlation between the 
reported appreciation of TEM and the need for more patient information about prognosis 
and TEM (p=0.047). The other four variables did not influence patients’ appreciation of TEM 
(Table III).
Professionals
In total 117 of the 167 (70%) invited professionals filled in the online questionnaire. The 
professionals were from all 12 regions and had been trained in all 8 academic centres in 
the Netherlands. Baseline characteristics of the professionals are summarised in Table IV. A 
minority of the professionals were male (33%), the mean age of the professionals was 45, 45 
(39%) were fertility doctors and the mean years of experience was 11. The mean reported 
adherence to TEM was 63%.
The percentages of professionals that experienced a barrier or facilitator are shown in Table 
V. In the domain of the intervention criticism on prognostic models, like missing factors 
was the most experienced barrier. The Body Mass Index and tobacco use were mentioned as 
missing factors in the prognostic models. 
In the domain of the professional him/herself, the barriers forget to use the model and 
difficulties in counselling and communicating chances were experienced most frequently. 
None of the professionals experienced financial barriers for TEM. 
In the patient domain the professionals experienced advancing female age, urgency for 
action expressed by the couple, couples expecting immediate treatment after the fertility 
work up and couples with a history of miscarriage(s) as main barriers. 
The facilitators experienced most frequently were: local consensus among colleagues, a 
regular fertility meeting where subfertile couples are discussed after the fertility work up 
and the availability of a local protocol regarding the use of prognostic models and TEM.
The Cronbach alphas of the sumscores of the domains, i.e. the domain of the intervention, 
the domain of the professional, the domain of the patient and the domain of the clinic were 
0.55, 0.66, 0.69 and 0.68 respectively.
Univariable analyses between the reported adherence to TEM as the dependent variable and 
the professional characteristics and the sum scores of the four domains as the independent 
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variable, selected six variables for multivariable analyses: type of physician (fertility doctor), 
a professional frequently seeing fertility patients, a local protocol, local consensus, a regular 
fertility meeting and the sumscore of the barriers in the domain of the professionals (Table 
VI). Interaction analysis of the included variables showed significant interaction between a 
regular fertility meeting and the sum score of the facilitators in the domain of the clinic. An 
interaction-term of those two variables was developed and included in the multivariable 
model. Multivariable analyses showed a positive correlation between the reported adherence 
to TEM and the professional being a fertility doctor instead of a gynaecologist (P= 0.041) and 
a non significant correlation with the facilitators in the domain of the clinic (P= 0.091). The 
sumscore of the barriers in the domain of the professional showed a negative correlation 
with adherence to TEM (P=0.008).
Table IV. Characteristics of the professionals (n= 117)
 Characteristics of the professionals  and the clinic n = 117
 Male 39 (33%)
   Mean age in years (SD) 45 (±9.7)
   Fertility doctor (%) 45 (38%)
   Mean years of experience (SD) 11 (±8.5)
 University hospital 37 (32%)
 Teaching hospital 55 (47%)
 Non-teaching hospital 23 (20%)
   Private clinic 2 (2%)
   Local protocol available 73 (62%)
   Fertility meeting 96 (82%)
   Mean Self reported adherence to TEM (range) 63% (1-100%)
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Table V. Barriers (b) and facilitators (f) for practice TEM experienced by professionals. 
Percentage of professionals that perceive this as a barrier (b) or facilitator (f) for TEM
Professionals 
n=117
Domain of the intervention
Incompleteness of the prognostic model (b) 47 (40%)
Not convinced about the model and the expectant management (b) 34 (29%)
The use of the model takes time (b) 19 (16%)
Domain of professionals
Forget to use the model (b) 42 (36%)
Difficulties in counselling and communicating chances (b)  21 (18%)
Limited knowledge about the prognostic models and TEM (b) 20 (17%)
Close relation with the couple (b) 19 (16%)
Not (always) have access to the model (b) 15 (13%)
Treatment will generate income (b) 0 (0%)
Domain of the patient
Advanced female age
Urgency for action in the couple (b)
94 (80%)
87 (74%)
Expectations’ of immediate treatment after the fertility work up (b)
Couples with a history of miscarriage(s) (b)
69 (59%)
42 (36%)
Domain of the clinic
Local consensus (f) 110 (94%)
A regular Fertility meeting (f) 104 (89%)
A local protocol (f)  98 (84%)
Centralisation of fertility care (f) 84 (72%)
Electronic Patient Dossier (f) 68 (58%)
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Table VI. Multivariable relationship between professionals’ self-reported adherence to TEM and the 
professional’ characteristics, barriers and facilitators of the four domains. Variables with p<0.15 in the 
univariable analyses were selected for the multivariable analysis.
Multivariable association  between the professionals’ reported adherence to TEM 
and the professional’ characteristics, barriers and facilitators P value
Professional and Clinical characteristics
      Type physician: fertility doctor 0.041
      Regular seeing fertility patients 0.195
      Local protocol 0.981
      Local consensus
      Fertility meeting
0.380
0.667
Sum score** barriers in the domain of the professional 0.008
Sum score** facilitators in the domain of the clinic
Interaction term fertility meeting * sumscore clinic
0.091
0.374
discussion
This nation wide study quantified patients’ and professionals’ considerations for treatment or 
expectant management. We found that patients’ appreciation of TEM was moderate and may 
be improved by developing adequate patient information material, since this was a factor 
increasing patients’ appreciation of TEM. Professional adherence to expectant management 
was moderate as well and may be improved by implementing regular fertility meetings and 
local protocols and by better knowledge and communication skills of professionals, since 
these were factors influencing professionals’ adherence to TEM.
A strength of this study is that both questionnaires were based on determinants identified 
by previous qualitative research (van den Boogaard et al. 2011b). The step from best evidence 
to best practice needs various strategies targeting obstacles to change at different levels. 
Plans for change have to be based on the barriers and facilitators for change (Curran et al. 
2008; Grimshaw et al. 2004). The high response rates and the large geographical spread of 
participants provided us with a representative setting. In a previous patient preference study, 
subfertile couples preferred IUI with or without stimulation above expectant management, 
if the treatment independent pregnancy chance in the next 12 months was lower than 50% 
and lower than 40%, respectively (Steures et al. 2005). Our study provides insight in their 
reasons for this preference and creates possibilities to improve the implementation of TEM.
This study is not without limitations. First, both patients and professionals may have given 
socially desirable answers. Second, a selection bias may have occurred as couples with a 
good outcome could have been more willing to respond and professionals not familiar with 
the model may have been less likely to respond. Taken these two limitations into account, 
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appreciation of and adherence to TEM can be lower in real life, which only emphasizes the 
importance of this study. Finally, as all data collection was carried out in the Netherlands, 
the reported findings may not be generalisable to other countries. However, the barriers and 
facilitators we quantified were not specifically related to the Dutch setting and we therefore 
consider our results applicable for an international setting, if the reimbursement system is 
comparable. In countries where the incomes depend on how many couples the doctor treats, 
this would obviously overrule all other barriers and facilitators of TEM. In countries where 
patients have to pay for their fertility treatment themselves, this financial argument works 
the other way around. In these countries TEM could become an important strategy, and 
knowledge of the barriers and facilitators of TEM is also then valuable.
This is not the first study that found that subfertile couples are not always content with 
expectant management. In our previous qualitative study in which we performed in depth 
interviews with couples who were counselled for TEM, we identified many dissatisfied 
couples (van den Boogaard et al. 2011b). In that qualitative study we concluded that patients 
did not really understand the reasons for expectant management but in this nation wide 
survey patients reported a good understanding of the reasons for expectant management. 
This discrepancy may be explained by a ‘social desirability response bias’ in the survey: it is 
possible that patients did not want to admit they did not understand the prognostic models 
and the reasons for the expectant management. This probably explains the need for more 
information and instructions about the prognostic models and the expectant management 
period, and provides a clear focus for improving implementation.
Forty-five percent of the couples who filled in the questionnaire conceived naturally in 
the TEM period, which confirms their good prognosis and the reason for the expectant 
management, which is in line with previous studies (Brandes et al. 2011; van der Steeg et al. 
2007a).
Before the first visit to the hospital almost 90% of the couples expected that a cause for 
their subfertility would be found, a third of the couples expected immediate treatment 
after the fertility work up and a quarter of the couples expected both. At the same time, 
a majority of the professionals experienced couples’ urgency for action and expectations 
for treatment as a barrier. It is thus likely that better knowledge of patients’ expectations 
improves communication and counselling, and eventually improves adherence to TEM. In 
clinical practice this may imply offering training to professionals to improve communication 
skills. 
The moderate professional adherence to the expectant management strategy is in line with 
one of our previous studies, in which a considerable percentage of couples were treated 
despite a good prognosis. In the same study we also saw a higher adherence in clinics where 
a fertility doctor was working (van den Boogaard et al. 2011a).   
The wide range in the reported use of TEM (0-100%) demonstrates a large variation between 
the professionals. This variability of guideline adherence between professionals corresponds 
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with the results of other implementation studies in Dutch fertility care (Mourad et al. 2008; 
van Peperstraten et al. 2008a) 
Since we found a clear association between patients’ appreciation of TEM and professionals’ 
adherence to TEM and the barriers and facilitators, a targeted strategy is likely to improve 
the implementation of TEM and to decrease harmful and costly overtreatment. This strategy 
has to focus on the development of adequate patient information material, implementing 
regular fertility meetings and a local protocol in a clinic and by teaching and training 
professionals to improve their communication skills and knowledge concerning TEM.
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ABsTRACT
Background 
Prognostic models in reproductive medicine can help to identify subfertile couples that 
would benefit from fertility treatment. Expectant management in couples with a good chance 
of natural conception, i.e. tailored expectant management (TEM), prevents unnecessary 
treatment and is therefore recommended in international fertility guidelines. However, 
current implementation is not optimal, leaving room for improvement. Based on barriers 
and facilitators for TEM that were recently identified among professionals and subfertile 
couples, we have developed a multifaceted implementation strategy. The goal of this study 
is to assess the effects of this implementation strategy on the guideline adherence on TEM.
Methods/design
In a cluster randomized trial, 25 clinics and their allied practitioners units will be randomized 
between the multifaceted implementation strategy and care as usual. Randomization will 
be stratified for IVF facilities (full licensed, intermediate/no IVF facilities). The effect of the 
implementation strategy, i.e. the percentage guideline adherence on TEM, will be evaluated 
by pre- and post-randomization data collection. Furthermore there will be a process and cost 
evaluation of the strategy. The implementation strategy will focus on subfertile couples and 
their care providers i.e. general practitioners (GPs), fertility doctors and gynecologists. The 
implementation strategy addresses three levels: (1) Patient level: education materials in the 
form of a patient information leaflet and a website; (2) Professional level: audit and feedback, 
educational outreach visit, communication training and access to a digital version of the 
prognostic model of Hunault on a website; (3) Organizational level: providing a protocol 
based on the guideline. The primary outcome will be the percentage guideline adherence on 
TEM. Additional outcome measures will be treatment-, patient- and process-related outcome 
measures.  
discussion 
This study will provide evidence about the effectiveness and costs of a multifaceted 
implementation strategy to improve guideline adherence on TEM. 
Trial registration 
www.trialregister.nl  NTR3405. This study is sponsored by ZonMW.
 79
Background
Subfertility is defined as the absence of conception after one year of unprotected intercourse 
(Zegers-Hochschild et al. 2009). It affects approximately 9% of all couples of reproductive age 
(Boivin et al. 2007 and Gnoth et al. 2003) In approximately 50% of the couples, no major cause 
is found after the basic fertility work-up (ECW Group, 2009). In those couples the chance of 
natural conception can be calculated via validated prognostic models (Hunault et al. 2004 
and van der Steeg et al. 2007). If the chance of natural conception within one year is good, 
meaning a probability of 30% or more, expectant management for 6-12 months is equally 
effective as treatment (Steures et al. 2008). Since this expectant management is restricted 
to couples with a good prognosis, we have called it tailored expectant management (TEM). 
European Society of Reproductive Medicine (ESHRE) and National Institute of Health (NICE) 
guidelines on the management of infertility both emphasize that couples should not be 
exposed to unnecessary risks or ineffective treatments and encourage that each subfertile 
couple should receive information about the estimate of their chance of natural conception 
(ESHRE guidelines infertility 2001 and NICE guidelines, 2004). In the Netherlands the national 
network guideline on infertility for gynecologists and general practitioners (GPs) explicitly 
the use of prognostic models and subsequent TEM for couples with unexplained or mild 
infertility (NHG  and NVOG). However, at this moment, implementation of TEM is poor. A 
recent Dutch multicenter cohort study showed overtreatment in 36% of the couples, i.e. 36% 
of the couples with a good prognosis eligible for TEM (> 30% chance of natural conception 
in one year) already started medically assisted reproduction (MAR)(van den Boogaard et al. 
2011a). 
This overtreatment in subfertile couples is worrisome for several reasons. First, fertility 
treatment still leads to a considerable number of multiple pregnancies, which are associated 
with a higher morbidity and mortality in both mothers and neonates(Helmerhorst et al. 
2004). Second, fertility treatment carries a significant physical and psychological burden and 
accompanying productivity loss (Verberg et al. 2008, Verhaak et al 2002, Bouwmans et al. 
2008, Custers et al. 2012). Third, fertility treatment and its complications are expensive and 
put considerable financial strain on societies where MAR is reimbursed or on the subfertile 
couples in societies where MAR is not or only partially reimbursed. 
The first step to improve guideline adherence on TEM and reduce overtreatment is to 
gain insight into barriers and facilitators for implementation of TEM and MAR reduction. 
Subsequently a tailored implementation strategy can be developed targeting obstacles to 
change, if necessary at different levels (Curan et al 2008. And Grol et al. 2003). In a previous 
qualitative and quantitative study among patients and professionals the main barriers 
among subfertile couples were lack of confidence in natural conception, perception that 
expectant management is a waste of time, inappropriate expectations prior to the first 
secondary care consultation and an overestimation of the success rates of treatment. Both 
couples and professionals regarded the lack of patient information materials as an important 
barrier. Among the professionals, limited knowledge about prognostic models and limited 
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communication skills to convince the couple, both leading to a decision in favor of treatment 
were recognized as main barriers. Facilitators experienced by the professionals were better 
management of patients’ expectations, local consensus and the presence of a local protocol 
and local fertility meetings (van den Boogaard et al. 2011a and van den Boogaard et al. 
2011b). 
A multifaceted implementation strategy to improve guideline adherence on TEM has now 
been developed based on these data. The aim of this study is to evaluate effectiveness and 
costs of this implementation strategy in a cluster randomized trial. 
METHods
setting
In the Netherlands, subfertile couples are usually referred by the general practitioner (GP) 
to secondary care. GPs usually perform only limited basic fertility workup or no workup at 
all and they do not prescribe fertility drugs. Secondary and tertiary care is provided by three 
different types of fertility clinics based on the kind of treatment they offer. Initial fertility 
assessment, ovulation induction (OI) and intra-uterine insemination (IUI) are carried out in 
all Dutch clinics. IVF and ICSI treatments are only carried out in intermediate and licensed 
fertility clinics. 
Every Dutch citizen has a basic insurance coverage, which fully reimburses all treatment 
cycles of OI and IUI, with or without controlled ovarian hyperstimulation, as well as a 
maximum of three IVF or ICSI cycles. 
study design
We propose a cluster randomized trial in 25 clinics and their allied GP units with an effect, 
process and economic evaluation alongside the trial. 
Randomisation
The 25 participating clinics and their allied practitioners units will be randomized between 
the multifaceted implementation strategy and care as usual. Randomization will be stratified 
for IVF facilities (full licensed, intermediate/no IVF facilities) and will take place after all 
clinics have approval to participate. Randomisation will be done be done by an independent 
physician and will be computer-generated. Results of the randomization will be personally 
communicated to all participating clinics.
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Effectiveness
For the effectiveness, a baseline measurement will be performed in all participating 
clinics, including guideline adherence on TEM, and a range of organizational, professional 
and patient characteristics (see outcome measures). Following baseline measurement the 
multifaceted implementation strategy will be applied in the intervention clinics. After ten to 
twelve months of intervention exposure, the after measurement will be performed again in 
all 25 participating clinics. 
Process evaluation
A process evaluation, according to Hulscher et al. (Hulsher et al. 2003), will be performed 
during and after the intervention to investigate the feasibility of the implementation strategy. 
Intervention
The multifaceted implementation strategy, based on a barrier analysis among professionals 
and patients, will focus on three different levels: patient, professional and organizational 
level (van den Boogaard et al. 2011b). The three levels and all associated tools are successively 
described here. 
Patient level:
We will develop patient educational materials in three different forms, a patient information 
leaflet, posters and a website.
The patient information leaflet will provide general background information on the fertility 
work-up procedure, prognostic factors that influence the chance on spontaneous conception, 
(dis)advantages of expectant management and (dis)advantages of fertility treatment. In 
every intervention clinic posters with information on the prognostic model and expectant 
management will be placed in the waiting areas. In the leaflet and on the posters patients 
can find a code which is needed to gain access to the website. There is a different code for 
each intervention clinic. The website will give more individualized information by access to 
a digital version of the prognostic model of Hunault (Hunault et al. 2004). Herewith patients 
can calculate their chances of natural conception within one year and experience the 
influence of altering characteristics. It will also provide additional information on the basic 
fertility workup, the chance of natural conception versus the chance of conception after 
fertility treatment, (dis)advantages of expectant management and (dis)advantages of fertility 
treatment. Furthermore, it advises patients what they can do to optimize their chances of 
spontaneous conception during the expectant management period, e.g. information on 
intercourse timing and frequency, weight regulation and lifestyle. This information will be 
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in accordance with the information provided in the Dutch national network guideline on 
infertility (NHG and NVOG).
This information material will be developed according to the International Patient Decision 
Aids Standards criteria for the dimensions ‘information’ and ‘probabilities’ (Elwyn et al. 2009) 
as well as according to the American Medical Association criteria (Winker et al. 2000).
Professional level (e.g. gynecologists (in training), fertility doctors and 
gPs) 
The strategy regarding the professionals contains 1) audit and feedback, 2) an education 
outreach visit, 3) supportive consultation tools and 4) a video-based communication training. 
The audit and feedback of the current care will consist of a feedback report based on the 
results of the baseline measurement. This feedback will report clinic’s guideline adherence 
on TEM in a twelve month period prior to the randomization compared with the other 
participating clinics.  It will give insight in how they are adhering to the guideline concerning 
the policy for couples with unexplained or mild infertility, e.g. use of prognostic models and 
subsequent TEM in case the prognosis is good. Furthermore the report will provide feedback 
on patient related measures like general experiences with fertility care, specific experiences 
with the prognostic model and tailored expectant management, quality of life and trust in 
their physician.
In addition to this audit and feedback, an educational outreach visit will take place with 
fertility doctors and gynecologists (in training), in which background information about how 
and when to use the prognostic model of Hunault and subsequent TEM will be given and in 
which the results of the baseline measurement and local barriers will be discussed. The result 
of this visit will be an individualized action plan per clinic.
The supportive consultation tools are developed containing a digital version of the prognostic 
model of Hunault on a website and we will provide professionals with a summary of the 
guideline on TEM in the form of a pocket card. 
Finally, a video-based training strategy will be provided to improve the communication 
techniques to counsel the patients on their chance of spontaneous conception versus 
conception after treatment, the (dis)advantages of expectant management versus fertility 
treatment and on the reason of TEM (i.e. making clear it is not a waste of time). Consistent 
with functional models of medical communication described in the field (de Haas et al. 2009), 
the LEAPS Framework, a pneumonic for Listen, Educate, Assess, Partner and Support will be 
used to develop the intervention (Roter et al. 2012). 
organizational level (gP units and fertility clinics).
During the educational outreach visits an example of an up to date local protocol will 
be offered to the fertility clinics, who do not already have an updated protocol available. 
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This local protocol will be based on the Dutch network guideline on infertility and it will 
focus on the initial fertility assessment (diagnostics), identification of patients with mild or 
unexplained infertility, the use of the prognostic model of Hunault and TEM. The clinics can 
adjust this protocol to their own lay out and they can distribute it either in the form of a 
hard-copy or digital-copy, depending on the preference of the professionals. 
Furthermore we will provide the GPs allied to the intervention clinics with feedback on their 
referral behavior, e.g. were patients referred according to the guideline recommendations.
study population/Participants
To include a representative patient group, we will select potential participating couples 
retrospectively in each clinic by means of the clinics’ financial registration database 
(Diagnosis Treatment Combination code). In this nationwide registration system, patients 
undergoing diagnostics or treatment for infertility are identified with a specific Fertility-
code (F-code). For the baseline measurement we will invite couples that were given the code 
for new fertility patients (F-11) between February 2011 to March 2012 to participate in this 
study. For the after measurement we will invite the couples that were given the F-11 code 
during the ten to twelve month intervention period. We will invite couples to participate by 
giving their permission for a medical record study and filling out a questionnaire. 
The couples are eligible to participate when they have been diagnosed with unexplained 
or mild infertility, have a good prognosis (>30%) according to Hunault’s prediction model, 
did not have previous fertility treatment and the female age is between 18 and 38 years. 
Couples with bilateral tubal pathology, severe male factor or anovulation are not eligible to 
participate. 
sample size
The expected adherence to TEM in the control arm is estimated based on previous studies at 
60% (van den Boogaard et al. 2011a). To increase this to 80% with an Intra Class Correlation 
(ICC) of 0.1, alpha at 5%, comparing 2 strategies, we estimate that with 25 clusters we would 
need a total sample size of 450 patients. This means we need to include 15 to 20 patients per 
clinic in the baseline as well as in the after measurement.
outcome measures 
Primary outcome effectiveness
The primary outcome measure of the proposed study for effectiveness will be the guideline 
adherence rate on TEM: the percentage of couples that are eligible for TEM (couples with 
mild or unexplained infertility with a prognosis of >30% of natural conception within one 
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year) who actually agree upon the expectant management period of at least six months after 
the initial fertility assessment is concluded. 
secondary outcomes effectiveness
-  Treatment related measures like time to the start of fertility treatment and the number 
and types of fertility treatments that the couples received. 
-  Treatment outcome related measures like (ongoing) pregnancy rate, miscarriage, extra 
uterine gravidity, multiple pregnancy rate and time to pregnancy. 
-  Patient related outcome measures like general experiences with fertility care such as 
information provision, respect for patients’ values and accessibility of care (to be measured 
with Patient Centeredness Questionnaire Infertility) (van Empel et al. 2010), specific 
experiences with the prognostic model and tailored expectant management, quality of 
life (estimated by FertiQoL)(Aarts et al. 2011) and trust in physician (measured by Wake 
Forest Trust Scale) (Bachinger et al. 2009).
-  Process related measures like percentage transition of patients to another fertility centre.
-  Background characteristics that could influence guideline adherence (e.g. age, referral 
status, type of infertility, duration and cause of infertility).
outcomes process evaluation
-  Actual ‘exposure’ of patients and physicians to the different elements of the implementation 
strategy
-  How frequently the website has been visited by patients and physicians
-  Experiences of patients and physicians with the different elements of the implementation 
strategy.
data collection
Effectiveness
Data collection will be performed from medical records and a patient questionnaire. 
Data abstraction from medical records will be performed using a standardized audit form. We 
will collect the background characteristics, treatment related measures, treatment outcome 
related measures and process-related measures.  
The questionnaire will be divided into four parts. The first part consists of background 
questions (e.g. highest educational level, country of birth). The second part regards the 
patients’ experience with the prognostic model and tailored expectant management as well as 
the patients’ trust in both the general practitioner as well as the fertility doctor/gynecologist. 
The third part is the Patient- Centeredness Questionnaire - Infertility, a validated instrument 
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measuring patient-centeredness of fertility care by asking about patients’ experiences with 
care. The last part is the FertiQol questionnaire, We will only use the Core module which 
involves questions about Mind-Body, Emotional, Relational and Social aspects. 
Process evaluation
For the process evaluation we will approach the local investigator, during the intervention 
period,  to provide us with feedback about the implementation strategy. We will also keep 
track of how often the website is visited by logging data. At the end on the ten to twelve 
month intervention period we evaluate the strategy by means of a professional questionnaire 
and an addendum to the patients’ questionnaire in the after measurement.
data analysis
To analyze the effectiveness of the implementation strategy, descriptive statistics and 
multilevel analysis will be used. The statistical analysis will be performed using SPSS version 
16.0 for Windows. 
The main outcome, the difference in baseline and after-measurement scores in guideline 
adherence on tailored expectant management, between the intervention and control group 
will be analyzed with the chi-square test. 
Descriptive analysis will be used to assess the difference in treatment related, treatment-
outcome related and patient related measurements between the intervention and control 
group. Furthermore, time to pregnancy and time to start fertility treatment will be analyzed 
using Kaplan Meier analysis with log-rank test. Univariate and subsequent multivariate 
logistic and Cox regression analyses will be used to analyze the relative contribution of the 
implementation strategy versus other predictive factors for guideline adherence on TEM.
Economic evaluation
We plan an economic evaluation alongside the clinical trial to investigate the cost-
effectiveness of the multifaceted implementation strategy to improve guideline adherence 
on TEM. This economic evaluation compares the multifaceted implementation strategy 
to usual care and is done from a societal perspective. A distinction will be made between 
costs of the development and introduction of the implementation strategy and the costs of 
maintaining the implementation strategy. The input of resources is assessed by collecting 
volumes of consumed resources (e.g. medical interventions like number IUI and IVF cycles 
and treatment related outcomes like ovarian hyperstimulation syndrome and multiple 
pregnancies) and multiplied by reported or guideline prices according to Oostenbrink 
(Oostenbrink et al. 2004). To asses non-medical and indirect costs we will build on the data 
collection and cost calculation frameworks from previous cost studies on IUI and IVF (Haagen 
et al. 2012 and Fiddelers et al. 2009). The incremental costs, expressed as costs/percentage 
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guideline adherence to TEM, are determined by the differences in resource consumption 
and adherence rates between the intervention group and the control group. Robustness of 
the results (costs and health outcomes) for various assumptions and parameters estimates 
will be explored in sensitivity analyses and visualized in ICER-graphs and cost-effectiveness 
acceptability curves.
Trial status
We are currently performing the baseline measurement in all participating clinics.
discussion
This cluster RCT will compare a multifaceted implementation strategy to usual care on 
improving guideline adherence to TEM. If TEM is more applied, it will reduce the number 
of performed IUI, IVF and ICSI cycles, the incidence of treatment related complications (e.g. 
ovarian hyperstimulation syndrome and multiple pregnancies) and we expect it reduces the 
physical and psychological burden. As a consequence the costs for fertility treatment will 
decrease. 
Many different interventions are available to implement guidelines, either focusing 
on professionals, patients, teams or organizational factors and with variable effects. A 
systematic review on interventions to improve guideline implementation showed that 
interventions tailored to prospectively identified barriers are more likely to improve 
professionals practice than only dissemination of guidelines (Ivers et al. 2012). The strategy 
that we developed is tailored to the recently identified barriers and facilitators for TEM, 
thus more likely to improve professionals practice, in this case: adherence to the guideline. 
Moreover, in general combined interventions are believed to be more effective than single 
interventions (Grimshaw et al. 2004). Therefore, to increase the potential effectiveness of our 
implementation strategy, we developed a multifaceted intervention that targets the specific 
barriers for TEM at different levels. 
For the specific interventions that will be used in the multifaceted implementation strategy 
the review showed that: audit and feedback and educational outreach visits can be effective 
(small to moderate) (Grimshaw et al. 2004, Ivers et al. 2012) and patient-directed interventions 
such as educational materials may result in moderate to large effects to increase adherence 
to recommended care (Grimshaw et al. 2004). Moreover, it has been proven that subfertile 
patients appreciate education and improved knowledge and it has also been demonstrated 
to influence their healthcare decisions (Mourad et al. 2011 and Kreuwel et al. 2012). In a 
systematic review, only the effect of paper version materials was studied. However, because 
surveys have shown that online health information retrieval and eHealth activities are 
becoming increasingly common, especially within young and high educated subfertile 
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patients (Aarts et al. 2012, den Breejen et al. 2012, Weissman et al. 2000 and Haagen et 
al. 2003), we decided to offer the patient information materials in both paper and digital 
forms (i.e. website and application). By doing so, and thus tailoring the patient-directed 
intervention to the infertility population, we hope to increase the effect of this intervention 
even more.
Aside from the multifaceted and barrier tailored aspects of the strategy, this study has several 
more strengths;
First, the number of participating clinics is a great strength of this study. A quarter of all Dutch 
clinics from all over the country participate in this study, ensuring the representativeness of 
the Dutch infertility population as well as the professionals who provide fertility care.
Second, the process evaluation provides us with more information on the effectiveness 
and usefulness of the different interventions used in the strategy and not only of the 
multifaceted implementation strategy as a whole. We know that the multifaceted aspect 
of the intervention does not necessarily make the intervention more effective, therefore we 
need to assess the effectiveness of each individual intervention separately as well (Kreuwel 
et al. 2012). This is of great value for further implementation research and development of 
implementation strategies. Furthermore, if the multifaceted implementation strategy proves 
to be effective, it could also be generalized to improve implementation of other guidelines.
Third, the cost evaluation that will take place is very important from a societal aspect. 
Nowadays healthcare is becoming increasingly expensive and cost reduction is a very 
important and common topic in most governments and health care institutes. This economic 
evaluation will provide further information on how we can reduce costs in healthcare by 
following the current and already existing guidelines for best practice and care.
A possible limitation of the study is the chance of contamination of the GPs between the 
intervention and control group. GPs can refer patients to more than one clinic, this makes it 
possible that a GP who is allied to an intervention clinic can also refer patients to a control 
clinic. However we think that the occurrence of actual contamination will be very small 
because the participating clinics are very well spread over the country. In case contamination 
of GPs does occur, we expect the effect on the outcome to be very small or even undetectable 
because the multifaceted intervention strategy is mostly targeted at the secondary and 
tertiary care. 
In summary, the main contribution of this study is that it seeks to identify the most 
effective strategy for implementing the guideline on tailored expectant management in 
subfertile couples. Ensuring the appropriate uptake of guideline recommendations by both 
professionals and patients will improve the care for these patient. 
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ABsTRACT
BACKGROUND: In New Zealand, public funding for assisted reproductive technology (ART) 
is restricted to subfertile women who are unlikely to conceive spontaneously, based on 
clinical and social criteria known as the clinical priority access criteria (CPAC-score). The 
objective of this study was to compare this CPAC score with a prediction model for predicting 
spontaneous conception, developed in the Netherlands (the Hunault model). 
METHODS:  We performed a cohort study and included couples with unexplained subfertility 
and assessed the measure of agreement and the performance of the CPAC score and the 
Hunault prediction score. 
RESULTS: Of 663 couples referred, 249 (38%) couples had unexplained subfertility. Of 246 
women with follow-up data, there were 143 (58%) who had a live birth or ongoing pregnancy 
during the follow up period, 65 (26%) after fertility treatment and 78 (32%) after natural 
conception. There were 100 couples (41%) who had a Hunault prediction score of < 30%, 
which is the Dutch treatment threshold and 36 (15%) couples who had a CPAC score of >65, 
which is the New Zealand threshold for publically funded treatment. There were 69 couples 
(28%) who meet the threshold for treatment in the Netherlands but did not meet the New 
Zealand threshold for public funding. The kappa coefficient as a measure of agreement of 
the two scores and their treatment thresholds was 0.30 suggesting a fair agreement. The 
area under the curve (AUC) for the CPAC and Hunault scores were both 0.63, but the Hunault 
model performed better in calibration. 
CONCLUSIONS: The CPAC score correlates fairly with the Hunault prediction score although 
using the Hunault prediction model 26% more couples would be recommended for ART. The 
discriminative capacities of both scores were comparable, but the Hunault prediction score 
performed better in calibration. Funding models in New Zealand should consider treating 
those women with unexplained subfertility who are least likely to conceive spontaneously. 
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Introduction
Having a baby is an important goal for many couples. However, after one year of regular 
protected intercourse about 10% couples will not have conceived and can be considered to 
be subfertile (Taylor 2003). After investigation, ~30% of couples have no definitive cause of 
subfertility identified, which is known as unexplained subfertility, and many of these couples 
will seek assisted  reproductive technologies (ART) (Boivin et al. 2007; Collins and Van 2004).
However, in most countries there are limitations in public health funding for ART because of 
cost (Chambers et al. 2009). In New Zealand, an approach has been developed that aimed to 
provide public funding for those couples with the greatest need to receive fertility treatment 
(Farquhar and Gillett 2006; Gillett et al. 2011). For the past decade, public funding in New 
Zealand has been restricted to infertile couples who are unlikely to conceive spontaneously, 
who are aged < 40 years old, have a body mass index < 32 kg/m2 and who do not smoke 
cigarettes (Gillett et al. 2006; Gillett et al. 2011).  In addition, seven separate criteria were 
developed for the clinical priority access criteria (CPAC) score, each having subcategories 
for which points were weighted reflecting the need and also the benefit obtained from ART 
treatment (Appendix 1). The CPAC score increases as the duration of subfertility becomes 
longer (reaching a maximum by ≥5 years) but decreases at 40. The highest score possible is 
100 points and the threshold for access to publicly funded ART is set at ≥65 points. Couples 
with unexplained subfertility appear to be at the most disadvantage as they must have had 
5 years of subfertility in order to reach the threshold of ≥65 points.  
In recent years there has been increased interest in prediction models for fertility treatments. 
A systematic review of 29 prediction models (Leushuis et al. 2009) reported that there were 
three models with good predictive performance; of these, the Hunault model dealt with 
prediction of treatment independent pregnancy with unexplained subfertility (Hunault et al. 
2004; Steures et al. 2004; Templeton 2000). The Hunault model has been validated in a large 
study of more than 3000 couples (van der Steeg et al. 2007a). This model has proven useful in 
helping clinicians to identify the likelihood of spontaneous pregnancy and to more effectively 
recommend fertility treatment or expectant management (Appendix 2). When the calculated 
prognosis on a spontaneous pregnancy is ≥30% likelihood of conceiving within 12 months, 
tailored expectant management is a cost effective strategy that prevents overtreatment, 
complications and costs (Steures et al. 2006). Therefore, expectant management in couples 
with a good prognosis is now recommended in the Dutch guidelines for management of 
infertile couples (NVOG guidelines 2009). 
This study sought to consider whether the New Zealand approach to fund fertility treatment 
for couples with unexplained fertility was based on the best prognostic factors and how 
this New Zealand approach differs from the Dutch approach. The objective of this study was 
to evaluate the measure of agreement between the CPAC score and the Hunault prediction 
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score and to compare the performance of both scores, using a NZ cohort of couples with 
unexplained subfertility. 
Methods 
We included couples who were referred by primary care for their first fertility specialist 
appointment to Fertility Plus (a specialist fertility clinic of National Women’s Health of the 
Auckland District Health Board that offers public and private care) between January 2007 
and December 2008 and who were diagnosed with unexplained subfertility.  The criteria 
for unexplained fertility were that the woman had to have at least one patent fallopian 
tube, ovulation confirmed with a luteal progesterone test, and a regular menstrual cycle. 
Menstrual cycles were defined as regular if they were between 23 – 35 days in length, 
with a variation of less than 8 days. Female exclusion factors were anovulation, significant 
adhesions or endometriosis greater than grade 2 (as judged by the revised AFS classification). 
A male exclusion factor was a total motility count of less than 10 million sperm cells. 
The CPAC score was calculated from criteria each having subcategories for which points were 
weighted, reflecting the need and also the benefit obtained from ART treatment (Gillett et 
al. 2006; Gillett et al. 2011; Hadorn and Holmes 1997; Elective Services 2001). The criteria 
included a diagnostic score derived from the subfertility diagnosis intended to reflect the 
probability of spontaneous pregnancy, the woman’s age, the woman’s basal FSH, whether 
the woman smoked or not, the duration of the couple’s subfertility, the number of children, 
whether either partner had been sterilized or not and the main cause of subfertility (ovulation 
disorders, endometriosis, other tuboperitoneal disorders and male factor).  A longer duration 
of subfertility and a higher female age increases the CPAC score, but if the female’s is ≥40, 
the CPAC score decreases. The highest score possible is 100 points and the threshold for 
access to publicly funded ART is set at ≥ 65 points (http://humrep.oxfordjournals.org/
content/26/11/3037/T3.expansion.html). The CPAC score is structured in such a way that 
couples require a minimum duration of subfertility of 1 year before potentially being eligible 
for access to publically-funded ART. In New Zealand, women who smoke and women with 
a body mass index (BMI) of ≥32 are immediately ineligible for publically funded ART. Once 
a couple has 65 points or more then they are eligible for two cycles of IVF or 8 cycles of 
intrauterine insemination or a combination of 4 cycles IUI and 1 cycle IVF. After a couple has 
reached eligibility, there is typically a further 12 month wait for cycle commencement.
The parameters used for the Hunault prediction score are female age, the duration of 
subfertility, the proportion of progressive motile sperm, the referral status and the subfertility 
being primary or secondary. Approximately half of the semen analyses were done at the 
on-site fertility laboratory and included progressive motility data and the remainder were 
completed at a community laboratory that only reported total motility. To account for this 
difference the mean difference between total and progressive motility was calculated from 
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the results where both were reported (12.4%) and this percentage was subtracted from the 
total motility where progressive motility was not reported. 
Data on subsequent fertility treatments and pregnancies resulting in live births after a 
couple’s specialist appointment were collected. If no data was available in the electronic 
medical record, then a letter was sent to the woman requesting information on pregnancy 
outcomes. Ethics Committee approval was received for this last part of the study that 
required contacting patients directly to ascertain pregnancy status (NTY/10/EXP/058 of the 
Northern Y Ethics Committee of the New Zealand Ministry of Health). 
Univariate analysis was used to compare demographic and fertility characteristics between 
couples with a spontaneous live birth, a treatment related live birth and couples without 
a live birth. Comparisons between continuous, bivariate and categorical variables were 
analysed with the one way ANOVA, the Kruskall-Wallis and the Chi-square respectively. 
The measure of agreement between the two scores and treatment thresholds was assessed 
by calculating a kappa coefficient. Discriminative capacity was assessed with receiver 
operation characteristics (ROC) analysis and the area under the curve (AUC) of the couples 
that conceived spontaneously within 12 months. Calibration was assessed by comparing the 
mean predicted probability of the CPAC score and the Hunault model with the mean observed 
fraction of spontaneous pregnancies at 12 months per percentile subgroup. Calculations were 
performed with SPSS 18. (Statistical Package for the Social Sciences: SPSS, Chicago, IL, USA).
Results
Of the 663 couples included in the study, 249 were diagnosed with unexplained subfertility 
and included in the study. Three of these women were lost to follow-up as they were known 
to have left the region. The mean age (SD) of all women was 33.5 (3.8) years, the mean BMI 
was 23.7 (3.5) kg/m2, the mean (SD) length of trying to conceive was 21 (20.8) months and 
35 (14%) couples had secondary subfertility. The median (IQR) CPAC score of all patients was 
19.5 (35) and the mean (SD) Hunault prediction score was 32.3 (12.0). 
Patient characteristics by pregnancy outcome are summarised in Table I. Of the 249 couples, 
126 (50%) had fertility treatment during the follow up period. Of the 246 women with follow-
up, 143 (58%) had a live birth, of which 65 (26%) as a result of fertility treatment and 78 
(32%) were spontaneous conceptions. Of the 65 women who conceived as a result of fertility 
treatment, 40 (61%) underwent ART cycles, 13 (20%) received IUI with clomiphene and 12 
(19%) conceived with clomiphene citrate. Of the 40 women who conceived with ART cycles, 
29 received public funding for their treatment and the remainder were privately funded. 
The median CPAC score (IQR) was 16 (14) for women with a spontaneous conception, 25 
(36) for women who conceived after treatment and 20 (34) for women who did not conceive 
(P=0.004). The mean Hunault prediction score (SD) for spontaneous conception was 36.1 
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(10.6), 30.7 (12.5) for couples that conceived after treatment and 30.6 (11.3) for women who 
did not conceive was (P=0.003). The median (IQR) time to conceive was significantly shorter 
in the women with spontaneous conceptions (8 (13) months) compared wit treatment 
related conceptions (18 (12) months) (P=0.004). The mean (SD) duration of subfertility was 
significantly greater in those women who conceived with treatment (34 (21) months) or did 
not conceive (36 (23) months) compared with those with spontaneous conception (25 (14) 
months (P=0.0001).  
Table II summarises the characteristics and outcomes of the couples with CPAC score ≥ 65 
and <65 and a Hunault prediction of score <30% and ≥ 30% chance on a spontaneous 
pregnancy, the treatment thresholds in New Zealand and the Netherlands respectively. There 
were 36 women (15%) who had a CPAC score ≥ 65 (the threshold which entitled them to 
receive publically funded fertility treatment), whereas 100 women (41%) had a Hunault 
prediction score of <30% (the treatment threshold according the Dutch fertility guidelines). 
The spontaneous live birth rates were significantly lower in the couples eligible for treatment 
according both treatment thresholds (P=0.004 CPAC-threshold, P=0.005 Hunault-threshold). 
The female age was higher and the duration of subfertility was longer in the couples eligible 
for treatment according both treatment thresholds (P= 0.014 and p< 0.0001 CPAC-threshold, 
p<0.001 and p<0.001 Hunault threshold, respectively). According to the CPAC treatment 
threshold and the Hunault treatment threshold, 31 (13%) couples would be recommended to 
receive fertility treatment in both countries, 141 (57%) couples would not receive treatment 
in either country, 69 (28%) couples would receive treatment in the Netherlands but would not 
receive treatment in New Zealand and 5 (2%) couples who would not receive treatment in the 
Netherlands but would receive treatment in New Zealand (Figure 1). The kappa coefficient 
as a measure of agreement of the two treatment selection strategies was 0.30, suggesting a 
fair agreement.
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Table I. Characteristics of the study population  a Note missing data for three women and for ethnicity  
b One way ANOVA, c Chi square, d  Kruskall Wallise.  From first specialist, Appointment to 6 weeks 
pregnancy
Women with 
spontaneous 
ongoing 
pregnancy a 
n=78
Women with 
treatment 
related  
ongoing 
pregnancies a 
n=65
Women 
with no 
pregnancies  
n=103
p-value
Mean female age (SD) 32.9 (3.5) 33.8 (3.5) 33.9 (4.2) 0.181b
Primary subfertility (%) 45 (58) 41 (63) 55 (53) 0.311 b
Duration of subfertility in months 
(median, IQR)
24.5 (13.8) 34.1 (21.0) 36.3 (23.6) <0.001 b
One-sided tubal pathology HSG or 
laparoscopy (%) 
7 (9) 6 (9) 14 (13) 0.557 c
Total Motility Count (median, IQR) 75.8 (124.35) 130.7 (97.49) 92.6 (103.75) 0.035 d
Ethnicity of woman, n (%)
- European
- Maori
- Pacific
- Asian
- Indian
- Other
40 (51)
0
3 (4.2)
15 (21)
7 (9.9)
5 (7)
43 (60.6)
1 (1.4)
2 (2.8)
11 (15)
9 (13)
5 (7)
48 (47)
5 (5)
4 (4)
20 (18.9)
17 (16.8)
6 (5.9)
  0.5884 d
BMI of woman (mean) 23.3 (2.9) 23.6 (3.4) 24.0 (3.8) 0.260 b
CPAC score (median, IQR) 16.0 (14) 25.0 (36) 20.0 (34) 0.004a
Women with CPAC score <65 74 (95) 53 (82) 83 (81) 0.016 c
Hunault prediction score (mean, 
SD)
36.1 (10.6) 30.7 (12.5) 30.6 (11.3) 0.003b
Women with Hunault 
predictionscore < 30 
21 (27%) 29 (45) 50 (49%) 0.019 c
Time to conceive  in months e
(median, IQR)
8 (13) 18 (12) - <0.001d
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Table II. Features and outcomes of couples with CPAC score ≥ 65 and <65 and a Hunault prediction 
(Hunault) of score <30% and ≥30% chance on a spontaneous pregnancy a Missing data = three women 
who moved from the district. IQR: interquartile range
Treatment 
threshold
Expectant 
management 
threshold
p-value
New Zealand CPAC score ≥ 65 
(n=36)
CPAC score <65 
(n=210)
Mean female age (SD) 35.0 (2.9) 33.3 (3.9)  0.014
Duration of subfertility in months (median, 
IQR)
60.0 (17) 24.0 (18) <0.001
Couples with Hunault prediction score 
<30%, n (%)
31 (86) 69 (33%) <0.001
Couples with a spontaneous livebirth, n (%) 4 (11) 74 (35%) 0.004
Couples received treatment, n (%) 24 (67) 92 (44%) 0.013
Couples with live birth after treatment, n (%) 12 (50) 53 (25%) 0.504
Total live birth, n (%) 16 (44) 127 (60%) 0.063
The Netherlands  Hunault score 
<30%  (n=100)
Hunault score 
≥30% (n=146)
Mean female age (SD) 35.8 (2.8) 32.0 (3.7) <0.001
Duration of subfertility in months (median, 
IQR)
36 (36) 24 (4) <0.001
Couples with CPAC score ≥ 65, n(%) 31 (31) 5 (3.4) <0.001
Couples with a spontaneous ongoing 
pregnancy, n (%)
22 (22) 56 (38) 0.005
Couples received treatment, n (%) 55 (55) 61 (42) 0.028
Couples with ongoing pregnancy after 
treatment, n (%)
29 (45) 36 (55) 0.496
Total live births, n (%) 51 (51) 92 (63) 0.047
The ROC curves of both scores are shown in Figure 2. The CPAC score and the Hunault prediction 
score both had an Area Under the Curve (AUC) of 0.63. The calibration plot in Figure 3 shows 
the association between the mean calculated CPAC score and the observed fraction of couples 
with a spontaneous pregnancy within 12 months in 4 percentile subgroups. Because a lot of 
couples had the same CPAC score the calibration could only be plotted in 4 subgroups which 
makes the calibration plot difficult to interpret: in 2 subgroups the calibration was good and 
in the other 2 subgroups the calibration was poor. Figure 4 shows the calibration plot of the 
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Hunault score, with the mean calculated probability on a spontaneous pregnancy on the X 
axis and the observed fraction of couples with an ongoing spontaneous livebirth within 12 
months on the Y-axis, for each of the 10 decile subgroups. The calibration plot of the Hunault 
score was moderate but performed best in the couples with a prognosis <30%. 
Figure 1 The correlation of CPAC score and the Hunault prediction model
The lines at the X-axis at 65 and at the Y axis at 30 represent the treatments thresholds for New Zealand 
and the Netherlands, respectively. In the lower right quadrant are the couples (n=31) who would 
receive fertility treatment in both countries, the upper left quadrant are the couples (n=141) would 
not receive treatment in either country. In the lower left quadrant there are couples (n=69) who would 
receive treatment according the Hunault prediction score but would not receive treatment according 
to the CPAC score and in the upper right quadrant are couples (n=5) who would not receive treatment 
according the Hunault prediction score but would receive treatment according to the CPAC score.
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Figure 2 The AUC of the Hunault prediction score (Dutch model) is 0.632 and the AUC of the CPAC score 
(New Zealand) is0.629. Only the spontaneous pregnancies are included in this analysis
Figure 3. Calibration plot of the CPAC score of the couples with an spontaneous pregnancy within 12 
months  (n=79).
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Figure 4. Calibration plot of the Hunault prediction model of the predicted and observed spontaneous 
pregnancies within 12 months (n=79)
discussion
The current approach in New Zealand of using a CPAC score to determine access to treatment 
for couples with unexplained subfertility correlates only fairly with the Hunault prediction 
scores and there were 26% fewer couples eligible for publically funded treatment in New 
Zealand compared with the Netherlands. The AUC for both approaches implies moderate 
discrimination for the prediction of pregnancy but the Hunault score performed better for 
calibration than the CPAC score. The calibration plot of the Hunault score performed best 
in couples with a prognosis <30%. In evaluating the performance of prediction models in 
fertility care the AUC is low for most prediction models in reproductive medicine. However, 
low values of the AUC do not imply that these models are of limited use in clinical practice. 
The calibration of the model (the correspondence between model-based probabilities and 
observed pregnancy rates) as well as the availability of a clinically useful distribution of 
probabilities are more meaningful concepts for model evaluation (Coppus et al. 2009) In that 
regard, the Hunault prediction model performs better on both aspects (calibration and a 
clinically relevant distribution of the probabilities). 
This study sought to consider whether the New Zealand approach to funding fertility for 
couples with unexplained subfertility was comparable to other prediction models. The study 
has compared the New Zealand scoring system for 249 couples with unexplained subfertility 
with a prediction score validated in more than 3000 couples and found that the CPAC scores 
correlated fairly with the Hunault prediction score. It has also shown that almost 70% of 
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women who met the criteria for funding in the Netherlands would not receive treatment 
with the CPAC system.   For example, if it is accepted that the prediction model threshold of 
30% identifies a population of couples who have a low chance of conceiving spontaneously, 
then it is unsatisfactory that only 14% of couples in this category have a CPAC scores ≥65 and 
would receive funded fertility treatment in New Zealand. 
Overall, women with unexplained subfertility have a reasonable chance of conceiving either 
spontaneously or with treatment. In our study a third of couples with unexplained subfertility 
conceived spontaneously in the 4-5 years of follow up and the median time to conceive was 8 
months from the time of the first consultation with almost half of them conceiving in the first 
year. When the women who conceived after treatment were included, then the proportion 
of women with a live birth was 57%. Overall the 57% of women who conceived in this study 
is lower than the 80% of women from the Netherlands with unexplained subfertility who 
conceived either spontaneously or with treatment within 36 months of their first specialist 
appointment (Brandes et al. 2011). The lower rates in New Zealand may in part be explained 
by the earlier presentation of women in the Netherlands as the mean duration of subfertility 
in the Dutch cohort study was 21 months compared to 32 months in New Zealand. 
There are several limitations to our study. Follow up may be incomplete, as although  we 
collected outcome data from two sources including electronic medical records and direct 
written contact with the patient it is possible that some treatment and pregnancy outcomes 
have been missed because of patients moving out of the region. Other differences between 
the two approaches are that some criteria in CPAC could be applied subjectively such as the 
stage of endometriosis, the extent of tubal adhesions and the extent of oligoamenorrhoea. In 
addition, the calibration model does not fit the CPAC approach well as CPAC tends to cluster 
scores and is therefore not a natural measure of continuous fertility outcomes. Finally, the 
CPAC score is not a prediction score as it increases with age but then decreases >40 years, 
yet we have compared it with a prediction model which makes the linearity for evaluation 
debatable. The strength of our study was that the CPAC scoring was independent as it was 
performed by the study investigator and not the clinician. In addition, the prediction model 
has been validated in more than 3000 couples with unexplained subfertility (van der Steeg 
et al. 2007a). Another strength of this study is that this is the first time the CPAC score is 
compared with a validated prediction model and it is the first time that the Hunault model 
has been validated in a New Zealand population. 
Should New Zealand consider changes to the CPAC on the basis of this study? This study 
has shown that the CPAC model has performed poorly compared to the Hunault prediction 
model. On the other hand, in New Zealand only 15% of couples were recommended to receive 
publically funded treatment whereas using the Hunault prediction model 41% of couples 
would have been recommended to have treatment. The Hunault prediction model is based 
on robust evidence, in contrast to the CPAC score which was developed for funding reasons. 
An alternative to introducing the Hunault system would be to lower the threshold of 65 
which would require additional funding. One of the challenges with the CPAC system is that 
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there is no difference in the score if you are 32 or 39 (all other things being equal), although 
it then ceases at the age of 40. As many of the women in this study were over 36 years old, 
then it can be argued that this older group should have priority over younger women. The 
Hunault system addresses the impact of age on spontaneous pregnancy and this is a further 
reason to consider using this model in New Zealand for women with unexplained subfertility. 
Whatever changes to the funding system are made it is clear that if more couples are treated 
then an increase in funding for fertility treatment will be needed. Treating those women who 
have a low prediction score makes both clinical and economic sense as with each additional 
year their chances of success with or without ART will decline. 
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APPENDIx 1: THE CPAC sCoREA.
 
Diagnostic score
Ovulation
Anovulation 2 hypopituitary hypogonadism, ovulatory with treatment, not 
pregnant after 9 months 6
Clomiphene ± metformin ± resistance to laparoscopic ovarian diathermy, oligo-
ovulation/luteal defects (fewer than nine ovulatory cycles per year) 3
No ovulation defect 0
Semen
Strict abnormal morphology, 10%/count <1 M motile/ml/severe Abs (mixed 
antiglobulin reaction over 40%)
6<1 M motile sperm after semen prep/IUI where <2 M motile recovered
3× IUI without conception where male factor but >2 M motile recovered
<50% motile or <20 million/ml on two occasions 3
No sperm defect 0
Endometriosis
Stage IV 6
Stage III 3
Stage II 2
Stage I 1
No endometriosis 0
Tubal
Occlusion/severe adhesions/unsuccessful surgery after 12 months 6
Moderate adhesions/unsuccessful surgery after 6 months 3
Polyps/mild adhesions/normal tube on one side 2
Minimal adhesions on best side 1
No tubo-peritoneal pathology 0
Other factors
Severe 6
Moderate 3
Mild 2
Minimal 1
None 0
Duration of 
exposure to 
pregnancy
≥5 years 6
≥4 and <5 years 3
≥3 and <4 years 2
<3 years 1
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Objective criteria Points Now +1 year +2 years
Diagnostic score (01) 
(see above)
Total score
≥6 1.0
3–5 0.7
2 0.4
0–1 0.2
Woman’s age (02)b
≤39 years 1.0
40, 41 0.5
≥42 0.1
Objective score (OS) OS = 01 × 02
Social criteria Points Now +1 year +2 years
Duration of infertility 
over time (S1)c
<1 year 5
1 or 2 years 20
3 or 4 years 40
5 years or more 50
Children at home (S2)d
None 30
1 by relationship 10
>1 by relationship 5
By previous relationship 8
Sterilization (S3)e
Neither partner 20
Yes, but death of child 20
Yes 10
Social score (SS) SS = S1 + S2 + S3
Score =OS × SS
aIn order to assess publically funded fertility treatment women must be aged <40 years old, non-
smoking and have a BMI ≤32 kg/m2. Only patients with a score of 65 or more can access fertility 
treatment in the next 12 months. 
bA category for age is included to accommodate the possibility of lowering the threshold in the future. 
cThe duration of infertility is cumulative over previous and current relationships except after sterilization 
reversal when duration is from when a child is planned in the current relationship. 
dChildren living at home are defined as children under the age of 12 who have lived with the couple for 
most of the child’s life. 
eSingle and lesbian women are eligible for scoring is there is a clear biological cause of infertility or at 
least 12 cycles of DI with pregnancy of which 6 must be undertaken with in an accredited unit. 
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Appendix 2: The Hunault prediction score
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ABsTRACT:
OBJECTIVE: The current evidence concerning the best treatment option for couples with 
unexplained and male subfertility is inconclusive. Most studies which have evaluated 
the effectiveness of treatment options like expectant management (EM), intra uterine 
insemination (IUI) with or without controlled ovarian stimulation (COS) and in vitro 
fertilisation (IVF), have not taken the couples’ prognosis into account. It is very likely that the 
individual prognosis of the couple influences the effect of treatment. Individual patient data 
analyses allow us to take these prognostic factors into account and to evaluate their effect 
on treatment outcome. This study aims to use anonimysed data from relevant published 
trials to perform an individual patient data meta-analysis evaluating the effect of couples’ 
prognosis on the effectiveness of EM, IUI with or without COS and IVF.
METHODS: Based on earlier systematic reviews and an updated search, randomised controlled 
trials will be considered for inclusion. Authors of the included studies will be invited to form 
a collaborative group to share their original anonymised data. The data will be assessed on 
validity, quality and completeness. The prognosis of the individual couple will be calculated 
with existing prognostic models. The effect of the prognosis on treatment outcome will be 
analysed with marker-by-treatment predictiveness curves, illustrating the effect of prognosis 
on treatment outcome.    
POPULATION: Untreated subfertile couples with unexplained or male subfertility included in 
trials comparing EM, IUI with or without COS and IVF. This study is registered in PROSPERO 
(registration number CRD42011001832).
CONCLUSION: Ultimately, this study may help to select the appropriate fertility treatment 
tailored to the needs of an individual couple. 
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InTRoduCTIon: 
Subfertility affects at least 10% of couples trying to conceive (Gnoth et al. 2003; Wang et 
al. 2003). In approximately half of them, no major underlying cause is found (Aboulghar M 
et al. 2009). Although intrauterine insemination (IUI) with or without controlled ovarian 
stimulation (COS) is often the first step in the treatment algorithm in these couples, the 
evidence for the effectiveness of IUI with or without COS over expectant management (EM) 
remains inconclusive (Cohlen et al. 2005; Hughes 2003). The results of trials comparing 
IUI alone, IUI with COS or EM with each other, have been pooled in several meta-analyses 
(Bensdorp et al. 2007; Helmerhorst et al. 2005a; Steures et al. 2008; Verhulst et al. 2006).  
A review on IUI for couples with unexplained subfertility showed a significant increase in 
pregnancy rates for treatment with both IUI and COS, separately. Data on multiple pregnancies 
and other adverse events for treatment with COS were insufficient to allow conclusions 
(Verhulst et al. 2006). A review on IUI for male subfertility concluded there was insufficient 
evidence to recommend IUI with or without COS above EM or vice versa (Bensdorp et al. 
2007). A review including studies with unexplained, male and cervical subfertility found 
higher pregnancy rates for IUI and COS in couples with unexplained subfertility, but not in 
couples with good prospects on a spontaneous pregnancy. In couples with cervical factor and 
male subfertility, IUI alone led to higher pregnancy rates (Steures et al. 2008). However, the 
quality of the included trials was poor, the sample sizes were small, and complications like 
multiple pregnancies were poorly reported.
In Vitro Fertilisation (IVF) and Intra Cytoplasmic Sperm Injection (ICSI) were initially introduced 
to help couples with infertility due to the inability of the male and female gametes to meet or 
the inability of the spermatozoa to penetrate the egg. Nowadays, IVF and ICSI are also used 
for couples in whom these conditions are not met and who thus have a chance of natural 
conception. The effectiveness of IVF as primary treatment or after failed IUI in those couples 
is debatable. The pooled results of trials that compared IVF with expectant management or 
intrauterine insemination (IUI) with or without controlled ovarian hyperstimulation (COS) in 
couples with mainly unexplained or mild male subfertility are difficult to interpret due to the 
heterogeneity of the studies and lack of prognostic information about the couples in relation 
to treatment outcome (Pandian et al. 2010). In a cohort of newly referred subfertile couples, 
the contribution of IVF in couples with unexplained subfertility and ovulation disorders 
was extremely limited -ongoing pregnancy rates of 13 and 4.5%, respectively- compared to 
patients with tubal factor, endometriosis and male factor in whom pregnancy rates were 45, 
45 and 37%, respectively (Brandes et al. 2010). Here, just like in the IUI studies, there was 
limited information about influence of prognostic factors on treatment outcome.  
This information can be derived from prognostic models which estimate the chances of 
spontaneous conception (Hunault et al. 2004; van der Steeg et al. 2007a) or following fertility 
treatment (Custers et al. 2007; Steures et al. 2004; Templeton 2000). The use of these models 
can help to discriminate between couples who would benefit from intervention from those 
who would not. 
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When conventional meta-analyses are inconclusive or contradictory, individual patient data 
meta-analysis (IPD-MA) can have additional value, because it allows this very evaluation of 
prognosis on treatment effect. This is important, because it may well be that, if treatment 
is tailored to couples with a low chance of conceiving spontaneously, the treatment effect 
increases and vice versa. Therefore, we plan to perform an individual patient data (IPD) meta-
analysis of randomized controlled trials evaluating the effect of couples’ individual prognosis 
on the effectiveness of Expectant management (EM), IUI, both with and without COS and IVF. 
objectives of the study
The main goal of this study is to evaluate the effect of prognosis on the effectiveness of EM, 
IUI with and without COS and IVF in couples with mainly unexplained subfertility using 
IPD-MA. Mainly unexplained subfertility is defined as couples in which the gametes are 
able to meet, and includes couples with unexplained and male subfertility. The prognostic 
models we will use are the Hunault model (Hunault et al. 2004) that predicts the chance on a 
spontaneous pregnancy within 12 months, the models of Steures that predicts the chance on 
pregnancy after IUI with and without COS (Steures et al. 2004) and the model of Templeton 
that predicts the chance on pregnancy with IVF (Templeton 2000). Those models are selected 
because they are the only models that performed well in the external validation (Leushuis 
et al. 2009).  
Hunault’s model includes the predictors female age, duration of subfertility, subfertility being 
primary or secondary, percentage of motile sperm and the referral status. Steures’ model 
includes female age, duration of subfertility, cervical factor, male factor, tuba pathology, 
uterus anomaly, endometriosis and the use of clomifene or recombinant -FSH. Templeton’s 
model includes female age, duration of subfertility, tubal subfertility, livebirth after IVF, 
livebirth which was not a result of IVF, a previous pregnancy after IVF which did not result in 
a livebirth and a  previous pregnancy not after IVF which did not result in a livebirth.
METHods And dEsIgn
literature-search and data sharing request
Previously, systematic reviews of trials comparing the included treatments-options for 
each diagnostic subgroup, i.e. unexplained, male  and cervical factor subfertility, have been 
performed (Bensdorp et al. 2007; Helmerhorst et al. 2005a; Pandian et al. 2005; Steures 
et al. 2008; Verhulst et al. 2006). By means of these reviews we will identify studies for 
our IPD-meta-analysis. We will update the performed search strategies to include studies 
published up to date and we will check references and ask authors whether they are aware of 
unpublished ongoing studies. In case of a cross over design the authors will be asked if they 
have the pre-crossover data available separately. Readers of this protocol, who are familiar 
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with studies performed in this field that are not integrated in the previous performed meta-
analyses, are also invited to approach us. 
Registration
The protocol is registered with PROSPERO.com (registration number CRD42011001832).
data acquisition
We plan to contact the first authors of the studies included by email and in case of no 
response we will also email the last authors. When there is still no reaction we will try to 
contact them by phone. We will ask them to send the complete anonimysed dataset as to 
minimise their efforts going through their dataset to select appropriate variables. We accept 
any data format, provided that variables and categories are adequately labelled within the 
dataset or with a separate dictionary. All participants will be identified by study number. 
Names and addresses will not be included in any of the datasets sent by the primary research 
groups. Anonymised data from relevant trials (the results of which have all been published in 
peer reviewed journals in the past), will be amalgamated and stored in a password protected 
University of Amsterdam Computer at the Amsterdam Medical centre Amsterdam and  usual 
precautions regarding confidentiality and access will be observed. The dataset will not be 
used for any other research apart from that described in the protocol. The data will be stored 
for 5 years beyond the life of this project (2011-2013). 
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Figure 1. Flowchart of the study protocol
quality assessment 
For each trial, information on the quality of the trial will be extracted based on a number 
of items: adequate randomisation, concealment of allocation, parallel design and exclusions 
after randomisation. If a trial does not adhere to these standards, its validity will be 
considered as compromised. Depending on the level of the compromise, the randomised trial 
can be excluded in the analysis. If there is a large variety in quality and completeness of data 
between different trials, separate analysis will be made in high and poor quality trials next 
to analysing all data as a whole. The same treatment arms of the different trials will be assed 
on comparability. Completeness of the datasets in terms of prognostic markers and outcomes 
will be reported. The consistency of data and the published manuscript will be assessed. 
If data are missing or inconsistent or the details of the treatment are unclear, the original 
investigator will be contacted. Incomplete data or major inconsistencies with published 
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results can lead to exclusion. There is no strict limit set for the fraction of acceptable missing 
data, since this depends on which variable and the type of missing data. The decision to 
include or exclude a study will be discussed in the project group. 
Analysis
All the different steps of this protocol are summarised in a flowchart, see figure 1. Before the 
start of the analysis, we aim to make the variable codes of all the acquired data compatible. 
Missing data will be imputed using multiple imputations within the original studies. All 
the prognostic factors will be used as predictors for the imputations. The prognosis of the 
patients will be calculated based on the prognostic models of Hunault, Steures and Templeton 
(Hunault et al. 2004; Steures et al. 2004; Templeton 2000). If heterogeneity allows, the original 
data will be merged into a single set. A study identification variable will be added to reflect 
the stratified nature of the pooled dataset. 
Initial analyses will be performed for the primary outcome livebirth or ongoing pregnancy 
per couple, depending on the availability of the data. Secondary outcomes are livebirth or 
ongoing pregnancy per cycle and multiple pregnancies per couple. Livebirth is defined as 
the delivery of at least one living child beyond 22 weeks. Ongoing pregnancy is defined 
as the presence of fetal cardiac activity at ultrasound at a gestational age of ≥ 12 weeks. 
The baseline characteristics and the outcomes will be summarised in a table, per study and 
overall. 
A marker-by-treatment predictiveness curve will be plotted per trial and per prognostic 
marker to illustrate the treatment effect as a function of the prognosis (Janes et al. 2011). 
The calculated prognostic variable will be used as the marker. If there is a differential benefit 
from treatment, these curves will show the treatment threshold for the prognostic marker. In 
that case, some patients benefit from treatment, whereas other do not, and the marker can 
be used to make the selection.
The effect of the prognostic marker based treatment strategy will be evaluated by comparing 
the outcome of treating all patients without taking the prognostic marker threshold into 
account versus treating couples according to the prognostic marker threshold (Vickers et 
al. 2007). Subsequently we will evaluate the proportion of patients for whom treatment 
recommendations would change after using the prognostic marker based treatment strategy 
(Oratz et al. 2007). Finally, we will compare the effects of the different prognostic marker-
based treatment strategies on pregnancy outcomes. 
If there is a relation between the treatment effect and the prognosis and the curves show a 
treatment threshold per prognosis, an algorithm will be developed for clinical practice. This 
algorithm will help the clinician to choose the best treatment strategy for the individual 
patient based on their prognosis.   
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Collaboration
Meetings 
To have the opportunity to discuss the project with the co-authors, meetings at international 
fertility congresses will be organised. During these meetings the project in general and the 
practical, methodological and data related aspects can be discussed. 
Authorship
We plan to provide one co-authorship for each contributor of individual patient data for 
the articles that we publish. In case the number of authors is limited by journal editors, 
we propose to publish under a collaborative group name. For articles explicitly focusing 
on methodological aspects of IPD-meta-analyses, where these data are used for illustratory 
purposes, contributors will be individually acknowledged in each article. The results of 
this project will be presented on international conferences and published in clinical and 
epidemiological journals.
Competing interests
Some of the authors are authors of the original trials on which the proposed IPD-MA is based.
disclosure of interest
There are no conflicting interests in this study
Contribution to authorship 
BWM is the principal investigator of this study. NB is responsible for the overall logistical 
aspects of this study, drafted the first version of this paper and will perform the analysis 
together with PT, PB, BM, FvdV, and PH. BM will supervise the whole process. SB, IC, AJG, DG, 
PS have agreed to share data and all authors read and approved the final article.
details of ethical approval
We propose to use only anonymised data from published trials. In response to our query 
the Ethics Committee of the Academic Medical Centre in Amsterdam did not feel that formal 
Ethics Approval was required.
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Chapter 8
ABsTRACT
Background. At present, it is unclear which treatment strategy is best for couples with 
unexplained or mild male subfertility. We hypothesized that the prognostic profile influences 
the effectiveness of assisted conception. We addressed this issue by analysing individual 
patient data RCTs.
Methods.  We performed an individual patient data (IPD) analysis of published randomised 
controlled trials (RCTs) on treatment strategies for subfertile couples. Eligible studies were 
identified from Cochrane systematic reviews and we also searched Medline and EMBASE. The 
authors of RCTs which compared expectant management (EM), intracervical insemination 
(ICI), intrauterine insemination (IUI), all three with or without controlled ovarian stimulation 
(COS) and IVF in couples with unexplained or male subfertility, and had reported live 
birth or ongoing pregnancy as an outcome measure, were invited to share their data. For 
each individual patient the chance of natural conception was calculated with a validated 
prognostic model. We constructed prognosis-by-treatment curves and tested whether there 
was a significant interaction between treatment and prognosis.
Results. We acquired data from 8 RCTs, including 2,550 couples. In three studies (n= 954) 
the more invasive treatment strategies tended to be less effective in couples with a high 
chance of natural conception but this difference did not reach statistical significance (p-value 
for interaction between prognosis and treatment outcome were 0.71, 0.31 and 0.19). In one 
study (n=932 couples) the strategies with COS (ICI and IUI) led to higher pregnancy rates 
than unstimulated strategies (ICI 8% vs. 15%, IUI 13% vs. 22%), regardless of prognosis 
(p-value for interaction in al comparisons >0.5), but at the expense of a high twin rate 
in de COS strategies (ICI 6% vs. 23% and IUI 3% vs. 30% respectively). In two studies (n= 
373 couples), the more invasive treatment strategies tended to be more effective in couples 
with a good prognosis but this difference did not reach statistical significance (p-value for 
interaction: 0.38 and 0.68). In one study (n=253 couples) the differential effect of prognosis 
on treatment effect was limited (p-value for interaction 0.52), perhaps because prognosis was 
incorporated in the inclusion criteria. The only study that compared EM with IVF included 38 
couples, too small for a precise estimate.
Conclusions. In this IPD analysis of couples with unexplained or male subfertility, we did not 
find a large differential effect of prognosis on the effectiveness of fertility treatment with IUI, 
COS or IVF.
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InTRoduCTIon 
Despite the frequent use of fertility enhancing treatments in couples with unexplained or 
male subfertility, evidence from randomised trials is scarce. Most international guidelines 
recommend starting with less invasive treatments, for example intrauterine insemination 
(IUI), and moving on to more aggressive interventions, such as IVF, if these are unsuccessful 
or when the woman is older and the duration of subfertility is longer (The Practice Committe 
of the American Society of Reproductive Medicine, 2012;NICE, 2004;ESHRE, 2001). 
Data from randomised controlled trials (RCTs) are contradictory and sometimes 
counterintuitive (Bhattacharya et al., 2008;Goverde et al., 2000;Guzick et al., 1999;Hughes 
et al., 2004;Reindollar et al., 2010;Soliman et al., 1993;Steures et al., 2006). These studies do 
not provide a clear recommendation on which couple would benefit from which treatment. 
For example, in a comparison between IUI and expectant management (EM) there is a 
non-significant beneficial effect for IUI (odds ratio: 1.53 confidence interval (CI): 0.91-2.56)
(Bhattacharya et al., 2008), while in another comparison between IUI with controlled ovarian 
stimulation (COS) and EM there is no significant beneficial effect for IUI with COS (risk ratio 
(RR):0.85 CI: 0.55-1.30)(Steures et al., 2006). In studies that compared IVF with EM one showed 
a significant beneficial effect of IVF over EM (RR 4,5, CI 1,44-14,6)(Hughes et al., 2004), while 
another found a non-significant beneficial effect of EM (RR: 2,7 CI: 0.97-7.49) (Soliman et al., 
1993). Several meta-analyses have pooled the results of these RCTs and also did not find 
convincing benefits of  one treatment strategy over the other (Bensdorp et al., 2007;Steures et 
al., 2008;Verhulst et al., 2006;Veltman-Verhulst et al., 2012). A possible explanation for this may 
be the inclusion of couples with varying prognostic profiles as evident from the wide range 
in female age and duration of subfertility within RCTs, which results in different chances 
of natural conception. When conventional meta-analyses are inconclusive or contradictory 
and the trials included are heterogeneous, individual patient data (IPD) analysis can have 
additional value, because factors influencing the outcome (in this case prognosis) can be 
taken into account in the analysis. As such, IPD is an extension of standard meta-analysis 
and may create new possibilities for evaluating treatments and treatment policies. In the 
Netherlands, standard treatment policy is to use the prognostic profile of a subfertile couple 
to select couples for EM. In the present IPD analysis we wanted to evaluate if this prognostic 
profile can be used to select couples for a specific treatment, such as IUI with or without COS 
or IVF. We evaluated if the treatment effects in the RCTs are influenced by the prognostic 
profile of the couples. We hypothesized that invasive treatments, such as IUI with COS or IVF, 
are more effective than EM in couples with limited chances of natural conception, but less so 
in couples with good prospects of natural conception. To test our hypothesis, we performed 
an IPD analysis of published RCTs, and evaluated whether a couples’ prognosis of natural 
conception attenuated or strengthened the impact of assisted reproduction. 
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Methods
We performed an IPD analysis of published RCTs on treatment strategies for subfertile 
couples. The protocol has been published previously (van den Boogaard et al., 2012). This 
study is registered in PROSPERO (registration number CRD42011001832) and the study 
protocol of this study is published in the BJOG.
selection of studies
We selected studies in couples who had been trying to conceive for at least 1 year, were 
diagnosed with unexplained, male or cervical factor subfertility, and who had never received 
COS, IUI or IVF in the past. Unexplained subfertility was defined as subfertility without any 
demonstrable cause after the basic fertility work up, including tests of ovulation, semen 
analysis and tubal evaluation. Mild endometriosis and one-sided tubal pathology were also 
categorised as unexplained subfertility. For the definition of male subfertility the World 
Health Organization criteria of 2009 were used (Cooper et al., 2010). The prognostic model 
used in our analysis includes the motility of the sperm as a predictor. This allows us to 
be liberal in the inclusion of studies with male subfertility. Cervical factor subfertility was 
defined as the absence of progressive motile spermatozoa in cervical mucus with normal 
semen parameters. 
RCTs were eligible if they had compared two or more of the following strategies: EM, timed 
intercourse with or without COS, IUI with or without COS, or IVF and if they had reported live 
birth or ongoing pregnancy as an outcome measure.
We included only truly RCTs. Quasi-randomised studies, where allocation relied on alternation 
or chart number, were not eligible. In case of a cross-over design the authors were asked for 
the pre-crossover data.
Eligible studies were identified based on Cochrane systematic reviews of studies comparing 
EM, intra-cervical insemination (ICI) or IUI with and without COS and IVF in couples with 
unexplained, male or cervical factor subfertility (Bensdorp et al., 2007;Helmerhorst et al., 
2005;Pandian et al., 2005;Steures et al., 2008;Verhulst et al., 2006). We additionally searched 
Medline and EMBASE to detect trials published after closure of the data collection of the 
Cochrane reviews. We used the following search terms (with synonyms and closely related 
words): ‘infertility’, ‘subfecundity’, ‘unexplained subfertility’, ‘male subfertility’, ‘cervical 
factor’, ‘intrauterine insemination’ ‘intrauterine insemination with COS’ and ‘in-vitro 
fertilisation’. We did not apply language restrictions. The final search was performed in 
January 2011. References were checked and authors of relevant studies were contacted to 
ask whether they were aware of any unpublished ongoing studies.
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Collection of IPd
For each eligible study, we tried to obtain contact information of the first author from 
Medline, EMBASE or from searching the Internet. We invited authors by email to share their 
data. If contact information of the first author was unavailable or when the first author did 
not respond after two or more emails, we contacted the second or last author. 
We provided authors who were considering participation with a more detailed study proposal 
and asked authors to send us their complete database in original format, to minimize their 
efforts to select the appropriate variables or to convert data to a specific format. If variables 
and categories were not adequately labelled, a separate data dictionary was requested. 
The data received were crosschecked against published reports of the study. Authors were 
contacted for clarification in case of discrepancies and asked to supply any missing data 
when possible.
data extraction
From each trial, we extracted information on the characteristics of the couples: female age, 
duration, type and cause of subfertility, previous miscarriages, percentage motile sperm, 
sperm concentration, grade of endometriosis, tubal patency, referral status, BMI, number of 
treatment cycles, number of follicles ≥16 mm during IUI , dose of gonadotrophins, number 
of embryos transferred; and the type of outcome, i.e. live birth, ongoing pregnancy and 
multiple birth.
Assessment of study quality
Assessment of the methodological quality of included studies was based on the information 
reported in the original published papers and responses to specific queries to the authors. We 
assessed the risk of bias assessed by checking the adequacy of randomisation, comparability 
of groups at baseline, the completeness of follow-up, and a priori sample size estimation. 
Generalizability was based on the description of the sample recruited. The adequacy of 
randomisation was assessed by checking methods used for sequence generation, treatment 
allocation and allocation concealment. When these details were unclear in the initial 
publication, we contacted authors to provide further clarification. 
Analysis 
For every RCT we calculated the chances of natural conception leading to live birth within 
12 months for each participating couple, using the validated prognostic model developed 
by Hunault  et al. (2004). This model takes into account female age, duration of subfertility, 
subfertility being primary or secondary, percentage of motile sperm and being referred by 
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a general practitioner or gynaecologist. Missing data were multiply imputed within each 
original dataset, using all prognostic factors and the outcome.
Using logistic regression we estimated the probability of live birth for each couple based on 
the Hunault score, the treatment allocation and an the interaction between the Hunault score 
and the treatment allocation. This interaction term explores whether the relation between 
the Hunault score and the treatment outcome. We evaluated the statistical significance of 
this interaction term with the Wald test statistic, using a conventional significance level of 
P<0.05.  If live birth was not registered ongoing pregnancy was used.  
We also graphically presented the regression model. We used a prognosis-by-treatment curve, 
similar to the marker-by-treatment predictiveness curves proposed by Janes et al. (2011). 
These graphs display for each treatment arm the probability of a live birth over the range 
of Hunault prognoses. When a differential benefit from treatment is present, the curves 
intersect: on the left side of the intersection the treatment line on top results in a higher 
number of live births, at the intersection point both treatments result in the same number of 
live births, this then switches and on the right side of the intersection the other treatment is 
favourable and results in a higher number of live births.
If heterogeneity allows, the original data will be merged into a single set and the 
abovementioned analyses will be performed for the merged data set as well. 
Data were analyzed using the Statistical Package for the Social Sciences
18.0 (SPSS Inc., Chicago, IL, USA). A p-value < 0.05 was considered statistically significant.
Ethical approval
We used anonymised data. The Ethics Committee of the Academic Medical Centre in 
Amsterdam indicated that formal approval of an ethics committee was not required. Ethical 
approval to share trial data was obtained by participating trial groups in their centres if 
necessary.
REsulTs
study selection
The systematic literature search and the results of the data sharing requests are summarised 
in a flowchart, figure 1. From previously published systematic reviews, 31 studies were 
selected as eligible. The additional literature search yielded 159 citations. Three full text 
manuscripts were further evaluated for eligibility, all had to be excluded for different reasons 
(Reindollar et al., 2010;Streda et al., 2007;Tummon et al., 1997). One, not yet published study 
was included via co-authors of included studies (Custers et al., 2011). The authors of 32 
eligible studies, containing 4.460 couples in total, were invited to share their IPD (Table 1). 
Authors of 12 studies did not have the original data available (Agarwal et al., 2004;Aribarg 
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et al., 1995;Chung et al., 1995;Cohlen et al., 1998;Crosignani et al., 1991;Crosignani et al., 
1994;Ho et al., 1989;Ho et al., 1992;Martinez et al., 1990;Murdoch et al., 1991;Nan et al., 1994;te 
Velde et al., 1989). The authors of 12 other studies did not respond to two or more emails 
(Arcaini et al., 1996;Arici et al., 1994;Deaton et al., 1990;Glazener et al., 1987;Gregoriou et al., 
1996;Janko et al., 1998;Jaroudi et al., 1998;Karlstrom et al., 1993;Kerin et al., 1984;Kerin et al., 
1987;Kirby et al., 1991;Melis et al., 1995). Eventually, the authors of eight of the 32 eligible 
studies contributed their data, containing data for 2,550 of the total 4,460 eligible couples. 
These eight studies were included in this IPD analysis (Bhattacharya et al., 2008;Custers et al., 
2011;Goverde et al., 2000;Guzick et al., 1999;Hughes et al., 2004;Steures et al., 2006;Steures et 
al., 2007a;Steures et al., 2007b). 
Figure 1. Flow diagram of study selection
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Table 1. Eligilble studies
Authors Publication year
1 Agarwal et al. 2004
2 Arcaini et al. 1996
3 Aribarg et al. 1995
4 Bhattacharya et al. 2008
5 Chung et al. 1995
6 Cohlen et al. 1998
7 Crosignani et al. 1994
8 Crosignani et al. 1991
9 Custers et al. 2011
10 Deaton et al. 1990
11 Glazener et al. 1987
12 Goverde et al. 2000
13 Gregoriou et al. 1996
14 Guzick et al. 1999
15 Ho et al. 1989
16 Ho et al. 1992
17 Hughes et al. 2004
18 Janko et al. 1998
19 Jaroudi et al. 1998
20 Karlstrom et al. 1993
21 Kerin et al. 1984
22 Kerin et al. 1987
23 Kirby et al. 1991
24 Martinez et al. 1990
25 Melis et al. 1995
26 Murdoch et al. 1991
27 Nan et al. 1994
28 Soliman et al. 1993
29 Steures et al. 2006
30 Steures et al. 2007
31 Steures et al. 2007
32 Te Velde et al. 1989
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study characteristics
The characteristics of the included studies are summarised in Table 2. The studies varied in 
inclusion criteria, duration of the interventions, controlled ovarian stimulation protocols, 
starting dose and criteria for cancellation of insemination. The controlled ovarian stimulation 
protocols and the number of embryos transferred varied in the different IVF arms. Six studies 
registered live births per couple (Bhattacharya et al., 2008;Goverde et al., 2000;Guzick et al., 
1999;Hughes et al., 2004;Steures et al., 2006;Steures et al., 2007a), whereas the other two 
studies only reported ongoing pregnancy (Custers et al., 2011;Steures et al., 2007b). All studies 
registered multiple births, which ranged from 0% to 100%.
One study compared IUI with and without COS with ICI with or without COS. ICI was 
considered as a surrogate for intercourse or EM in this study (Guzick et al., 1999). 
Some of the data on two studies could not be included: in one study 101 couples had received 
other treatments (COS or IUI) before randomisation; these couples were excluded from the 
analysis (Hughes et al., 2004). In another study couples started with three cycles of IUI 
without COS. If those three cycles failed, subsequent IUI cycles were performed with COS 
(Steures et al., 2007b). We only included the first three cycles of IUI without COS reported in 
this study. 
Assessment of study quality
The methodological quality of included studies is summarized in the last column of Table 2. 
Of the eight included studies (Guzick et al., 1999), all had performed a power calculation. All 
reported adequate methods of randomization and concealment of allocation. All studies had 
a parallel design and all studies except one (Goverde et al., 2000) were multicentre studies. 
In all studies the randomised groups were comparable at baseline and had a follow-up of at 
least 80%. Comparison of the data received from authors with the published results revealed 
only minimal differences in duration of subfertility, which were ignored. The quality of the 
data received was considered satisfactory for all included studies. There were no missing 
data.
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Chapter 8
Table 3. The prognosis according the prognostic model of Hunault, the chance of natural conception 
within 12 months according the prognostic model of Hunault et al. (2004)
Study Mean prognosis according the model of Hunault (SD)
Bhattacharya 2008 Expectant management                                30.1%  (9.4)      
IUI                                                                  30.3%  (10.1) 
Timed intercourse with COH                         29.5%  (9.4)
Custers 
2011
IUI-COS                                                         20.8% (6.8) 
IVF eSET                                                       20.7% (5.4)
Goverde 
2000
IUI without COS                                             25.5% (10.2)
IUI-COS                                                         24.4% (10.8)
IVF                                                                 24.2% (12.0)
Guzick 
1990
ICI without COS                                             29.6% (13.3)
IUI without COS                                             28.2% (12.7)
ICI- COS                                                        29.9% (12.6)
IUI- COS                                                        29.5% (12.4)
Hughes 
2004
Expectant management                                22.7% (13.9)
IVF                                                                 24.1% (10.6)
Steures
 2006
Expectant management                                 28.7 % (6.0)
IUI- COS                                                        28.6 %  (5.3)
Steures
 2007
IUI without COS                                             23.4%   (6.9)
IUI-COS                                                         24.1%   (6.2)
Steures
 2007
Expectant management                                 39.3 %  (8.5)
IUI without COS                                             37.0%   (8.2)
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Interaction between prognosis and efficacy of treatment
The chance of a natural conception within 12 months was calculated for all included couples 
based on the variables in the datasets (Hunault et al., 2004). For the variables female age, 
duration of subfertility, subfertility being primary or secondary and sperm motility, there 
were no missing data. In four studies (Bhattacharya et al., 2008;Goverde et al., 2000;Guzick et 
al., 1999;Hughes et al., 2004) the datasets did not include a variable concerning the referral 
status (secondary or tertiary care), but based on the context of the publication or after 
contacting the author, we categorized all couples in these four studies as secondary care 
patients. The prognosis of natural conception is summarized in Table 3. The mean prognosis 
was comparable between treatment arms in the included trials and the standard deviation 
of prognosis varied from 5.3 and 13.9%. 
The intercepts, slopes and interaction terms for the treatment strategies in each study are 
shown in Table 4. To facilitate interpretation, we have integrated the treatment term in 
the intercepts, and the interaction term in the slope. Differences in the overall treatment 
effect would then become apparent as a difference in the intercept; differences in the effect 
of prognosis would show themselves as a difference in slope. The far right column in Table 
4 shows the p-value to indicate differences in slopes: the interaction between treatment 
and prognosis. The interaction term was not statistically significant in any of the trials, 
indicating that there was no evidence of a significant differential effect of prognosis on the 
efficacy of treatment.
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Prognosis by treatment curves
The prognosis-by-treatment curves are shown in Figure 2a-g. To facilitate interpretation of 
the curves we discuss four studies in more detail. The curve for the trial of Bhattacharya et 
al. (2008) is shown in Figure 2a. Most couples had a probability between 20% and 30% of 
conceiving naturally within 12 months. With all three treatment strategies the probability 
of live birth increased with a better prognosis of natural conception. In couples with a poor 
prognosis of natural conception the probability of live birth was higher for those treated with 
IUI without COS compared to EM and timed intercourse with clomiphene citrate. In couples 
with a prognosis of natural conception of more than 50%, the probability of live birth was 
higher in couples who received EM. In couples receiving only clomiphene citrate (CC) the 
probability of live birth was lower in all couples, regardless of prognosis. The slopes of all 
three lines in the curve differ, but as shown in Table 4, this difference did not reach statistical 
significance (interaction IUI and EM p= 0.711 and interaction CC and EM p=0.694).   
In the study of Custers et al. (2011) (Figure 2b) the probability of ongoing pregnancy also 
seems to differ between the two treatment strategies. The curve shows a higher probability 
of ongoing pregnancy in couples with a poor prognosis of natural conception when treated 
with IVF. In couples with a good prognosis of natural conception the probability of ongoing 
pregnancy was higher if they received IUI with COS. This difference in slope did not reach 
statistical significance (p= 0.312, Table 4).  
The prognosis-by-treatment curves of the study of Goverde et al. (2000) (Figure 2c) shows that 
in couples with a poor prognosis the probability of live birth is higher in couples treated with 
IUI with COS and IVF compared to couples treated with IUI without COS. In couples with a 
good prognosis the predicted probability of live birth is higher in couples who received IUI 
without COS. This difference in slope did not reach statistical significance (p= 0.190 and 
0.219, Table 4).  
In the study of Guzick et al. (1999) ICI  in a natural cycle (n=233) and in a stimulated cycle 
(n=234) were compared with IUI  in a natural cycle (n=234) and in a stimulated cycle 
(n=231), in couples with unexplained subfertility or male subfertility. The prognosis-by-
treatment curves (Figure 2d) show a higher predicted probability of live birth in all couples 
treated with IUI or ICI with COS. In this study prognosis does not help in differentiating 
between treatment options. All interaction terms between prognosis and treatment in this 
study were not significant (p= 0.617, p= 0.878, p= 0.776, Table 4).
The trends of the curves of the two other studies can be observed in Figure 2e-f. We did not 
plot curves for the study of Hughes et al. (2004) which compared IVF (n= 18) with EM (n= 
20) because after excluding the couples who received treatment before randomisation, the 
number of included couples was too small to draw a reliable curve.
To compare the prognostic marker female age with the Hunault score on the effectiveness of 
assisted conception we also plotted female age-by-treatment curves for all studies (data not 
shown). Age appeared to be a poorer predictor than the Hunault score. 
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The heterogeneity in treatment protocols precluded the use of meta-analysis and the benefits 
of increased precision from pooling data. 
Figure 2: Predictiveness curves of different treament strategies
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dIsCussIon
Currently, there is no consensus on the best treatment strategy for couples with unexplained 
or mild male subfertility. In this study we explored the possibility of using prognosis of 
natural conception to select the best treatment strategy for these couples. We collected 
data from 8 primary studies including 2,550 couples, almost 60% of all treatment-naïve 
couples ever randomised between EM, IUI or IVF and published. Our results showed that the 
probability of live birth or ongoing pregnancy tended to be higher with a better prognosis of 
natural conception but we were unable to confirm a statistically significant differential effect 
of prognosis of natural conception on treatment efficacy.
A major strength of this study is that we were able to collect data for almost 60% of all couples 
ever randomised in studies evaluating the efficacy of EM, TI, ICI or IUI with or without COS 
and IVF in couples without a major cause for their unfulfilled child wish. Authors of 12 
studies did not have their data anymore and authors of another 12 studies could not be 
traced: overall these studies were older, which explains why it was harder to trace the data 
or the author. Untraceable studies were relatively small and the majority of these studies had 
a cross-over design. The studies that we included in this IPD analysis were the largest ones, 
the most recent ones and also those of high quality.
The importance of patient selection based on prognosis of natural conception has been 
stressed before and validated prognostic models estimating the chances of treatment 
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independent, i.e. natural conception are available (Collins et al., 1983;Leushuis et al., 2009). In 
an impact study of the prognostic model of Hunault, couples with an intermediate prognosis 
were randomly allocated to EM or IUI with COS, both for six months. The live birth rates in 
both groups were comparable, suggesting couples with an intermediate or a poor prognosis 
are better off with EM Steures et al. 2006). The present study aimed to confirm an association 
between prognostic profiles and the efficacy of assisted conception, but failed to find a 
significant effect of prognosis on treatment outcome.
One explanation for our negative findings may be differences in stimulation protocol and 
embryo transfer policies between the included studies which may override the impact of 
patient profile. Especially in the treatment arms of IUI with COS, higher dosage of controlled 
ovarian stimulation and milder cancellation criteria are not only associated with higher 
pregnancy rates but also higher risks of multiple pregnancies. For example, treatment of IUI 
with COS for 6 cycles resulted in one study in a live birth of 36% and multiple birth rate of 
29% (Goverde et al., 2000) compared to the same treatment for 6 months in another study 
with a live birth rate of 21% and a multiple pregnancy rate of 7% (Steures et al., 2006). At 
the moment most countries find multiple birth rates of 29% not acceptable (ESHRE position 
paper, 2008), as multiple births are associated with higher morbidity and mortality rates for 
both mother and child compared to singleton pregnancies (Gerris et al., 2005; Helmerhorst et 
al., 2004). This high multiple birth rate reduces the applicability of the results of our study and 
also of the original study (Guzick et al., 1999): unfortunately this is the largest RCT performed 
in this field (n=932). This issue emphasizes the need for more large RCTs evaluating the 
efficacy of IUI and IVF for couples with unexplained or male subfertility. 
Our results indicate that the effect rate of IUI COS is largely correlated with twin rates. 
Our results question the impact of prognostic profile on the efficacy of IUI COS, implicating 
that the treatment effect is also limited in poor prognosis couples. Consequently, acceptable 
pregnancy rates in these couples are only achieved through a high multiple pregnancy 
rate. We should keep in mind here that studies reported on, at maximum, 6 cycles whereas 
many couples with unexplained subfertility will have 5 to 10 years of reproductive chances 
ahead, corresponding to 60 - 120 cycles. Thus, the contribution of these IUI COS cycles on the 
overall reproductive outcome might be rather limited and should be considered with care, 
specifically when high multiple pregnancy rates occur.
Only three studies in this IPD analysis included IVF, of which one was relatively small (Hughes 
et al., 2004) , one used IVF elective single embryo transfer (Custers et al., 2011) and one was 
relatively old (Goverde et al., 2000 ). As a consequence, no firm conclusions can be drawn 
regarding the relation between prognosis and treatment outcome after IVF. Nevertheless, 
these are the only data available on treatment-naïve couples ever randomised between 
assisted conception or EM (Pandian et al., 2012). Only one relatively old study that compared 
IVF with EM did not supply data because the data were no longer available (Soliman et al., 
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1993). The fact that all the data on IVF cycles performed within clinical trials are, in one way 
or another, of relatively poor quality stresses the need for RCTs studying IVF.
ConClusIon
Although we did observe a trend in the prognosis-by-treatment curves towards a relation 
between the chances of natural conception and the outcome of treatment, we did not find a 
significant effect of prognosis on treatment outcome. The included studies in themselves are 
too small to detect any differential capacity of the prognostic models on treatment outcome. 
The heterogeneity in treatment protocols precluded the use of meta-analysis and the benefits 
of increased precision from pooling data. Additional data from larger trials are needed to 
evaluate the existence of a differential effect of prognosis on treatment outcome with greater 
precision. 
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The effectiveness of more than 50% of all interventions in medicine is unknown (BMJ 
Evidence Centre 2011). As Donald Rumsfeld, the former American minister of Defence, 
mentioned in 2002, it is important to distinguish the known unknowns from the unknown 
unknowns (Donald Rumsfeld 2002). The extent of the latter is unclear, but critical judgement 
of available evidence can create awareness of the unknown unknowns and move them to the 
category known unknown. It is then possible to evaluate them according to the principles of 
evidence-based medicine and transfer them to the category of known knowns. 
We have also rather recently become aware that this process does not end when a known 
unknown has become a known known, because the known knowns summarized in clinical 
guidelines, do not implement themselves. Literature from several countries suggest that 
approximately 30-40% of patients still do not receive care based on the best available evidence 
and 20-25% of provided health care is considered unnecessary or potentially harmful (Grol 
2001; McGlynn et al. 2003; Schuster et al. 1998). 
In reproductive medicine the evidence concerning the effectiveness of fertility treatments 
in couples without a major cause for their unfulfilled child wish is inconclusive (Bensdorp 
et al. 2007; Steures et al. 2008; Verhulst et al. 2006; Veltman-Verhulst et al. 2012) . In 
these cases, prognostic models can help to predict the chance of treatment (in)dependent 
pregnancy for the individual couple (Leushuis et al. 2009). For instance, an impact analysis 
of a prognostic model predicting the chance of natural conception showed that in couples 
with an intermediate or high chance of natural conception, intra uterine insemination 
with ovarian stimulation had no beneficial effect on livebirth rate compared to expectant 
management (Steures et al. 2006). Based on this impact analysis our national guideline 
concerning subfertility recommends an expectant management for 6-12 months in couples 
with a favourable prognosis (NVOG: national guideline subfertility 2011). We call this strategy, 
i.e. an expectant management in subfertile couples with a good/intermediate prognosis of 
natural conception, tailored expectant management (TEM). Optimal adherence to TEM can 
lead to the prevention of unnecessary treatment, complications, physical and psychological 
burden and costs. 
To what extent these prognostic models can be used to select couples for IUI or IVF is unclear. 
In this thesis we tried to contribute to optimal implementation of TEM and the role of 
prognostic models in treatment selection, in two ways. 
Firstly we assessed how tailored expectant management is implemented in daily Dutch 
practice. In a prospective cohort study we found a moderate adherence to TEM and this 
adherence decreased when the woman is older and the duration of the subfertility is longer. 
The presence of a fertility doctor in a clinic may prevent early treatment (chapter 2). Potential 
weakness of this cohort study is that we measured the adherence to a study protocol instead 
of the adherence to an (inter-) national guideline. At the time of this study the subfertility 
guideline was not so explicit in advice for TEM. As the recruiting doctors in this study cohort 
were probably more dedicated compared with an ‘average doctor’, we hypothesize that 
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early treatment in daily practice must be even higher, as has been demonstrated previously 
(Mourad et al., 2008).
Professionals’ and patients’ barriers and facilitators for tailored expectant management 
were evaluated qualitatively and quantitatively. Multivariate analyses were performed to 
evaluate which factors predict patients’ appreciation of TEM and professionals’ adherence 
to TEM. Based on these studies we conclude that the implementation of tailored expectant 
management in couples with a good prognosis can be enhanced by developing adequate 
patient information material, implementing regular fertility meetings where patients 
are discussed after the fertility work-up, implementing local protocols and by improving 
the knowledge of doctors about prognostic models and their communication skills with 
interactive training sessions (chapters 3 and 4). 
An implementation strategy focussing on these findings was developed and will be tested in 
a cluster randomised trial. In this trial, clinics and their allied general practitioner units are 
randomised between the multifaceted implementation strategy versus usual care. According 
the new guideline, the general practitioner can also perform a fertility work-up, calculate a 
prognosis for the couple and in case of a good prognosis advice TEM. The prognosis can be 
calculated with the validated model of Hunault with or without the post-coital test (Hunault 
et al. 2004). The effect of the strategy will be evaluated by a pre- and post-randomisation 
data collection and a process and economic evaluation. The study protocol of this cluster 
randomised trial is described in chapter 5.
In addition to the implementation study we aimed in the second part of this thesis to evaluate 
the applicability of prognosis of natural conception. This evaluation was twofold. Firstly, we 
compared two methods for fertility treatment selection: a funding based selection strategy 
used in New Zealand and a selection strategy based on the validated prognostic model of 
Hunault. In a cohort of 663 couples we found a fair agreement between the two treatment 
selection methods, a comparable discrimination and a better calibration in the selection 
method with the validated prognostic model of Hunault (chapter 6).
Secondly, we evaluated to what extent prognostic models can help to select subfertile couples 
for IUI or IVF. To accomplish this, we gathered data of published randomised controlled 
trials in which treatments options for these couples were compared. We managed to collect 
data of almost 60% of all treatment naïve couples, ever randomised between expectant 
management, IUI or IVF. After analysing these data of 2551 randomised couples, we found 
no significant differential effect of prognosis on treatment outcome. Between the studies 
the same treatment arms followed different treatment protocols which made it impossible 
to merge the data in a meta-analysis. However, a non-significant trend was observed that 
couples with a high chance of natural conception are better off with less invasive treatment 
strategies like expectant management or IUI in a natural cycle and vice versa (chapter 7 and 
8).
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At this moment, the management of couples with unexplained subfertility is empirical and 
many different regimens are used. Among these various treatment options are expectant 
management, intrauterine insemination with or without ovarian stimulation and IVF. There 
is no definitive evidence to show that any treatment is better than the other.
In this thesis we showed that at the moment evidence for prognosis of natural conception 
as a treatment selection marker for couples with unexplained subfertility is not available. 
There is a need for large randomized controlled trials to identify the best treatment option 
in couples with unexplained infertility. It is important to include prognostic factors in such 
trials so we can determine the effect of a pre-treatment calculated prognosis on treatment 
outcome. One ongoing multicentre randomised controlled clinical trial in the Netherlands 
is comparing six cycles of intra uterine insemination with controlled ovarian stimulation 
with six cycles of modified natural cycle IVF and three cycles with IVF-elective Single Embryo 
Transfer (eSET) within a time frame of 12 months. Couples with unexplained subfertility or 
mild male subfertility and a poor prognosis for natural conception (<30% according to the 
Hunault model) are included in this study. The results of this trial are expected in 2013 and 
it would be of interest to include these data in our individual patient data analysis on the 
relationship between prognosis and treatment outcome (Bensdorp et al. 2009).
As long as there is no evidence for optimal treatment we have to base our management 
on the best available evidence. Within this thesis the relevance of expectant management 
in couples likely to conceive naturally within 12 months has been stressed repeatedly. 
Treatments such as IUI or IVF should only be proposed to couples with a sufficiently low 
probability of treatment-independent pregnancy to avoid unnecessary medication and 
procedures and subsequent complications. 
The discussion on when and how to treat couples with unexplained subfertility also brings us 
to the issue whether unexplained subfertility is a disease or not. If a patient with abdominal 
pain visits the hospital and no abnormalities are found after the diagnostic work-up, we send 
the patient home with the message: “There is nothing wrong, we cannot help you, good 
luck.” Or we may diagnose the patient with irritable bowel syndrome and give her some diet 
advices, but we would not give her a potential harmful therapy leading to more morbidity 
and mortality if there is no evidence for effectiveness of this therapy.
The question to be asked is why we do so in reproductive medicine. Is it because of pressure 
for treatment from the patient, have we been seduced by the pharmaceutical industry 
or do we exploit despair from infertile patients for our own purposes or income? In our 
national survey described in this thesis nobody declared to have economic arguments to 
refrain from TEM, but maybe the social desirable answer was given. Seventy-four percent of 
the professionals that participated in our survey experienced the urgency for action of the 
patients as a barrier for TEM. 
Is it now still possible to perform a solid evaluation of IVF for couples with unexplained 
subfertility? The new Cochrane review concerning IVF in couples with unexplained 
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subfertility has come to the same conclusion as in 2005: “IVF may be more effective than 
IUI+SO. Due to paucity of data from RCTs the effectiveness of IVF for unexplained infertility 
relative to expectant management, clomiphene citrate and IUI alone remains unproven. 
Adverse events and the costs associated with these interventions have not been adequately 
assessed” (Pandian et al. 2005; Pandian et al. 2012). More studies are needed comparing IVF 
with expectant management in couples with unexplained subfertility and in these studies 
prognostic factors must be registered. The question is whether patients will participate in 
such trial or whether they will seek their comfort in commercial clinics in the Netherlands or 
abroad, if randomised to expectant management (Shenfield et al. 2010).
The time for large trials comparing IVF with expectant management taking prognosis into 
account is now, before the commercialisation in our medical care system makes such trials 
even more challenging or even impossible.
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suMMARy
Tailored expectant management in reproductive medicine
Subfertility is defined as a failure to conceive after at least one year of regular unprotected 
intercourse. It affects approximately 10% of couples in their reproductive lives(Boivin et al. 
2007; Gnoth et al. 2003). The incidence of subfertility is increasing in the developed world 
mainly due to postponement of maternity. After a basic fertility work up about 25% of all 
subfertile couples is diagnosed with unexplained subfertility, 30% with a mild male factor, 
5% with a severe male factor, 20% with an ovulation disorder and in 20% of the couples 
other diagnoses are made. 
In couples with unexplained or mild male subfertility, i.e. >50% of all subfertile couples, 
fertility treatments as intra uterine insemination (IUI) with or without ovarian stimulation 
(OS) and in vitro fertilisation (IVF) are not always leading to higher pregnancy rates than 
expectant management. To select couples for expectant management prognostic models 
that predict the chance of natural conception have been developed. One large randomised 
controlled trial showed that if chances of natural conception are intermediate or good, an 
expectant management for 6-12 months is as effective as IUI with OS. We call this strategy, 
i.e. expectant management in couples with good prospects of natural conception, tailored 
expectant management (TEM). TEM is not always practiced, leading to overtreatment, 
unnecessary complications and costs. A common complication of fertility treatment is 
a multiple pregnancy, which is associated with a higher morbidity and mortality in both 
mothers and neonates. 
It is unclear how TEM is implemented in the Netherlands, but two large prospective cohort 
studies suggest a poor implementation. This thesis aimed to contribute to the implementation 
of TEM. To improve the implementation of TEM a systematic approach is needed including: 
acquiring data of current practice; identification of potential determinants; analysis of 
barriers and facilitators for the implementation, development of an implementation strategy 
and finally an evaluation of the implementation strategy. In this thesis this systematic 
approach was used to gain insight in the options to improve the implementation of TEM. 
In addition to the implementation study we aimed in the second part of this thesis to 
evaluate the applicability of prognosis of natural conception. This evaluation was twofold. 
Firstly, we compared two selection methods for fertility treatment: a funding based selection 
strategy used in New Zealand and a selection strategy based on the validated prognostic 
model of Hunault. In New Zealand public funding for fertility treatment is restricted to 
subfertile women who are unlikely to conceive naturally, based on clinical and social criteria 
known as the clinical priority access criteria (CPAC-score). In the Netherlands couples are 
selected for treatment based on their prognosis of natural conception. The performance of 
both selection methods were compared in a New Zealand cohort of 663 couples.
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Secondly, we aimed to explore the selective capacities of the prognostic model predicting the 
chance of natural conception in more detail. At the moment it is unclear if prognosis can help 
the physician to choose the proper - i.e. most (cost-) effective- treatment for subfertile couples 
with unexplained or mild male subfertility. In this last part of the thesis we will evaluated if 
prognosis can select couples for a specific treatment. We addressed this issue by analysing 
individual patient data (IPD) of published randomised controlled trials. Authors of published 
randomised trials comparing expectant management (EM), intracervical insemination (ICI), 
IUI, all three with or without OS and IVF, in couples with unexplained or male subfertility 
were contacted and invited to share their original data. In all datasets, we calculated the 
chances of natural conception for each couple with the validated prognostic model. We then 
constructed prognosis-by-treatment curves and tested whether prognosis can help to choose 
the most effective treatment strategy for the individual couple. 
Chapter 1 gives an outline and describes the objectives of this thesis. 
Chapter 2 reports the results of a cohort study in which we assessed risk factors for non-
adherence to tailored expectant management (TEM). Couples with mild male, unexplained 
and cervical subfertility were included in this multicentre prospective cohort study. If the 
probability of natural conception according to the prognostic model of Hunault within 12 
months was ≥40%, the study protocol advised an expectant management for 6–12 months. 
Multivariable logistic regression was used to identify patient and clinical characteristics 
associated with non-adherence to TEM. In total 3021 couples were included in this cohort of 
whom 1130 (38%) had a ≥40% probability of natural conception. Follow-up was available for 
1020 (90%) couples of whom 214 (21%) had started treatment between 6 and 12 months and 
153 (15%) within 6 months.
A higher female age and a longer duration of subfertility were associated with treatment 
within 6 months (OR: 1.06, 95% CI: 1.01–1.1; OR: 1.4; 95% CI: 1.1–1.8). A fertility doctor in 
a clinical team reduced the risk of treatment within 6 months (OR: 0.62; 95% CI: 0.39–0.99). 
We concluded that in couples with a favorable prognosis of natural conception, there is 
considerable overtreatment, especially if the woman is older and duration of the subfertility 
is longer. The presence of a fertility doctor in a clinic may prevent early treatment. 
In chapter 3 we aimed to identify any barriers or facilitators for tailored expectant 
management among professionals and subfertile couples. A qualitative study was performed 
with semi structured in-depth interviews among 21 subfertile patients who were counselled 
for TEM. In addition, three focus-group interviews were held with 21 professionals within 
the field of reproductive medicine. Two theoretical models were used to guide the interviews 
and the analyses. The primary outcome was the set of identified barriers and facilitators 
which influence implementation of TEM.
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Among the subfertile couples, main barriers were a lack of confidence in natural conception, 
a perception that expectant management is a waste of time, inappropriate expectations 
prior to the first consultation, misunderstanding the reason for expectant management and 
overestimation of the success rates of treatment. Both couples and professionals saw the lack 
of patient information materials as a barrier. Among the professionals, limited knowledge 
about prognostic models leading to a decision in favour of treatment was recognized as a 
main barrier. A main facilitator mentioned by the professionals was better management of 
patients’ expectations. 
Chapter 4 describes a nationwide survey to assess the prevalence of the barriers and 
facilitators identified in chapter 3 and to evaluate which factors predict patients’ appreciation 
of TEM and professionals’ adherence to TEM. Two questionnaires were developed based on the 
identified barriers and facilitators and sent to 195 couples and 167 professionals. Multivariate 
analysis was performed to evaluate which factors predicted patients’ appreciation of TEM 
and professional adherence to TEM. 
In total, 118 (61%) couples and 117 (70%) professionals responded and 96 couples and 117 
professionals were included in the analysis. Patients’ mean appreciation of TEM was 5.7, 
on a 10-point Likert scale. Patients with a lower appreciation of TEM had a higher need for 
patient information (p = 0.047). The professionals reported a mean adherence to TEM of 
63%. Adherence to TEM was higher when professionals were fertility doctors (p = 0.041). 
Facilitators in the clinical domain were associated with a higher adherence to TEM (p = 
0.091). Barriers in the professional domain had a negative impact on adherence to TEM (p = 
0.008).
Chapter 5 describes the study protocol of an ongoing cluster randomized trial that tests 
a multifaceted implementation strategy to improve the implementation of tailored 
expectant management (TEM). Current implementation of TEM is not optimal (chapter 
2). Based on the barriers and facilitators of TEM that were identified among professionals 
and subfertile couples in chapter 3 and 4, we developed a multifaceted implementation 
strategy. This implementation strategy focuses on infertile couples and their care providers 
i.e. general practitioners (GPs), fertility doctors and gynecologists. The implementation 
strategy addresses three levels: (1) Patient level: education materials in the form of a patient 
information leaflet and a website; (2) Professional level: audit and feedback, educational 
outreach visit, communication training and access to a digital version of the prognostic 
model of Hunault on a website; (3) Organizational level: providing a protocol based on the 
guideline. In a cluster randomized trial, 25 clinics and their allied practitioners units are 
randomized between the multifaceted implementation strategy and care as usual. The 
effect of the implementation strategy, i.e. the percentage guideline adherence on TEM, will 
be evaluated by pre- and post-randomization data collection. Furthermore there will be a 
process and cost evaluation of the strategy.
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Chapter 6 describes a study on the performance and measure of agreement of two fertility 
treatment selection methods: the CPAC score and the prognostic model of Hunault.  In 
New Zealand public funding for fertility treatment is restricted to subfertile women who 
are unlikely to conceive naturally, based on clinical and social criteria known as the clinical 
priority access criteria (CPAC-score). In this study this CPAC score was compared with the 
prognostic model developed in the Netherlands (the Hunault model). 
For this comparison a New Zealand (NZ) cohort of 663 couples with unexplained subfertility 
was used. Of the 663 couples referred, 249 (38%) couples had unexplained subfertility. Of 
246 women with follow-up data, there were 143 (58%) who had a live birth or ongoing 
pregnancy during the follow up period of 4-5 years, 65 (26%) after fertility treatment and 78 
(32%) after natural conception. 
There were 100 couples (41%) who had a Hunault prediction score of < 30%, which is 
the treatment threshold according the Dutch National Fertility guidelines and 36 (15%) 
couples who had a CPAC score of >65, which is the New Zealand threshold for publically 
funded treatment. There were 69 couples (28%) who met the threshold for treatment in the 
Netherlands, but did not meet the New Zealand threshold for public funding. The kappa 
coefficient as a measure of agreement of the two scores and their treatment thresholds was 
0.30 suggesting a fair agreement. The discriminative capacity was comparable between the 
two selection methods (AUC: 0.63), but the Hunault model performed better in calibration. 
In chapter 7 the study protocol of an individual patient data (IPD) analysis of the relation 
between the prognostic profile of subfertile couples and treatment outcome after EM, 
IUI and IVF is described. Most studies that evaluated the effectiveness of these treatment 
options have not taken the couples’ prognosis into account, which may or may not influence 
the effect of treatment. Individual patient data analyses allow us to take these prognostic 
factors into account, and to evaluate their effect on treatment outcome. This study aimed 
to use anonymised data from relevant published trials to perform an individual patient data 
meta-analysis, evaluating the effect of couples’ prognosis on the effectiveness of EM, IUI, 
with or without COS, and IVF. Based on earlier systematic reviews and an updated search, 
randomised controlled trials were considered for inclusion. Authors of the included studies 
were invited to share their original anonymised data. The data were assessed on validity, 
quality and completeness. The prognosis of the individual couple was calculated and its’ 
effect on treatment outcome analysed.
Chapter 8 reports the results of the study protocol described in chapter 7. We acquired 
data from 8 RCTs, including 2,550 couples. In three studies the more invasive treatment 
strategies appeared less effective in couples with a high chance of natural conception, but 
this difference did not reach statistical significance (p-value for interaction 0.71, 0.31 and 
0.19). In one study the strategies with OS (IUI and ICI) led to higher pregnancy rates than 
unstimulated strategies, regardless of prognosis, but at the expense of a high twin rate. In 
two studies, the more invasive treatments strategies appeared more effective in couples 
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with a good prognosis, but this difference did not reach statistical significance (p-value for 
interaction 0.38 and 0.68 respectively). In one study, prognosis was already incorporated in 
the inclusion criteria and its’ differential effect on treatment effect was limited. The only 
study that compared EM with IVF included 38 couples, and was too small for a precise 
estimate.  Our analyses exclude large differential effects of prognosis on effectiveness of 
fertility treatment. 
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Afwachtend beleid bij subfertiele paren met een goede kans op 
natuurlijke conceptie 
Een paar is subfertiel als er na een jaar onbeschermde geslachtsgemeenschap geen 
zwangerschap optreedt. Naar schatting wordt 10% van alle paren met een kinderwens 
hiermee geconfronteerd. De incidentie van subfertiliteit neemt toe in de ontwikkelde wereld, 
voornamelijk als gevolg van de toenemende leeftijd waarop de vrouw de keuze maakt 
voor het moederschap. Na een oriënterend fertiliteitsonderzoek wordt ongeveer 25% van 
alle subfertiele paren gediagnosticeerd met onverklaarde subfertiliteit, 30% met een milde 
mannelijke factor, 5% met een ernstige mannelijke factor, 20% met een ovulatiestoornis 
en in 20% van de paren wordt een andere diagnose gesteld. Bij paren met onverklaarde 
of milde mannelijke subfertiliteit die meer dan 50% van alle subfertiele paren uitmaken, 
leiden vruchtbaarheidsbehandelingen zoals intra-uteriene inseminatie (IUI) met of zonder 
ovariële stimulatie (OS) en in vitro fertilisatie (IVF) niet altijd tot betere zwangerschapscijfers 
dan een afwachtend beleid. Om de juiste koppels voor een afwachtend beleid te selecteren 
zijn prognostische modellen ontwikkeld die de kans op natuurlijke conceptie kunnen 
voorspellen. In een groot gerandomiseerd onderzoek bleek dat bij paren met een gemiddelde 
zwangerschapskans een afwachtend beleid van 6-12 maanden net zo effectief was als 
een behandeling van IUI met OS. Een afwachtend beleid bij paren met een goede kans op 
natuurlijke conceptie wordt niet altijd toegepast, wat leidt tot overbehandeling, onnodige 
complicaties en kosten. Een meerlingzwangerschap is een veel voorkomende complicatie 
van vruchtbaarheidsbehandelingen en wordt geassocieerd met een hogere morbiditeit en 
mortaliteit bij zowel moeders als pasgeborenen. 
Het is onduidelijk hoe dit afwachtend beleid bij paren met een goede kans op natuurlijke 
conceptie is geïmplementeerd in Nederland. Twee grote prospectieve cohortstudies 
suggereren een slechte implementatie. Dit proefschrift heeft onder andere als doel meer 
inzicht te krijgen in de implementatie van een afwachtend beleid bij paren met een goede 
kans op natuurlijke conceptie en te evalueren hoe dit verbeterd kan worden. Om deze 
implementatie te optimaliseren is een systematische aanpak nodig: het verwerven van 
gegevens van de huidige praktijk; een analyse van belemmerende en bevorderende factoren 
voor de implementatie; de ontwikkeling van een implementatiestrategie en ten slotte een 
evaluatie van deze implementatiestrategie. In dit proefschrift is deze systematische aanpak 
gebruikt om inzicht te krijgen in de mogelijkheden om de uitvoering van dit afwachtend 
beleid bij paren met een goede kans op natuurlijke conceptie te verbeteren.
Naast deze implementatiestudie hebben we in dit proefschrift de toepasbaarheid van de 
prognose op natuurlijke conceptie verder geëvalueerd. Deze evaluatie bestaat uit twee 
delen. Ten eerste hebben we twee selectiemethoden voor vruchtbaarheidsbehandelingen 
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vergeleken: de in Nieuw Zeeland gebruikte “CPAC score” en het gevalideerde prognostische 
model van Hunault. In Nieuw-Zeeland worden vruchtbaarheidsbehandelingen alleen 
vergoed als paren een lage kans hebben op natuurlijke conceptie volgens bepaalde klinische 
en sociale criteria. Deze criteria staan bekend als de “Clinical Priority Access Criteria” (CPAC-
score). In Nederland worden paren geselecteerd voor behandeling op basis van hun kans 
op natuurlijke conceptie, berekend met het gevalideerde prognostisch model van Hunault. 
In deze studie werd de kwaliteit van beide selectiemethoden vergeleken in een cohort uit 
Nieuw Zeeland bestaande uit 663 subfertiele paren.
Ten tweede hebben we geprobeerd meer inzicht krijgen in de selectieve capaciteiten 
van het prognostisch model van Hunault dat de kans op natuurlijke conceptie voorspelt. 
Op dit moment is het onduidelijk of dit prognostische model de arts kan helpen om de 
juiste behandeling te kiezen voor subfertiele paren met onverklaarde of milde mannelijke 
subfertiliteit. In dit laatste gedeelte van het proefschrift hebben we geëvalueerd of prognose 
kan helpen patiënten te selecteren voor een specifieke behandeling. We hebben dit probleem 
aangepakt door individuele patiëntgegevens van gepubliceerde gerandomiseerde studies te 
verzamelen en te analyseren. Auteurs van gepubliceerde gerandomiseerde studies die een 
afwachtend beleid (EM), intracervical inseminatie (ICI), IUI, alle drie met of zonder ovariële 
stimulatie en IVF vergeleken bij paren met onverklaarde of mannelijke subfertiliteit, werden 
benaderd en gevraagd hun oorspronkelijke data te delen. In alle datasets hebben we de 
kans op natuurlijke conceptie voor elk koppel berekend met het gevalideerde prognostische 
model. Vervolgens hebben we geanalyseerd of deze prognose een significant effect had op 
de uitkomst van de behandeling.
Hoofdstuk 1 geeft een overzicht en een beschrijving van de doelstellingen van dit proefschrift.
Hoofdstuk 2 beschrijft de resultaten van een cohortstudie waarin we risicofactoren 
onderzochten voor het niet naleven van afwachtend beleid bij paren met een goede prognose. 
Paren met een milde mannelijke, onverklaarde en cervicale subfertiliteit werden opgenomen 
in deze cohortstudie. Als de kans op natuurlijke conceptie binnen 12 maanden volgens het 
prognostisch model van Hunault ≥40% was, adviseerde het studieprotocol een afwachtend 
beleid gedurende 6-12 maanden. Multivariabele logistische regressie-analyse werd gebruikt 
om de patiënt en de klinische kenmerken die geassocieerd waren met het niet naleven van 
dit afwachtende beleid te identificeren. In totaal werden 3021 paren opgenomen in dit 
cohort waarvan 1130 (38%) een kans van ≥40% hadden op natuurlijke conceptie. Follow-up 
was beschikbaar voor 1020 (90%) paren. Tweehonderdveertien (21%) paren waren begonnen 
met een behandeling tussen zes en twaalf maanden en 153 (15%) binnen zes maanden. Een 
hogere leeftijd van de vrouw en een langere duur van de subfertiliteit waren geassocieerd 
met de behandeling binnen zes maanden (OR: 1,06, 95% CI: 1,01-1,1, OR: 1,4, 95% CI: 1,1-
1,8 respectievelijk). Een fertiliteitsarts in een klinisch team verminderde het risico van de 
behandeling binnen zes maanden (OR: 0,62, 95% CI: 0,39-0,99). Wij concludeerden dat er bij 
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paren met een gunstige prognose op natuurlijke conceptie een aanzienlijke overbehandeling 
is, vooral als de vrouw ouder is en de duur van de subfertiliteit langer. De aanwezigheid van 
een fertiliteitsarts in een kliniek kan te vroege behandeling voorkomen.
Hoofdstuk 3 beschrijft een kwalitatieve studie waarin de belemmerende en bevorderende 
factoren van een afwachtend beleid bij paren met een goede prognose bij subfertiele paren 
en professionals werden geïdentificeerd. Deze belemmerende en bevorderende factoren 
werden geïdentificeerd door middel van semigestructureerde diepte-interviews met 21 
subfertiele patiënten die een afwachtend beleid hadden gekregen. Daarnaast werden drie 
focusgroep interviews gehouden met 21 professionals werkzaam in de fertiliteit. De primaire 
uitkomstmaat waren de geïdentificeerde belemmerende en bevorderende factoren die de 
uitvoering van een afwachtend beleid bij een goede prognose beïnvloeden. Bij de subfertiele 
paren waren de belangrijkste barrières een gebrek aan vertrouwen in natuurlijke conceptie, 
het idee dat een afwachtend beleid tijdsverspilling is, verkeerde verwachtingen voorafgaand 
aan het eerste consult, het niet begrijpen van de reden van het afwachtend beleid en een 
overschatting van slagingspercentages van behandelingen. Zowel koppels als professionals 
zagen het gebrek aan patiënt informatiemateriaal als een belangrijke barrière. Onder de 
professionals was beperkte kennis over prognostische modellen één van de belangrijkste 
barrières. Eén van de belangrijkste bevorderende factor genoemd door de professionals was 
het beter sturen van de verwachtingen van de patiënt.
Hoofdstuk 4 beschrijft een landelijk onderzoek naar de prevalentie van de in hoofdstuk 
3 geïdentificeerde belemmerende en bevorderende factoren. Hiernaast wordt in dit 
hoofdstuk geëvalueerd welke factoren invloed hebben op de waardering van patiënten op 
het afwachtend beleid en de naleving door professionals op het afwachtend beleid. Twee 
vragenlijsten werden ontwikkeld op basis van de in hoofdstuk 3 vastgestelde factoren en 
naar 195 koppels en 167 professionals gestuurd. Multivariabele analyse werd uitgevoerd 
om te evalueren welke factoren invloed hebben op de waardering van patiënten op het 
afwachtend beleid en de naleving door professionals van het afwachtend beleid. In totaal 
reageerden 118 (61%) paren en 117 (70%) professionals. De gemiddelde waardering die 
patiënten gaven aan het afwachtend beleid bij een goede prognose op een 10-punts schaal 
was 5,7. Patiënten die het afwachtend beleid lager waardeerden hadden meer behoefte aan 
patiëntinformatie (p = 0,047). De professionals rapporteerden een gemiddelde naleving van 
een afwachtend beleid bij een goede prognose van 63%. De naleving was hoger wanneer 
professionals fertiliteitsartsen waren (p = 0,041). 
Hoofdstuk 5 beschrijft het protocol van een lopende evaluatie van een implementatie-
strategie ter bevordering van een afwachtend beleid bij subfertiele paren met een goede 
prognose. De huidige implementatie van een afwachtend beleid bij paren met een goede 
prognose is niet optimaal (hoofdstuk 2). Op basis van de belemmerende en bevorderende 
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factoren die werden geïdentificeerd onder professionals en subfertiele paren in hoofdstuk 
3 en 4, hebben we een implementatiestrategie ontwikkeld. De implementatiestrategie 
richt zich op subfertiele paren en hun zorgverleners d.w.z. huisartsen, fertiliteitsartsen en 
gynaecologen. Deze implementatiestrategie richt zich op drie niveaus: (1) Patiëntniveau: 
ontwikkelen van een informatiefolder en een informatieve website, (2) Professioneel niveau: 
audit en feedback, educatieve bezoeken aan ziekenhuizen, communicatietraining en toegang 
tot een digitale versie van het prognostische model van Hunault, (3) Organisatorisch niveau: 
een lokaal protocol gebaseerd op de richtlijn. In een cluster gerandomiseerde studie worden 
25 klinieken en de hieraan gelieerde huisartsenpraktijken gerandomiseerd tussen deze 
implementatiestrategie en “care as usual”. Het effect van deze implementatiestrategie zal 
worden geëvalueerd door een pre-en post-randomisatie dataverzameling. Hiernaast zal er 
een proces-analyse en een kosten-analyse plaatsvinden. 
Hoofdstuk 6 beschrijft de kwaliteit van twee selectiemethoden om paren te selecteren 
voor een vruchtbaarheidsbehandeling: de in Nieuw Zeeland gebruikte CPAC-score 
en het prognostische model van Hunault. In Nieuw-Zeeland is vergoeding voor een 
vruchtbaarheidsbehandeling alleen beschikbaar voor subfertiele vrouwen met een lage 
kans op natuurlijke conceptie, gebaseerd op klinische en sociale criteria die bekend staan 
als de “Clinical Priority Access Criteria” (CPAC-score). In deze studie werd deze CPAC score 
vergeleken met het gevalideerde prognostisch model van Hunault dat in de Nederlandse 
richtlijn Onverklaarde Subfertiliteit wordt geadviseerd om patiënten te selecteren voor 
een behandeling. Voor deze vergelijking hebben we een cohort van 663 subfertiele paren 
gebruikt uit Nieuw-Zeeland. Van deze 663 paren hadden 249 (38%) paren een onverklaarde 
subfertiliteit. Van 246 vrouwen waren follow-up gegevens beschikbaar, hiervan hadden 143 
(58%) paren een levendgeborene of doorgaande zwangerschap tijdens de follow-up periode 
van 4-5 jaar; 65 (26%) na vruchtbaarheidsbehandelingen en 78 (32%) na natuurlijke conceptie. 
Er waren 100 paren (41%) die een Hunault score hadden van <30%, de behandelgrens 
volgens de Nederlandse richtlijn. Zesendertig paren (15%) hadden een CPAC-score van> 65, 
de behandelgrens in Nieuwe Zeeland. In totaal waren er 69 paren (28%) die een behandeling 
zouden krijgen volgens de Nederlandse richtlijn maar niet volgens richtlijn in Nieuw 
Zeeland. De kappacoëfficiënt, als een mate van overeenstemming tussen de twee scores en 
hun behandelgrens was 0.30, duidend op een matige overeenstemming. Het discriminerende 
vermogen van beide selectiemethoden was vergelijkbaar (AUC: 0.63), maar de Hunault score 
presteerde beter in de kalibratie. 
Hoofdstuk 7 beschrijft het studieprotocol van een individuele patiënt data (IPD) analyse van 
de relatie tussen het prognostische profiel van subfertiele paren en het effect hiervan op 
de behandeluitkomst. De meeste tot nu toe gepubliceerde studies die behandelstrategieën 
voor paren met een onverklaarde of mannelijke subfertiliteit hebben onderzocht, hebben 
prognose niet meegenomen in de evaluatie van het behandeleffect. Het zou kunnen dat 
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de individuele prognose van een paar het effect van de behandeling beïnvloedt. Met 
deze IPD-analyse kunnen we rekening houden met deze prognostische factoren en het 
effect hiervan op de behandeluitkomst evalueren. Data van gepubliceerde studies werden 
verzameld om deze IPD-analyse uit te voeren. De behandelingen die zijn geëvalueerd zijn 
ovariële stimulatie met getimede coïtus, Intra Cervicale Inseminatie (ICI) en IUI beide met 
en zonder ovariële stimulatie en IVF. Op basis van eerdere systematische reviews en een 
nieuw literatuuronderzoek werden studies geïncludeerd. Auteurs werden uitgenodigd om 
hun oorspronkelijke geanonimiseerde data te delen. De gegevens werden beoordeeld op 
validiteit, kwaliteit en volledigheid. De prognose van het individuele paar werd berekend en 
het effect van prognose op de behandeluitkomst werd geanalyseerd met logistische regressie 
analyse. 
Hoofdstuk 8 rapporteert de resultaten van de in hoofdstuk 7 beschreven studie. Data van 8 
gerandomiseerde studies met in totaal 2.550 paren werden verkregen. In drie studies bleken 
de meer ingrijpende behandelstrategieën minder effectief bij paren met een hoge kans 
op natuurlijke conceptie, maar dit verschil was niet  significant (p-waarde voor interactie 
0,71, 0,31 en 0,19). In één studie leidden alle strategieën met ovariële stimulatie (ICI en 
IUI) tot hogere zwangerschapcijfers dan bij de niet gestimuleerde strategieën, ongeacht 
prognose, maar ten koste van een hoog percentage meerlingzwangerschappen van van 
23 en 30%. In twee studies leken de meer ingrijpende behandelstrategieën effectiever bij 
paren met een goede prognose, maar dit verschil was niet statistisch significant (p-waarde 
voor interactie 0,38 en 0,68). De enige studie waarin een afwachtend beleid werd vergeleken 
met IVF includeerde 38 paren hetgeen te weinig is voor een nauwkeurige schatting. Onze 
analyses excluderen grote differentiële effecten van de prognose op de effectiviteit van 
vruchtbaarheidsbehandelingen.
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